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ix
This thesis seeks to develop new methods to study the glycosylation of cell
surfaces, with a particular interest in apoptosis. Existing methods in glyco-
biology include mass spectrometry and glycan identification by lectin bind-
ing. The use of new carbohydrate binding proteins (CBP) and microfluidic
techniques will improve the field of glycobiology and its relevance in the area
of apoptosis.
A method using the Lab in a Trench (LiaT) platform was developed
to allow sequential labelling of cell surface glycans using lectins. Cells are
captured in the trench, fluorescently labelled lectins are then added and
allowed time to bind. The lectins are then released by their corresponding
free sugar, allowing probing with subsequent lectins without steric hindrance
due to adjacent sugars of interest. This study represents the first sequential
labelling of the same cell surface by lectins.
It has been established, that exposure of terminal N-acetylglucosamine
(GlcNAc) occurs in late apoptosis and has a role in immune recognition and
clearance of dead cells. AAL-2 is a recombinantly produced lectin or CBP
with an affinity for the terminal sugar N-acetyl glucosamine (GlcNAc). It
has a binding profile matching that of the commercial GSL II in flow cy-
tometry and western blot, but has the advantage of not requiring additional
ions in its buffer. Using flow cytometry, this study has shown that AAL-
2 binds exclusively to late apoptotic cells. GafD is another recombinantly
produced CBP with an affinity for terminal O-linked GlcNAc (O-GlcNAc).
It was determined by flow cytometry that GafD binds to a subset very late
apoptotic cells. The proteins to which GafD binds were identified through
isolation of the cell membrane followed by mass spectrometric analysis. The
proteins were found to be predominantly cytosolic, indicating a migration
of the intracellular membrane to the cell surface during late apoptosis.
x
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Chapter 1
Introduction
In 2012, the National Academy of Sciences in conjunction with the National
Institutes of Health, the National Science Foundation and other interested
parties, published a document calling for improved methods and tools to
transform glycoscience (of Sciences et al., 2012). Progress in the study of
glycobiology has not matched the rapid advances in the fields of molecular
biology and protein analysis in the last fifty years. This thesis aims to
contribute new methods to further the field of glycobiology.
Complex sugar structures called glycans, bound to various proteins and
lipids of the cell, have important roles in permitting cells to communicate
with and adhere to one another. Problems with cell glycosylation may lead
to disease (section 1.1.3), whereas correct glycosylation has a protective
effect (section 1.1.4) and may indeed be useful for therapeutics (section
1.1.5). Understanding the role glycosylation plays in the complex process of
apoptosis (section 1.2) could potentially lead to new understanding of and
diagnostics for autoimmune disease (section 1.2.2).
The current methods for studying glycans are primarily limited to mass
spectrometry (section 1.3.1), which may be expensive, and carbohydrate
binding proteins called lectins (section 1.3.2) that may be used as probes for
techniques such as flow cytometry or western blotting (section 1.3.3).
It is hoped, that by using microfludic systems such as Lab in a Trench
(section 3.1), the use of lectin probes may finally be expanded beyond using
a single probe on a single cell to using multiple probes in sequence on the
same cell. Furthermore, novel carbohydrate binding proteins (section 1.4)
could be used in conjunction with flow cytometry (section 1.6) to further
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enhance our understanding of apoptosis.
Over the course of this work, new methods to analyse the sugars on
the surface of cells will be devised, using advances in microfluidics and car-
bohydrate binding probes to further understand the nature of cell surface
glycosylation.
1.1 Glycosylation
Glycosylation covers a range of post-translational modifications whereby
carbohydrates are covalently attached to a protein or lipid. These carbo-
hydrates may be in the complex form of long straight chains or branched
tree-like structures, or in the more simple form of single sugar modifications.
Glycosylation has been identified in all kingdoms of life, and is absolutely
crucial for multi-cellular organisms. Apweiler et al. estimate that over half
of all eukaryotic proteins are glycoproteins (Apweiler et al., 1999). Glycans
are built in a stepwise manner through the addition of sugar subunits by
enzymes called glycosyltransferases. This process is driven by the enzymes
in the pathways and the available sugars, unlike protein production that is
based strictly on an RNA template.
Glycoproteins and glycolipids are proteins or lipids with attached gly-
cans. Where the mass of carbohydrate on a protein is greater than the
mass of protein, it is referred to as a proteoglycan. The glycome repre-
sents the totality of glycans and their interactions in the cell and is many
times more complex than the genome or proteome. As glycosylation can
occur on a whole range of proteins and lipids, in many possible orientations,
formed from tens of possible sugar subunits, the possible permutations of
the glycome are staggering (Laine, 1997). Furthermore, glycosylation is not
directly encoded on the genome. Although glycosyltransferases that medi-
ate glycan construction are so encoded, many do not have known consensus
sequences for their site of activity, causing bioinformatic modelling of the
glycome to be highly challenging. Some limited predictions of glycosyla-
tion can be made based on these enzymes, however much of our knowledge
of glycan structure and localisation is through experimental measurement
(Bertozzi & Sasisekharan, 2009). Competing glycosyltransferases and vari-
ations in dietary monosaccharides have been demonstrated to affect the
glycome (Bertozzi & Sasisekharan, 2009; Zachara & Hart, 2006), further
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Figure 1.1: Glycans are composed of common monosaccharides. From
top left: D-glucose, D-galactose, D-mannose, D-N-Acetylglucosamine, D-N-
Acetylgalactosamine, L-fucose, D-N-Acetylneuraminic acid, D-Xylose. With the
exception of fucose, the monosaccharides found in mammalian glycans are predom-
inantly D-stereoisomers.
Image ”Glykoproteine Zucker” by Yikrazuul, downloaded from WikiMedia.org
26/11/2015
increasing the challenges in its study.
Glycosylation may occur intracellularly as an antagonist for phosphoryla-
tion of proteins in the form of the addition of a single N-Acetylglucosamine
(GlcNAc) (Zachara & Hart, 2006), or extracellularly where complex gly-
cans are displayed on proteins and lipids and act as signalling and adhesion
molecules (Figure 1.2)(Varki et al., 2009a).
Surface glycans generally fall into two categories, N-linked glycans and
O-linked glycans. N-glycans represent approximately 90 % of multimeric
glycan structures, with O-linked making up the remainder. N-linked glycans
are found on asparagine residues and have a branched structure with a
mannose at its core. O-linked glycans are frequently bound to a serine or
threonine residue via an N-acetylgalactosamine (GalNAc) and can have a
variety of glycan structures stemming from them. The glycans are attached
to the proteins post-translationally in the endoplasmic reticulum and Golgi
compartments. Glycosylation of proteins can confer solubility and thermal-
stability on them (Schwarz & Aebi, 2011).
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Figure 1.2: Glycan structures at the cell surface. Glycans on the surface
of cells can be found attached to proteins or lipids and face the extracellular space
where they act as signalling molecules or have roles in adhesion (Varki et al., 2009a).
1.1.1 Glycans are structurally diverse
Glycans have great structural diversity. Glycan modifications of proteins
range from the single sugar addition of O-linked β-N-acetyl-glucosamine
(O-GlcNAc), to the complex branching structures of the N-glycans, and the
long chains of O-glycans. Although glycans can be attached to lipids also,
glycoproteins are more commonly studied. The final capping structure of
glycans is also important for their function, in particular in their various
roles on the surface of a cell.
1.1.1.1 O-linked β-N-acetyl-glucosamine
O-linked β-N-acetyl-glucosamine (O-GlcNAc) is a very common post trans-
lational modification of nucleo-cytosolic proteins, with a role as an antago-
nist to phosphorylation (Hart & Akimoto, 2009). O-GlcNAc is attached to
serine or threonine residues of proteins exclusively via O-GlcNAc transferase
(OGT). There is no clear consensus site for the enzyme to bind, though about
half of O-GlcNAcylated proteins have a proline-valine-serine sequence. Un-
like N- and O- glycans it is not confined to the Golgi or extra cellular spaces.
The addition of the single molecule of GlcNAc does not confer any change
in charge on the protein, and likely acts through steric hindrance of phos-
photase binding and may interfere with the proteins conformation (Banerjee
et al., 2013).
O-GlcNAcylation was first discovered in 1983, and its importance wasn’t
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realised until 1990 when it was discovered to be involved in the regulation
of ribosomal proteins (Torres & Hart, 1984; Hart & Akimoto, 2009). It
cycles readily on and off proteins, through the complementary actions of
OGT and O-GlcNAc hydrolase (OGA), the former catalysing the addition
of O-GlcNAc from UDP-GlcNAc on to the protein and the latter enzyme
its removal. As its addition does not alter charge, it does not change a
protein’s migration on electrophoresis, and, as it is readily hydrolysed by
lysosomal hexosaminidases, the ubiquity of O-GlcNAcylation was slow to
be recognised. It is now apparent that O-GlcNAcylation is essential for
the survival of metazoans, and the OGT/OGA that manage its activity
in the cell are highly conserved across many species. O-GlcNAc is likely
to be found anywhere that serine/threonine phosphorylation occurs. OGT
is cleaved during apoptosis by caspase-3, and lysosomal proteins cleave O-
GlcNac from its protein sites.
Altered O-GlcNAcylation has been implicated in a number of diseases.
O-GlcNAcylation is known to be widespread in nuclear and mitochondrial
proteins in heart disease (Ma et al., 2015). Cycling of UDP-GlcNAc and Glc-
NAc has a role in regulating cellular metabolism. UDP is a potent feedback
inhibitor of OGT, and UDP-GlcNAc appears to act as an “energy sensor”
for the cell. UDP-GlcNAc is a by-product of glucose metabolism, and its
overproduction leads to inappropriate GlcNAcylation of cellular proteins in
diabetes, altering cellular metabolism (Hanover et al., 2010; Vosseller et al.,
2002; McClain et al., 2002). O-GlcNAc has been demonstrated to be a key
link between hyperglycaemia and cardiomyopathy through the increased O-
GlcNAcylation of nuclear regulatory proteins (Clark et al., 2003).
Current methods for identification of O-GlcNAcylation are based around
carbohydrate binding proteins such as sWGA or the antibody CTD 110.1,
chemical modifications for mass spectrometry, and the addition of galactose
based groups for easy of labelling (Banerjee et al., 2013; Ma & Hart, 2014).
Affinity columns based on CTD 110.1 or sWGA have been used to enrich O-
GlcNAcylated peptides for mass spectrometry, these methods rely on good
specificity of binding and do not provide detail on the localisation of the
O-GlcNAc modification on the peptide. Addition of modified galactoses
to O-GlcNAc residues by a mutated galactosyl transferase also allows the
O-GlcNAcylated proteins to be bound by the lectin ricin and enriched for.
The modified galactoses can have radioactive elements or be derivatised
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to allow ”click” chemistry labelling of the protein. This method is useful
for quantification of O-GlcNAc sites and enrichment of O-GlcNAcylated
proteins but does not provide localisation data. Beta-elimination followed
by Michael addition removes the OGlcNAc from the protein and replaces it
with an easily detectable DTT or biotin molecule. The method was adapted
from phosphorylation studies, and if using distinguishable labels can be
run simultaneously with phosphorylation detection. This method has the
advantage of being able to localise the OGlcNAc sites on the proteins of
interest, though it does require expertise in mass spectrometry and careful
sample preparation.
1.1.1.2 N-Glycosylation
N-glycans are branched glycans that are covalently attached to proteins at
the nitrogen of the side group of asparagine residues. The asparagine is part
of a recognised consensus sequence of asparagine - X - serine/threonine,
where X can be any amino acid but proline. Although this sequence is nec-
essary for N-glycosylation, it is not a guarantee that the site will have a
glycan (Gavel & Heijne, 1990). N-glycans represent up to 90 % of the multi-
meric glycans found on cells and are exclusively found on the cell surface or
attached to secreted proteins. N-glycosylation can be complex-biantennary,
oligomannosylated, or a hybrid of the two.
The process of N-glycosylation begins on the cytoplasmic surface of the
endoplasmic reticulum (ER), where a precursor 14-glycan core is built on the
lipid dolichol-P-phosphate (DPP). The use of lipid carriers such as DPP for
N-glycosylation appears to be highly conserved across eukaryotes (Schwarz
& Aebi, 2011). The proto-N-glycan is then flipped to the luminal surface
of the ER where it is transferred ”en bloc” by oliggosaccharyl transferase
to the nascent protein as it is produced by the ribosome. Some further
modification of the glycan occurs in the late ER before the immature glyco-
protein is transferred to the Golgi apparatus for final remodelling and matu-
ration. Glycosyltransferases are spatially arranged as an enzymatic array in
the golgi, with successive reactions catalysed by neighbouring transferases
positioned in the fashion of an assembly line. After final capping, the gly-
coprotein is transferred to the cell surface where it remains or is secreted.
There is no evidence for mature N-glycans in the intracellular space, even
on the cytosolic portions of transmembrane proteins (Stanley et al., 2009).
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Figure 1.3: N-glycosylation begins in the endoplasmic reticulum and
continues in the golgi apparatus. Image from Nakayama et al. (2013).
Proteins that are incorrectly folded or glycosylated are degraded via an
ER associated degradation pathway. The proteins are also deglycosylated by
a peptide N-glycanase (PNGase) (Tanabe et al., 2006; Stanley et al., 2009)
that allows recovery of the glycans independant of the peptide. The removal
of the glycan by PNGase leaves a negative charge on the amino acid, result-
ing in a change from an asparagine to an asparate residue. This is useful for
identification of N-glycan sites by mass spectrometry (subsection 1.3.1).
For a summary of the process of N-glycosylation and how its enzymes
have been conserved and diversified through evolution, refer to Schwarz
& Aebi (2011). N-glycosylation has been observed in bacteria and lower
eukaryotes, but it is not a primary method of glycosylation for them.
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1.1.1.3 O-Glycosylation
O-glycans are defined by the core sugar that forms the foundation of the
chain, with N-acetyl galactosamine (GalNAc) being the most common initi-
ating sugar unit of O-glycans. They can be attached to a number of amino
acids, with the most common being serine, threonine, tyrosine and hydrox-
yproline.
The most common type of O-glycan are the mucins, whose primary role
is in retaining water at epithelia and repelling microorganisms. Mucins are
initiated as a GalNAc on a serine or threonine and extended with a selection
of GlcNAc, fucose, galactose or sialic acids, which may later be acetylated
or sulphated (Brockhausen et al., 2009). Mucins often form a bottle brush
style conformation, where the mucins branch and can block exposure of the
protein epitopes. This has functions in resisting protease degradation, which
can help to maintain the mucosal barrier. Mucins bind water and salts, and
come in a soluble or gel format, with the gel form being more complex with
surface-exposed, crosslinkable cysteines on the ends of the proteins.
The truncated O-glycan known as the Tn antigen is formed when the
initiator GalNAc is not extended, and is highly antigenic. Both it and its
sialyated form are known tumour markers.
O-glycosylation commencing with other sugars than GalNAc is less com-
mon. O-fucosylation and O-glucosylation of the EGF-like notch receptor
appears to be critical in its function, with incorrect glycosylation causing
abberrant cell signalling (Freeze & Haltiwanger, 2009). O-mannosylation of
α-dystroglycan is critical for its correct function, with dysregulation leading
to muscular dystrophy (Yoshida et al., 2001).
1.1.1.4 Cell surface glycosylation
The final capping of N- and O- glycans and of glycolipids in mammalian
cells is generally with an α 2-3 sialic acid, with galactose or α 2-6 sialic acids
being less common (Stanley & Cummings, 2009). It is rare to see the final
sugar on N- and O- glycans being mannose or GlcNAc in mammalian cells,
although these are common on yeasts and some microorganisms, allowing
these sugars to be an immune signal for foreign antigen.
The glycosylated proteins protrude from the exterior of the cell, acting
as signalling molecules and adhesion molecules. It is estimated that some 80
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% of membrane proteins are glycosylated (Apweiler et al., 1999). Dube et al.
(2006) used a small molecule to modify golgi functions in order to alter cell
surface glycans and observe the effects dysregulation of glycosylation had
on cell function.
Cell surface carbohydrates interact with a variety of carbohydrate bind-
ing proteins, or lectins, in the body. These lectins can have specific glycans
that they can recognise, often in clusters. Some are soluble, such as the
galectin family, and others are bound to the surface of cells. Lectin proteins
are also critical for cell attachment to the extracelluar matrix and to other
cells, where the cell-based lectin can interact with the glycans on cells or in
the matrix (Varki & Lowe, 2009).
The selectins recognise sialyl Lewisx antigen and a number of mucins and
are critical for the functioning of the immune system (Cummings & McEver,
2009). P-selectin (platelet) is exposed on activated platelets and induces its
binding to vessel walls. E-selectin (endothelial) is an inducible lectin on
the walls of the endothelium of blood vessels that encourages the capture
of leukocytes and platelets to an inflamed area. L-selectin (leukocyte) helps
white blood cells to localise to areas of inflammation and to the lymph nodes
and Peyer’s patches (Collins & Paulson, 2004).
Neural cell adhesion molecule (NCAM) is a surface protein on neurons
that binds with NCAM on neighbouring neurons to signal. It has been
shown to be polysialylated in the embryonic form, which physically reduces
binding through steric hindrance and repulsion by the negatively charged
sialic acids (Varki & Lowe, 2009).
The sialylation of CD22 causes homo-oligermisation of the CD22 on B-
cells, as CD22 itself has a binding affinity for α2-6 sialic acid (Barnes et al.,
1999). This modulates the threshhold of B-cell activation, decreasing acti-
vation. The homo-oligmers can be disrupted by CD22 binding from another
cell surface, thus permitting B-cell activation by an antigen presenting cell
(Marth & Grewal, 2008).
Many immune cells recognise foreign sugars or changes in the glycans of
tumours or dying cells (Marth & Grewal, 2008), for example, the removal
of the capping sugar is a known eat-me signal for macrophages to remove a
dying cell (see subsection 1.2.1).
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1.1.2 Glycosylation is critical for multicellular organisms
Cell-surface glycosylation plays a number of roles. Cell-surface glycans can
mediate cell-cell interactions such as differentiation, cell signalling, contact
inhibition, immune recognition of apoptosis and non-self cells, in addition,
glycosylation is important for both cell-cell adhesion and cell adhesion to
basement membranes, host-pathogen reactions, metastasis and disease de-
velopment (Varki et al., 2009a).
When major glycan classes are knocked out in mice, the phenotype
is lethal during early embryogenesis (Freeze & Schachter, 2009; Furukawa
et al., 2001). In order to overcome embryonic lethality, many research
groups have turned to the Cre-Lox system to selectively knockout glyco-
syltransferases in model organisms. The Marth group have used Cre-Lox
mice to demonstrate the requirement for hybrid N-glycans, but not complex
N-glycans in neuronal development (Ye & Marth, 2004); and the importance
of GlcNAc transferase II on bone, intestinal, neuronal and muscular health
(Wang et al., 2001). O’Donnell et al. (2004) demonstrated the necessity for
OGT for cell function and embryonic development, also using Cre-Lox mice.
1.1.3 Role of glycosylation in disease
Congenital defects of glycosylation (CDGs) result in a number of syndromes
with severe phenotypes that manifest in early childhood affecting nearly ev-
ery organ system (Ungar, 2009; Freeze & Aebi, 2005; Ohtsubo & Marth,
2006). Changes in glycosylation are a common phenotypic alteration found
in cancer cells. In particular the Tn antigen is associated with certain
types of metastatic breast and colon cancers (Ghazarian et al., 2011; Ril-
lahan & Paulson, 2011; Ha¨uselmann & Borsig, 2014). Increased levels of
N-acetylglucosamine (GlcNAc) found in type II diabetes can lead to ele-
vated levels of proteins with O-GlcNAc attached to them and can cause
cardiac dysfunction (Zachara & Hart, 2006; Vosseller et al., 2002).
Mutations in glycosyltransferases may lead to metabolic disorders as-
sociated with inappropriate glycosylation. Not all glycosyltransferases are
seen with mutations, as some are so critical to the organism that the mu-
tations are embryonic lethal. CDGs that relate to N-glycans are divided
into two major classes, Class I where the precursor oligosaccharide is inap-
propriately constructed and not transferred to the glycoprotein, and Class
10
II where the mutations are in downstream glycosyltransferases that mature
the N-glycan in the golgi apparatus (Freeze & Aebi, 2005). Class I patients
still have some residual N-glycosylation that may be due to a leaky pathway,
but a complete absence of N-glycosylation is not seen and is hypothesised
to be embryonic lethal. Mutations in N- and O- glycans and glycolipids
are strongly associated with neurological disorders, with defects seen in de-
velopmental pathways leading to an altered brain structure (Freeze et al.,
2015).
α dystroglycan is a glycoprotein responsible for the attachment of the
cytoskeleton to extracellular laminin in basal membranes. It has been ob-
served that defective glycosylation of dystroglycan can cause muscular dys-
trophies, and mutations in certain glycosyltransferases have been associated
with muscular dystrophy (Yoshida et al., 2001). Under mannosylation of α
dystroglycan destabilises the cell’s interaction with the extracellular matrix,
altered neuronal migration, and reduced stability of muscle fibres (Moremen
et al., 2012).
Cystic fibrosis is characterised by dysregulation in chloride ion channels,
resulting in mucins that contain insufficient salt and are excessively viscous.
In addition, it has been identified that abnormal fucosylation in the mucins
produced by cystic fibrosis patients may cause the increased susceptibility to
airway pathogens (Lazatin et al., 1994; Stoykova et al., 2003). The fucose is
an attractive binding site for many pathogens such as Pseudomona aerugi-
nosa and Burkholderia cepacia, which, combined with the reduced clearance
of mucus, results in increased morbidity for cystic fibrosis patients.
The terminal α 2-6 sialic acids on the surface of cells are recognised
by the haemagglutinin protein on the surface of influenza viruses and are
released by the viruses neuraminidase on infection (Stanley & Cummings,
2009; Gamblin & Skehel, 2010). Many viruses, bacteria and parasites can
recognise sugars on human cell surfaces, Imberty & Varrot (2008) review
the range of sugar structures they can adhere to and the adhesins they use.
Hyper-O-GlcNAcylation of the neuronal tau protein has been impli-
cated in the development of Alzheimer’s disease and subsequent hyper-
phosphorylation (Kanninen et al., 2004; Liu et al., 2002; Wells et al., 2002).
Adult tau protein is generally phosphorylated, with O-GlcNAcylation as-
sociated with infant tau protein and with Alzheimer’s disease. Indeed, the
region of the genome that encodes OGT has been implicated in Alzheimer’s
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disease and other neurological disorders (Wells et al., 2002).
Diabetes is associated with increased O-GlcNAcylation due to excess for-
mation of UPD-GlcNAc as excess glucose is fed into the hexoamine signalling
pathway. UDP-GlcNAc is then used by OGT to O-GlcNAcylate certain
proteins, resulting in their downregulation (Vosseller et al., 2002). Overex-
pression of OGT and consequent hyper-O-GlcNAcylation has been shown
to induce insulin-resistant diabetes in mice (McClain et al., 2002). The
increased O-GlcNAcylation associated with diabetes has also been demon-
strated to damage the mitochondria of heart muscle cells (Hu et al., 2009)
and alter the calcium cycling of heart cells (Clark et al., 2003).
Cancers have been associated with a variety of changes in cell glycosy-
lation, including increased, decreased, truncated, embryonic and generally
aberrant surface glycans. For a review of the effects of altered glycosyla-
tion on tumour metastasis, refer to Ha¨uselmann & Borsig (2014) . Work is
ongoing to develop glycoprotein biomarkers for cancer diagnostics and prog-
nostics, and to identify drug targets based on cell surface glycans or modula-
tion of glycosyltransferases (Dube & Bertozzi, 2005; Ghazarian et al., 2011;
Vasconcelos-dos Santos et al., 2015). Although there is a general trend
towards identifying glycosylation markers for cancer, the often conflicting
studies may mean that this may be ultimately futile as a general cancer
marker (An et al., 2009).
Gene expression of glycosyltransferases in breast cancers was analysed
by Potapenko et al. (2010), who noted that there was great variance in the
mRNA levels. Some glycosyltransferases were up regulated and others down,
altering the cell surface and how it interacts with the tumour microenviron-
ment and immune cells. Malignant and non-malignant tumours could be
clustered, with a small subcluster from normal biopsies was observed that
had upregulation of lectin genes and down regulation of initiators of O- and
N- glycosylation.
Prostate specific antigen is used as a screening marker for prostate cancer
but is also associated with non malignant disease such as benign prostate
hyperplasia. It has been observed that PSA in malignant cases has a higher
rate of fucosylation, and so there is work ongoing to develop this as an
improved diagnostic marker (Dwek et al., 2010).
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1.1.4 Protective functions of glycosylation
Appropriate glycosylation of proteins increases the stability and solubility of
secreted glycoproteins. Glycoproteins that are missing their sialic acid cap
are rapidly sequestered by the liver, thanks to clatherin mediated uptake ini-
tiated by the asialoglycoprotein receptor on hepatocytes (Rigopoulou et al.,
2012). Asialyoglycoprotein receptor is also responsible for the clearance of
activated platelets and vonWillibrand factor in the blood. Insufficiently
sialyated therapeutics such as erythropoietin (EPO) and monoclonal anti-
bodies are also rapidly cleared by this receptor (Liu, 2015; Lee et al., 2012;
Sethuraman & Stadheim, 2006).
Glycosylation is important for host-pathogen interactions. Many mi-
croorganisms use host glycans as anchors. Human milk is abundant in
oligosaccharides, many of which are not digested by the infant gut. Such
oligosaccharides appear to act as decoy molecules, encouraging pathogenic
microorganisms to bind to them instead of the infant’s gut. It has been
demonstrated that human milk oligosaccharides inhibit rotavirus binding
to human cells and porcine guts (Hester et al., 2013); and are effective at
preventing colonisation by Campylobacter jejuni (Sharon, 2006).
Gastric mucins protect against Helicobactor pylori. α 1-4 GlcNAc forms
part of the mucin MUC6 in the deep gastric mucosa, and is taken up by
the H. pylori as if it were glucose. H. pylori then substitutes the glucose in
cholesterol-α-D-glucopyranoside for α1-4 GlcNAc, which, when incorporated
into the cell wall destabilises it and causes the death of the bacterium. It
has also been observed that porcine milk also acts as a therapeutic against
H. pylori due to α1-4 GlcNAc it contains (Gustafsson et al., 2006).
Carbohydrate based vaccines are a possible way to encourage the body to
resist microorganisms, however the low response that is generally acquired
requires the use of adjuvants and peptide backbones in order to generate suf-
ficient immune response (Sharon, 2006; Ghazarian et al., 2011). In principle
vaccinating against the sugars that are specific to bacterial walls or viral
capsids should encourage an immune response that recognises and clears
the microorganisms more rapidly than waiting for a primary response.
Sialyation of the glycans found at the core of the immunoglobulin IgG is
proven to have anti-inflammatory effects (Anthony & Ravetch, 2010). When
large volumes of α 2-6 sialyated IgG were infused, they were found to have
protective effects, although therapeutic infusions of proteins rarely reach
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such volumes.
1.1.5 Glycosylation and therapeutics
Many modern pharmaceutical products are biologics, proteins that are re-
combinantly produced by large volumes of cells in culture. Antibodies in
particular represent a large part of the biologics market, with targets in-
cluding receptors on cancer cells and inflammatory proteins such as TNF-α.
The pharmacodynamics of such drugs is of great interest to the pharma-
ceutical industry and to regulators. Of particular note is the influence of
protein glycosylation on the serum half life of such drugs in the body (Li
& d’Anjou, 2009; Liu, 2015). There is noted heterogeneity in the glyco-
forms of the produced proteins (Butler, 2005) and there has been attempts
at understanding how to control glycosylation to maximise production of
the best glycoform (St. Amand et al., 2014). The glycosylation of other
proteins such as EPO also has a very significant effect on their serum half
life, with researchers attempting to select for production cells that produce
the glycoform of interest (Park et al., 2010; Lee et al., 2012). Hyperglyco-
sylated EPOs have been devised with additional glycosylation sites in order
to increase the molecule’s longevity in the blood (Egrie & Browne, 2001).
Indeed, the necessity to be able to correctly assess glycosylation at all
stages of biologics production is driving glyco-analytical tools (Higgins, 2010;
Wacker et al., 2011). Variations on mass spectrometric techniques (Wagner-
Rousset et al., 2008), including native mass spectrometry (Thompson et al.,
2013), and use of lectins to detect desired end products (Xu et al., 2010).
Lectin affinity chromatography may also play a role in enriching for desired
glycoforms in the final therapeutic product (Keogh et al., 2014).
Cell therapies, including bone marrow transplants, pancreatic islet cell
transplants and red blood cell transfusions require matching of donor and
recipient cell antigens to ensure there is no rejection of the implanted cells.
The ABO blood group glycans are highly antigenic, and much work is fo-
cussed on removing or hiding these antigens.
A number of groups have attempted to use glycosidases to remove the
ABO antigens (Olsson & Clausen, 2008), with Liu et al. (2007) specifically
using bacterial glycosidases. Nacharaju et al. (2005) used PEGylation to
hide the ABO antigens. Although the use of stem cells is at present pro-
hibitively costly and unreliable at producing large quanities of mature red
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blood cells (Douay & Andreu, 2007), Seifinejad et al. (2010) have generated
red blood cells from induced pluripotent stem cells derived from a Bombay
phenotype individual. The Bombay phenotype features a truncated glycan,
where even the base O blood group is not present, and is potentially a useful
starting point for ABO-free red blood cell production.
Platelets are similarly matched for transfusion as red blood cells, but
are more challenging to store. During cold storage β O-GlcNAc is exposed
on the platelet surface, resulting in their rapid clearance after transfusion,
thanks to the asialyoglycoprotein receptor on hepatocytes (Ohto & Nollet,
2011). Attempts have been made to reduce the appearance of β O-GlcNAc
on the platelet surface after cold storage by galactosylating the platelets
(Wandall et al., 2008). Unfortunately, although galactosylation has been
successful in murine models, it does not improve cold storage of human
platelets.
As human sugars can be so different from animal sugars, a major chal-
lenge in xenografts is altering the donor animal so that it does not dis-
play foreign glycans. It was recently published that a pig kidney with an
α galactose knockout was successfully grafted into a baboon for 136 days
(Iwase et al., 2015). The ability to modify pig organs for xenotransplan-
tation would greatly alleviate the pressures on organ transplantation lists,
whether they could be used long term or as bridging organs until a human
organ could become available.
Indeed, the difference in human glycosylation from many animal glyco-
sylations has permitted the development of a test for recombinant human
EPO used as a doping agent in horse racing (Hardy et al., 2010). As the
sialyated human form lasts longer in the blood, it has extended the window
for testing also.
1.2 Apoptosis
Apoptosis is the controlled death of a cell brought about through a num-
ber of proteolytic pathways. It is an important cellular process that is of
great interest to cell biologists. Dysregulation of apoptosis can lead to a
number of diseases. Inhibition of apoptosis is a hallmark of cancer, whereby
aberrant cells do not undergo programmed cell death as they normally do
and instead continue to proliferate. Increased apoptosis can lead to atrophy
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and various wasting diseases including neurodegenerative disorders (Elliott
& Ravichandran, 2010).
Apoptosis is a form of programmed cell death (PCD) that permits cells
to be degraded and cleared by the immune system in a fashion that does not
disturb neighbouring cells. Early apoptotic cells dampen the inflammatory
effect in the nearby area but late apoptotic cells that have not yet been
cleared are pro-inflammatory. The proteins involved in apoptosis have been
long studied, however there has been much less research into the study of
glycosylation changes during apoptosis, some examples include Meesmann
et al. (2010) and Franz et al. (2006).
Apoptosis is characterised by cell shrinkage, blebbing of the cell mem-
brane, exposure of phosphatidyl serine (PS), fragmentation of the nuclear
DNA, and general degradation of the cell contents. The cell is in a perpet-
ual balance between pro-apoptotic factors and anti-apoptotic factors. When
there is a shift towards an excess of pro-apoptotic factors, apoptosis is ini-
tiated. Extrinsic (activated by the death-induced signalling cascade) and
intrinsic (mediated by the mitochondria) pathways share many common
factors, most of which lead to a cascade of proteases called caspases acti-
vating further caspases to degrade the cellular components. Caspases are
abundant in the cell, but are inactive until they are enzymatically cleaved.
Fuchs & Steller (2015) have a comprehensive of review the various modes of
programmed cell death, including apoptosis, and the signals the dying cells
release.
The activation of glycoproteins on the surface of cells by lectins can
induce apoptosis. For example, galectin-1 and galectin-3 binding of the O-
and N-linked glycans on CD45 on T-cells induces apoptosis (Xue et al.,
2013), and jacalin also induces apoptosis in B-cells by binding the glycans
on CD45 (Ma et al., 2009).
Measurement of apoptosis can be carried out by flow cytometry, detect-
ing the appearance of fluorophore labelled PS, often with the pentameric
protein - Annexin-V, and the uptake nuclear stains that are generally ex-
cluded by an intact membrane. Identification of activated caspases can be
performed by western blot or on a microtitre plate using caspase cleavable
substrates. Destabilisation of the mitochondrial membrane is another sign
of apoptosis that can be investigated in the laboratory.
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1.2.1 Glycosylation changes in apoptosis
It has been demonstrated that during late apoptosis, enzymes on the cell sur-
face such as neuraminidase are activated and cleave the terminal sialic acid
caps of membrane bound glycans (Meesmann et al., 2010; Franz et al., 2006).
The removal of the sialic acid caps by cellular sialidases or by treatment
with exogenous neuraminidase exposes sugars such as N-Acetylglucosamine
(GlcNAc) which can then be recognised by macrophages and phagocytosed
(Meesmann et al., 2010).
There are no changes seen in lectin binding in early apoptosis (Franz
et al., 2006) and a decrease in mitochondrial membrane potential precedes
the change in GSL II binding.
An increase in mannose binding, such as with NPL, seems to indicate
the transfer of immature glycans in the ER and Golgi bodies to cell surface.
The transfer endoplasmic reticulum to the cell surface was demonstrated by
Franz et al. (2007) using a dysfunctional immunoglobulin chain that could
not transfer to the cell surface under normal conditions, but was observed
on the cell surface after induction of apoptosis.
1.2.2 Apoptotic bodies have a role in autoimmune disease
Microparticles derived from activated cells and apoptosing cells appear to
have a role in the pathogenesis of autoimmune disease such as Systemic
Lupus Erythamatosus (Pisetsky et al., 2012; Dye et al., 2013; Bilyy et al.,
2012). The microparticles contain nucleic acids and epitopes that are not
normally accessible to the immune system and can stimulate the generation
of autoantibodies. Display of ribosomal and endoplasmic reticulum proteins
on the surface of late apoptotic cells have also been implicated as a cause
of autoimmune disease such as SLE (Sun et al., 1996) and appear to form
sub-populations of apoptotic bodies.
It may be possible to identify late apoptotic bodies and microparticles in
the blood based on their glycosylation pattern using new tools, as it is known
that late apoptotic cells and blebs display desialylated and immature glycans
(Bilyy et al., 2012). By developing better techniques to detect desialyated
blebs, it may be possible to improve the diagnostics of certain autoimmune
diseases.
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1.2.3 B-lymphocytes are a convenient cell for studying apop-
tosis in vitro
B-lymphocytes or B-cells are the cells of the immune system that produce
antibodies. They are produced from haematopoetic stem cells in the bone
marrow, and remain in the marrow to mature. Mature lymphocytes then
migrate to the lymph nodes where they wait until they are activated by
antigen presenting cells. When they are so activated, they clonally expand
and begin to produce antibodies to the antigen that was presented. A small
proportion of the activated B-cells then become long lived memory cells
so they can be reactivated quickly if another encounter with that antigen
happens.
The B-cell receptor (BCR) consists of a heavy chain immunoglobulin
paired with a light chain. The structure of the BCR is very similar to the
antibody that the B-cell will produce if stimulated appropriately. When
B-cells are produced, the gene coding for the BCR binding site is shuﬄed
to produce a range of binding sites across the range of B-cells. The binding
site of the BCR recognises antigen and when it binds the matching antigen,
if given the correct co stimulus, causes the B cell to clonally expand and
produce antibody. In addition, the B-cells will undergo some shuﬄing of
the DNA coding for the binding site of the BCR and undergoes affinity
maturation, whereby a better binding antibody may be produced. (Lebien
& Tedder, 2008)
As the range of antigens the BCR can recognise includes some self-
antigens, mechanisms are required to prevent the B-cells from producing
antigens against the body. Indeed, when such antibodies are produced, the
result is auto-immune disease, where the body’s own tissues are targeted
by the immune system. When antigen is presented by antigen-presenting
cells (APC’s) or presented bound to complement, a co-stimulus of nearby
receptors to the BCR enhances the binding signal for the B-cells to activate.
In the absence of the co-stimulus, the B-cells undergo apoptosis to remove
the self-recognising B-cell from the immune system’s repertoire. As an al-
ternative to apoptosis, some B-cells undergo annergy, where they no longer
can clonally expand but the cell is not induced to die.
The cross-linking of the BCR in the absence of a co-stimulus is therefore
a biologically relevant method of activating apoptosis in B-cells in vitro. As
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the BCR is identical to the IgM immunoglobulin, saving that it has a trans-
membrane domain, anti-IgM antibody can be used to bind and activate the
BCR. As this does not activate the co-receptors on binding the BCR, the cell
undergoes apoptosis. B-cells at different stages of maturation appear to un-
dergo apoptosis and anergy through various mechanisms (Eeva & Pelkonen,
2004; Lebien & Tedder, 2008).
Ramos is a Burkitt’s lymphoma cell line that undergoes apoptosis after
anti-IgM cross-linking of the BCR. The cross-linking of the BCR initiates
the intrinsic apoptotic pathway by causing mitochondrial destabilisation
through the incorporation of excess ceramide in the mitochondrial mem-
brane, and thus activating downstream effector caspases (Eeva & Pelkonen,
2004; Kroesen et al., 2001).
1.3 Current methods for the detection of glycosy-
lation
Detection, localisation and understanding the structure of glycans is cru-
cial to understanding the role of glycans in cellular pathways. Due to the
possible combinations of sugars in multiple orientations that can make up
glycan structures, the glycome is massively more complex than the genome
or proteome, where the respective subunits can only be joined up in a linear
fashion (Bertozzi & Sasisekharan, 2009). Furthermore, the glycome appears
to be even more dynamic than genome or proteome, with multiple isoforms
of glycans found within apparently homogeneous cell populations. As the
predictive power of computational glycomics is limited, it is crucial that
accurate measurements of glycosylation are carried out in order to build
databases that allow scientists to understand the role of glycosylation in
relation to the proteome and genome.
Crude identification of glycosylation can be carried out using Periodic
Acid Schiff (PAS) labelling of SDS-PAGE gels or tissue samples. The stain
does not provide information on the nature of the glycosylation, but does
allow general detection of glycans and localisation on gels and tissue sections.
Lectins are carbohydrate binding proteins that recognise specific sugar
groups, but have no enzymatic activity. Commercially available lectins are
generally derived from plants, where they act as toxins to deter predators
(Vandenborre et al., 2011). Proteins with carbohydrate binding proper-
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ties are also found in mammals, including selectins, galectins and mannose
binding lectin and have roles in cell adhesion and immune recognition (Varki
et al., 2009a). Proteins such as HSP-70 have lectin-like properties as they
can detect glycosylation changes on other proteins (Guinez et al., 2004).
Prokaryotes also have carbohydrate binding proteins that are important
pathogenic mechanisms for attaching to host cells. The Irish Separation
Science Cluster has taken advantage of such proteins to create novel tools
for probing glycans.
Identifying key groups on a glycoprotein using lectins can offer a simpler
method than using mass spectrometry to identify the glycans as the specifici-
ties of commercial lectins are well characterised. Labelled lectins have been
used to stain cells for microscopy and flow cytometry (Varki et al., 2009a;
Roth, 2011; Wang et al., 2008) or to detect glycosylation on glycoproteins
by enzyme linked lectin assay (ELLA) (Gornik & Lauc, 2007; Thompson
et al., 2011). Lectins can also be used to create microarrays for detection
of glycoproteins in solution or on cells (Li et al., 2011; Rillahan & Paulson,
2011).
Although not as straightforward to study as glycoproteins, glycolipids
are also analysed for their glycan structures. It is possible to separate lipids
using thin layer chromatography and to blot these onto a membrane to
probe with lectins in the same fashion as western blotted proteins (Taki
et al., 1994).
Metabolic labelling with radio-labelled sugars may be performed, to iden-
tify where sugars are incorporated into glycan structures, their turn over,
and localisation in the cell (Mulloy et al., 2009). Fluorescence Assisted Car-
bohydrate Electrophoresis is an alternative to radio labelling, where easily
tagged sugars are given to the cells to metabolise and are then fluorescently
labelled after extraction prior to electrophoresis (Gao & Lehrman, 2006).
1.3.1 Mass spectrometry
Mass spectrometry can provide a great deal of information about protein
and peptide sequences, and can also be used to identify glycan structures.
The challenge, however, is performing both of these analyses, allowing infor-
mation about the peptide to be tied with its related glycan (Nilsson et al.,
2013). Mass spectrometry requires specialist training, access to equipment,
and requires very careful sample preparation.
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There are a number of strategies employed to study the glycoproteome
using mass spectrometry. Generally an enrichment is performed, by chemical
or lectin chromatography, followed by mass spectrometric analysis. Enrich-
ment by lectin pull-down columns relies on lectin affinity for the glycopro-
teins of interest, and can be problematic where lectins have multiple binding
specificities and can bind a non carbohydrate ligand (Nilsson et al., 2013),
for example, Annexin V is a known binder of phophatidyl serine but also
recognises bisecting GlcNAc (Gao et al., 2005). Chemical methods rely on
binding specific glycans, in particular, a lot of work has been carried out on
the chemical capture of sialic acid bearing glycans. These glycans are held
covalently to beads, and can be washed well and digested prior to elution
by means of a mild acid wash to break the sialic acid from the rest of the
glycopeptide. The released glycopeptides can be analysed by standard mass
spectrometric methods.
It is preferable to use Electron Transfer Dissociation (ETD) or Fast Atom
Bombardment (FAB) methods to ionise the glycopeptides for mass spectro-
metric analysis, as the more common method of Collision Induced Dissocia-
tion (CID) breaks the bond between glycan and peptide, losing localisation
data (Mulloy et al., 2009; Nilsson et al., 2013). ETD and FAB are regarded
as ”soft” fragmentation methods that leave the peptides in relatively in-
tact charged chunks, and so post translational modifications are more likely
to remain intact. However, ETD and FAB are usually upgrade ionisation
methods for standard mass spectrometers, and are so not always available.
PNGase-F is an enzyme that cleaves N-glycans from their peptide back-
bone, and permits separation of glycan and peptide for analysis. Unfor-
tunately, although N-glycans and their originating peptides can be easily
identified with various LC-MS protocols, it is challenging to associate the
specific glycans with their location on the glycoprotein itself (Nilsson et al.,
2013).
Localisation of O-linked glycans can be performed through beta-elimination
followed by Michael addition of DTT (BEMAD). The DTT link to the pep-
tide backbone is stable, and the added DTT is of known mass, allowing rela-
tively straight forward identification of the sites of O-linked glycan binding.
Although BEMAD offers localisation data, the glycan is lost during sam-
ple preparation and its structure cannot be correlated with its site on the
peptide (Banerjee et al., 2013; Mulloy et al., 2009).
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Furthermore, mass spectrometry techniques are primarily performed on
purified proteins or bulk lysates, offering no resolution at the single cell
level. Although a number of single cell mass spectrometry techniques are
being developed, thanks to advances in capillary electrophoresis and mi-
crofluidics, they are not yet suitable for such complex samples and analyses
as glycobiology requires (Mellors et al., 2010; Yin & Marshall, 2012; Simone,
2014).
1.3.2 Currently available carbohydrate binding proteins
Although lectins were first identified in 1888, there was no great interest in
them until their usefulness in ABO blood typing was realised in the early
20th Century (Varki et al., 2009b). Lectin is derived from ”legere” meaning
”to select”, and lectins are very selective in their binding of carbohydrates.
Lectins are defined by their carbohydrate binding activity, and it is possible
to inhibit the binding of lectins with sugars. Enzymes with carbohydrate
binding abilities are not lectins. Many lectins appear to have defence func-
tions in plants, discouraging animals from grazing on them.
The availability of pure, reliable plant lectins has catapulted the field
of glycobiology into the modern era (Cummings & Etzler, 2009). This en-
abled a range of techniques, from agglutination assays to western blot style
detections to be performed to identify the presence of particular glycans on
a protein or cell. Lectins are largely classed based on their origins and the
familys of sugars they bind.
At present, the majority of commercially available carbohydrate binding
proteins are lectins that are purified from plant sources. This process is time
consuming and expensive. Thanks to modern manufacturing methods, batch
to batch variation is rarely an issue, and many lectins can be purchased with
useful modifications such as biotin or dye labels, or conjugated to agarose
beads for purification purposes.
Lectins are usually low affinity binders with their dissociation rate con-
stants (Kd) ranging from 10−4 to 10−7 mol−1 s−1. However, lectins are
generally multimeric, with multiple glycan binding sites, and it is this avid-
ity that gives lectins their binding strength. It is this avidity that also makes
lectins better at binding proteins and cells than free sugars, in particular on
cell surfaces where glycoproteins are often found in clusters (Varki et al.,
2009b). When a lectin has bound to a glycoprotein on a cell or blot, it
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can have multiple binding partners, requiring a high concentration of free
sugars to overcome mass transport effects in order to compete at the bind-
ing sites that can be blocked by the lectin. Inhibition of lectins with free
sugars before binding is a common way to demonstrate specificity, as this
also shows that it is only the binding site of the lectin that is involved in
the binding process and not affinity for other parts of the lectin structure.
Use of larger haptens such as compound sugars or purified glycoproteins can
help interfere with lectin binding at a lower concentration than that of the
corresponding free sugar as they more closely represent the more complex
ligands the lectin prefers to bind.
A number of anti-glycan antibodies are also available but rarely achieve
the exquisite specificities of lectins. Anti-glycan antibodies have a high
binding affinity compared with lectins (Gemeiner et al., 2009). Raising anti-
glycan antibodies is challenging, and inoculating an animal with a glycopro-
tein generally causes antibodies to be produced against the protein epitopes
or glycan-protein epitopes rather than the glycan itself. In addition, as gly-
cosylation is so critical to all multi cellular organisms, it is difficult to get
an animal to raise antibodies against self antigens, including common gly-
cans. Examples of anti-glycan antibodies in humans include those against
the ABO blood group, and α-galactose which causes a red meat allergy
(Apostolovic et al., 2015).
Antibodies against glycans are often raised against a glycan-epitope and
are often specific to a limited number of glycoproteins, missing other forms
of the same glycan that are bound to a different protein.
In principle, where antibodies have been raised, it should be possible
to mutate the antigen recognition site of the antibody and perform rounds
of panning to find the optimum binder, however in practise this is a time
consuming procedure that may not produce the desired results.
1.3.3 Current uses of carbohydrate binding proteins to de-
tect cellular glycoproteins
Lectins are used for a range of methods for detecting glycoproteins both on
cells and in lysates. Flow cytometry can be carried out on large populations
of single cells using a fluorophore conjugated lectin to detect the presence
of lectins on the cell surface (Varki et al., 2009a). Lectins can also be used
for microscopy, whether fluorescence or immunohistochemical (Wang et al.,
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2008). This permits visual localisation of the glycans that the lectin binds.
Lectins are a useful tool in the histological identification of some cancers as
changes in the display of certain glycans is associated with malignant change
(Roth, 2011).
Micro arrays are useful for identifying glycoproteins in lysates or pro-
teinaceous samples such as serum. The protein mixture is stained with a
non-specific fluorescent protein dye, then flowed over the array, and detec-
tion of binding is carried out on a specialised reader(Zheng et al., 2005).
Alternatively, the sample is adhered to the surface or otherwise captured,
and fluorescently labelled lectin is used to bind the analyte (Zhao et al., 2007;
Gemeiner et al., 2009). Antibody sandwich assays are a form of microar-
ray where the glycoprotein is caputured on an antibody array and probed
with a lectin (Yue & Haab, 2009). Further advances in microarray detec-
tion include the use of evanescent field fluorescence-assisted measurements
that allow such sensitive measurements that on-off rates can be calculated
on the arrays (Kuno et al., 2005). While microarray data has allowed great
advances in the field of glycoproteomics (Hirabayashi et al., 2013; Rillahan
& Paulson, 2011), it relies on the measurement of bulk lysates and does
not have single cell resolution. Diffusion blotting against microarrays of
lectins can allow high-throughput analysis of multiple glycoforms of range
of proteins on an SDS-PAGE gel in a single assay (Etxebarria et al., 2012).
Cell capture with microarrays is challenging, as the shear force between
the large cell and the small capture area of the lectin array makes it difficult
to retain the cells at the spot for measurement (Li et al., 2011). Cell capture
with microarrays is possible (Zheng et al., 2005), but due to the nature of
microarrays, only a small number of cells can be interrogated at any time
for a particular glycan.
The Enzyme Linked ImmunoSorbent Assay (ELISA) is a common tool
for quantification of proteins, and the lectin equivalent, the enzyme linked
lectin assay (ELLA) is a useful way to quantify glycoproteins (Gornik &
Lauc, 2007; Thompson et al., 2011). The ELLA, like the ELISA, can be
performed in a variety of modes, from competitive inhibition to sandwich
style assay. The sample can be adsorbed to a microtitre plate, probed with
lectin and an enzyme labelled secondary antibody with matching substrate
used to generate signal. Likewise, where a lectin is bound to the surface,
an antibody against the glycoprotein of interest can be used to detect if the
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lectin has captured the glycoprotein.
By mounting lectins on beads or similar surfaces, lectins can be used to
separate out particular glycoproteins which can then be eluted and analysed
further (Alwael et al., 2011; Hirabayashi, 2008).
Lectins have been used as a probe for western blots (Freeze, 2001),
whereby the lectin takes the place of a primary antibody. Blotting is a
common technique in biology laboratories, and blotting with lectins is a
straightforward way to begin glycobiological analysis of proteins of interest.
By combining a variety of lectins with various enzymatic digestions of the
glycans being probed, a great deal of information on the likely structure of
a glycoprotein can be elucidated, which can further guide the choice of mass
spectrometry technique for complete identification. Furthermore, changes
of lectin binding between samples can give insights into the impact gly-
cosylation may have on the pathway under investigation. Like traditional
blotting, blocking of the membrane must be considered, the use of glycan
free blocking solutions is critical, with the polymer polyvinylalcohol (PVA)
and gelatine being useful agents.
1.4 Recombinant lectins as novel carbohydrate bind-
ing probes
Lectins are ubiquitous in nature and have been identified in all kingdoms
of organisms. Traditionally plant lectins have been the most widely studied
and by far the most common type of lectin used commercially. However,
plant lectins are, for the most part, not amenable to recombinant produc-
tion as they are often multimeric and glycosylated. More recent research
into lectins from non-plant sources, such as prokaryotic, fungal and animal
lectins, has yielded new lectin sources that are amenable to being recom-
binantly produced as alternative carbohydrate binding proteins (Oliveira
et al., 2012; Lam & Ng, 2011).
The production of recombinant lectins serves a number of functions.
Mutations of the binding site can allow identification of key amino acid
residues for ligand recognition, expression in non-plant vectors can be used
to see what post translational modifications are critical for lectin activity,
and purification of protein for crystallography can be performed (Streicher &
Sharon, 2003). As yields of plant lectins can be quite high from the amount
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of source material, purification is the primary method of production rather
than using recombinant sources (Lam & Ng, 2011).
The yields from non-plant sources of lectins can be quite poor when di-
rectly purified, and so cloning into an alternative expression vector should al-
low for production of useful amounts of protein (Lam & Ng, 2011; Gemeiner
et al., 2009). Furthermore, as many plant lectins are glycosylated, they can
interfere with the detection of the sample glycosylation by giving high back-
ground due to self recongition, it is hoped that non glycosylated prokaryotic
proteins could be a useful alternative for glycoanalysis (Arnaud et al., 2013;
Keogh et al., 2014; Vanderschaeghe et al., 2010).
GafD is a prokaryotic carbohydrate binding protein from E. coli ’s fim-
brial adhesin complex that recognises β terminal N-Acetylglucosamine (Glc-
NAc) (Saarela et al., 1996; Merckel et al., 2003). GafD is part of a larger
fimbrial complex that contains other carbohydrate binding proteins that are
important for bacterial attachment to a host’s surfaces. In particular, GafD
was isolated from pyelonephritogenic E. coli that causes rare urinary tract
infections. GafD permits the E. coli to bind to the basement membrane
protein laminin, which has many GlcNAc units exposed.
The isolation of the GlcNAc specific AAL-2 protein from the dried fruit-
ing bodies of the mushroom Agrocybe aegerita was first reported by Jiang
et al. (2012). It has terminal non-reducing GlcNAc specificity, similar to
that of the plant lectin GSL II, and has been demonstrated to have a higher
binding affinity than GSL II and has the advantage of being metal-ion in-
dependent (Jiang et al., 2012).
1.4.1 Advantage of recombinant lectins over commercially
available lectins
Production of recombinant lectins has many benefits over purification from
plant sources (Gemeiner et al., 2009). Purification of plant lectins , us-
ing conventional purification protocols, has also yielded significant batch-
to-batch variation in the performance of the commercial plant lectins. Re-
combinant production of lectins yields consistent batches of proteins thus
eliminating the batch to batch variation that has limited the use of com-
mercial plant lectins to date. Recombinant lectins can be further refined
through directed mutagenesis of the binding site and general lectin struc-
ture. This gives the potential to generate a library or array of related lectins
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with slightly altered affinities or even specificities. It is possible to engineer
in multivalency to recombinant lectins to improve binding through increased
avidity (Arnaud et al., 2013).
The addition of linkers permits further labelling methods such as the
addition of lysine groups for conjugation of small molecules such as biotin
using N-Hydroxysuccinimide (NHS) chemistry, or the direct attachment of
fluorescent proteins such as GFP, RFP or dsRed. Furthermore, the purifi-
cation tag of the protein can also be targeted with, for example, anti-his
antibodies, allowing detection without the need for direct labelling. The
process of purification from plant extracts can be much more complex and
time consuming than than using affinity purifications such as nickel-NTA
(Lam & Ng, 2011; Keogh et al., 2014).
As prokaryotic lectins tend to be smaller and monomeric, some can be
less toxic than the larger multi-meric plant lectins which can cross-link cell
surface receptors and induce cellular change (Data not published, O’Connor
lab). Their smaller size can allow multiple binding sites across a cell surface
with no steric hindrance, and as each individual prokaryotic lectin is labelled,
can give an increased signal across the cell.
Due to their low affinity, generating lectins through phage-display is
challenging as the displaying-bacteria do not bind strongly to the substrate
(Streicher & Sharon, 2003).
1.5 Isolation of cell surface proteins
A number of methods exist for the fractionation of cells for further analysis
(Smith, 2011). Of particular interest is the plasma membrane, as this is
the main point of interaction of a cell with its surroundings. Mature N-
and O-glycans are found predominantly on the outer cell membrane, while
O-GlcNAc is found interior to the cell. Fractionation permits the removal of
cytosolic proteins and organelles that may display immature glycans or that
might mask an investigation into surface proteins. It may be more worth-
while to examine outer membrane proteins when investigating findings from
flow cytometry, as this is generally all that is labelled in such experiments.
It is estimated that more than 30 % of expressed human proteins are mem-
brane bound, however only 1 in 100 of the structures deposited in the Protein
Data Bank are membrane proteins (Walian et al., 2004).
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Fractionation by ultracentrifugation is a common method. Cells are
mechanically lysed through a narrow gap, whether by the tiny bore of a
high gauge needle or by a Dounce homogeniser. The organelles and unlysed
cells are pelleted, and the finely shredded plasma membrane should exist
as micelles in the supernatant. The supernatant is then ultracentrifuged to
pellet the plasma membrane micelles which can be disrupted with detergent
to release the plasma membrane proteins. The fractionation can also take
place using discrete sucrose concentrations to collect the membrane micelles
at the interface.
Solvent isolation of the plasma membrane proteins can be carried out
after crude separation of the membrane from the cytoplasm and organelles
(Smith, 2011). Such extraction, using butanol for example, relies on the
hydrophobic solvent dispersing the lipids of the plasma membrane and the
released protein moving to the polar phase. Phase extraction can also be
carried out using detergents with cloud points at low temperatures such as
Triton-X114 (Arnold & Linke, 2008).
Kits based on surface biotinylation also allow membrane isolation with-
out complex equipment (Jang & Hanash, 2003; DeBlaquiere & Burgess,
1999). A sulfo-NHS-biotin is used to label exposed lysines from the surface
of live cells as it is not water soluble and cannot enter the intracellular com-
partment through the intact cell membrane. The biotin can then be pulled
down by a streptavidin bound to beads, and after washing the protein can
be cleaved from the linker and examined. This method relies on the surface
proteins having labellable side groups that are exposed to the environment
and may not label all surface proteins.
Another common method relies on WGA affinity columns (Ghosh et al.,
2004; Lin & Guidotti, 2009). As glycans are generally a feature of extracellu-
lar proteins, the WGA affinity column pulls out any GlcNAc bearing proteins
which can then be eluted for analysis. Drawbacks of this approach include
missing any proteins that do not contain GlcNAc and possible collection of
immature proteins that have been glycosylated but not yet transported to
the cell surface. Furthermore, enrichment of GlcNAc bearing proteins can
influence later analysis of glycosylation to be biased towards GlcNAcylated
proteins.
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1.6 Flow cytometry for single cell interrogation
Flow cytometry is a powerful technique capable of analysing thousands of
cells per second. Cells are hydrodynamically focussed to pass through an
optical detection system in single file. Lasers excite any fluorescent stains in
or on the cells and this fluorescent signal is captured per cell. In addition,
the amount of laser light that passes around the cell is collected as “forward
scatter” and is roughly correlated with cell size. Light scattering at 90 ◦is
collected as “side scatter” and this refraction roughly correlated to the in-
ternal complexity of the cell. By collecting fluorophore, forward and side
scatter data on each cell, a large volume of data about cell populations can
be gathered rapidly. By collecting sufficient cell numbers, rare events can be
studied with necessary statistical power. Many flow cytometers are also cell
sorters and can electrostatically sort hundreds of cells per second into collec-
tion tubes or well plates. Flow cytometry is used in a range of research and
clinical applications, from identifying apoptotic cells to monitoring residual
disease in leukaemia. (
1.6.1 Principles of flow cytometry
Flow cytometry is used to measure populations of particles in suspension,
generally mammalian cells, but sometimes micro-vesicles, bacteria or viruses.
Samples can be stained with fluorophore labelled antibodies or lectins, stained
with DNA dyes that fluoresce on intercalation between base pairs, can con-
tain native pigments such as chlorophyll (Dubelaar et al., 1999) or recom-
binant fluorescent proteins such as green fluorescent protein (GFP), or be
unstained and rely on the autofluorescence and scattering properties of the
cell.
Samples are aspirated by direct pumping or by increasing the air pressure
above the sample and therefore pushing it up a loading capillary. Direct
pumping allows volumetric measurements to be made and along with cell
count, cell concentration can be calculated. Air pressure driven flow does
not have accurate volumetric information, but cell concentration can be
calculated by adding a known volume of calibrated counting beads to the
sample.
The sample is focussed into the centre of the fluidic channels by hydro-
dynamic focussing. Sheath fluid is injected at high speed into a channel and
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Figure 1.4: Schematic of a flow cytometer. Cells are focused in a sheath fluid
and pass a laser, one by one. Each cell has its fluorescent signal and optical prop-
erties measured. The light emitted and refracted by the cell passes through a series
of dichroic mirrors and band pass filters to be detected by photo multiplier tubes.
Image ”Flow cytometer” by Kierano, downloaded from WikiMedia.org 26/11/2015
the sample is injected into the core of this stream at a lower flow rate. The
particles in the sample tend towards the centre of the stream, and the dis-
tance between the particles increases, such that the particles are travelling
in single file at the core of the fluidics. There is little mixing between the
sheath fluid and the sample. Generally much larger volumes of sheath fluid
in relation to sample volume are required (Austin Suthanthiraraj & Graves,
2013).
Alternatives to hydrodynamic focussing allow the user to reduce fluid
waste. Acoustic focussing can be used instead of or in addition to hydrody-
namic focussing (Ward et al., 2009). Acoustic focussing uses sound-waves
to centre the particles in the fluid stream. Some systems, such as the Milli-
pore Guava are sheathless, where the sample is focussed through the fluidics
having a very narrow diameter. The Guava also has the possibility to mag-
netically focus cells where they have been stained with a magnetic dye (Huh
et al., 2005).
Excitation of fluorophores is carried out by lasers, with cytometers hav-
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ing from one to four lasers on board. Many instruments, especially older
instruments, have air-cooled gas lasers whereas newer instruments use solid
state lasers that permit a smaller footprint and lower energy usage (Shapiro
& Telford, 2009). Some older instruments may be retrofitted with solid state
lasers as their gas lasers need replacing.
Laser light is directed at the centre of the focussed stream of particles
travelling through the flow cell and the emitted light is collected and diverted
to the detector array via fibre optic cables. Optical detection is generally
carried out by passing the emitted light through a series of dichroic mirrors
and filters to separate the light into discrete bands on to photomultiplier
tubes (PMT). The collected light can be fluorescent emissions or light that
is scattered due to the optical properties of the cell. The voltage across
the PMTs can be adjusted to change their sensitivity, but there is always
background noise at the low end of the signal (Wood, 2009). As there is often
spectral bleed-over between dyes used, it is usual to perform compensation
to remove the contribution of dyes into neighbouring channels.
Sony, in their SP-6800 spectral cytometer, use a series of prisms to direct
the captured light on to a series of 32 PMTs, collecting the entire spectral
emission rather than discrete bands as obtained with filters. They then per-
form spectral deconvolution to identify the signal contributed by individual
fluorophores. Although this technology is not yet able to process signals
fast enough for cell sorting, it provides a lot more spectral information for
autofluorescence than traditional filter based cytometers.
Removing the need for discrimination of fluorophores, mass cytometry
relies on heavy metal isotopes as antibody labels and uses time of flight mass
spectrometry to detect the tags (Bandura, 2009). Fluidigm’s Helios CyToF
has the capability of measuring in 135 channels and requires new ways to
analyse such potentially large datasets. As the cells are atomised to release
the heavy metal tags, it is not possible to recover the cells after analysis.
Image cytometry permits micrographs of cells to be taken instead of
simply measuring fluorescence signal of the cells. Examples include the
Fluid-SPIM (Gualda et al., 2015), an open source single plane illumination
microscope with a flow-cell for imaging cell clusters and zebrafish embryos;
and Millipore’s ImageStream which takes high-speed images of thousands
of cells per minute at a moderate magnification. Image analysis coupled
with fluidics can permit high throughput screening of cell populations and
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provides a great deal of data for analysis. Such high throughput techniques
requires robust software capable of unsupervised analysis of the images ob-
tained.
Microfluidics for cytometry is an emerging field, using miniaturised flu-
idics and detection systems while attempting to approach the high through-
put of typical flow cytometry. Few are in current commercial use, with the
Sony SH800 being a notable example as it features a disposable microfluidic
cuvette that can be easily replaced after clogs or dirty samples (Piyasena
& Graves, 2014), although the analyser itself occupies a similar footprint to
other cell sorters. For a review of microfluidics in flow cytometry, Piyasena
& Graves (2014) focus on the emerging applications of microfluidics to mod-
ern flow cytometry, where Huh et al. (2005) review microfluidics are they
are currently integrated into flow cytometry devices.
1.6.2 Analysis of flow cytometric data
The power of flow cytometry lies in its ability to generate large amounts of
data rapidly. The bare minimum data set contains 10,000 events with at
least two parameters of forward and side scatter each, but often they can
be hundreds of thousands of events with multiple fluorescent parameters
in addition to the scatter measurements. Although a sample may contain
thousands of data points, it is but a single replicate, and care must be taken
not to overinterpret single results. Indeed, the International Society for the
Advancement of Cytometry recommends minimum information that should
be deposited with flow cytometry publications to ensure the data is robust
and appropriately interpreted (Lee et al., 2008)
Samples are generally analysed as single parameters or on bivariate plots.
Fluorescence signal is compared to the unstained levels to identify back-
ground from signal. Forward scatter against side scatter can be used to
screen out debris and as a crude way to identify populations. Populations
can be selected on histograms or scatter plots and analysed as a subpop-
ulation. This generation of subpopulations based on relationships between
parameters is called gating, and is usually performed in a sequential manner
until the population of interest is fully characterised and identified. Removal
of debris, doublet cells and, in many cases, dead cells is an important part
of the data refinement and should be a clear part of the gating strategy.
As the number of measurable parameters is increasing, new techniques
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to handle the data are required. A variety of supervised and unsupervised
multivariate analyses have been devised in recent years. Lugli et al. (2010)
present a review covering the pro’s and con’s of SPICE (Simplified Presenta-
tion of Incredibly Complex Evaluations) and principal component analysis,
which are two of the most used methods in use for multivariate flow cytom-
etry analysis.
1.6.3 Applications of flow cytometry
Flow cytometry has made a major impact in clinical haematology laborato-
ries where it is used for diagnosis and monitoring of haematological diseases
such a leukaemias and paroxysmal nocturnal haemoglobinuria, monitoring
CD4+ count of HIV positive patients, identification of foetal-maternal haem-
orrhage, and enumerating CD34+ stem cells in stem cell transplants. Stan-
dardisation of measurements on the flow cytometers of haematology labs is
led by the EuroFlow consortium and various EQA labs such as UK-NEQAS.
In the research laboratory, flow cytometry is used for characterisation of
cells, bacteria and microvesicles. Immunophenotyping, investigation of cell
death, cell cycle analysis, and sorting of cell subsets are but a few examples
of the application of flow cytometry in the research laboratory. western blot
for example. Many flow cytometers are also cell sorters and can be used to
isolate cells for subculturing, or selecting subpopulations for further analysis
by western blot for example.
Apoptotic cells are characterised by a decreasing forward scatter due
to cell shrinkage, increasing side scatter due to condensation of cellular or-
ganelles, and the binding of fluorophore labelled annexin-V which binds the
phosphotidyl serine that becomes exposed on the apoptotic cells (van En-
geland et al., 1998). Late apoptosis is characterised by also taking up a
fluorescent nuclear stain that should be excluded by an intact membrane.
An increase in debris is also usually observed.
Surface glycosylation may also be measured using flow cytometry. Using
fluorophore labelled lectins, it is possible to probe the cell surface for the
presence of particular glycan structures. By selecting an appropriate fluo-
rophore, labelled lectins can be combined with a range of other cytomet-
ric stains. Lectins have been used with cytometry to investigate apoptosis
(Batisse et al., 2004; Meesmann et al., 2010; Heyder et al., 2003; Franz et al.,
2006) and cancer (Bergmann et al., 1998; Arndt et al., 2011; Wang et al.,
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2009).
1.7 Microfluidic platforms for single cell interro-
gation
Microfluidic devices typically have at least one dimension in the sub-100
µm range. This allows close control over the system as the liquid flow
is predictably laminar. In addition, the small size of microfluidic systems
allows scale down of reagents used in experiments, greatly reducing costs.
Devices can be made optically transparent with structures to mix, measure,
and meter liquids as well as trap particles such as cells. Microfluidic devices
generally have scope for parallelisation for multiplexing and high throughput
analyses.
Liquid handling for microfluidics requires control over the flow rate
through passive or active pumping, and direction of the fluid through chan-
nel geometries and valving. Pumping can be carried out directly using sy-
ringe pumps, by relying on centrifugal force or by relying on the liquid
height in a reservoir to form a pressure head. Valving can present a chal-
lenge, whether to use passive single use valves or active valves that can be
actuated again and again, although some devices for single cell analysis use
valving many use unvalved systems (Roman et al., 2006; Huh et al., 2005).
Further considerations include the materials for manufacturing the device,
the fluid itself and how it interacts with the cells and the device surfaces,
how long the assay will be carried out, and how the cells will be studied.
For single cell analysis, the geometries used to capture the cells are of
particular interest. Some geometries allow detailed probing of large numbers
of cells while other systems are limited in cell number or in how they can be
assayed. A variety of geometries are discussed here, with Lab in a Trench
specifically expanded on in section 3.1.
Rowat et al. (2009) presented a device that allows for the trapping of
single cells in a linear channel designed to monitor single cells as they divide
and multiply. The device allows for medium term culture and monitoring
of cells, and later staining of the cells for analysis.
An elegant design to capture two different cell types for fusion studies
was devised by Skelley et al. (2009) based on flowing cell into cup shaped
traps. By capturing the cells in a shallow trap, then reversing the flow, the
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cells are transferred into a deeper trap, ensuring a single cell per deep trap.
The secondary cells are then flowed into the system to fall into the deep traps
directly and allowed to fuse with the cells for production of hybridomas.
Another cup based method for single cell capture is the centrifugal V-cup
array presented by Burger et al. (2015, 2012). The advantages of centrifugal
microfluidics is that all fluidic flow is controlled by the rotation of the disc,
and therefore requires no intervention beyond changing spin speeds. The
cups are oriented axially, so the settling force on the cells is due to the
centrifugal force of the spinning disc. As the capture chamber is primed with
fluid before cell capture, shear forces on the cells can be better controlled.
The cups are scaled to fit single cells, to reduce the capture of multiple cells
in the cups. A further addition of optical tweezers (Burger et al., 2015)
increases the flexibility of this device by allowing selective manipulation of
cells, and their transfer to a side chamber for potential downstream analysis.
Lin et al. (2013) present a system based on sieve traps with side pillars to
maximise trapping of cells in the sieves. Not only are the cells trapped in the
sieve, but one side of the device is micropatterned with adhesive patches for
the cells to adhere to and grow. As the spaces between the micropatterning
are made of non-fouling materials, stray cells cannot adhere outside of the
defined micropatterns. The microfluidic traps can be removed, leaving the
cells growing on their designated patches. This system allows for tracking
of cells that are grown on specifically defined adherent patches.
Microwell traps for single cells come in a variety of formats. Kobel et al.
(2010) trap cells in microwell divots in the sidewall of long channels, where
the cells are retained by the pressure differential between the fluid flow on
either side of the divot. A limitation with Kobel’s device is that the area
required to capture a single cell means that it is not possible to have many
cells located under the microscope objective at the same time. Carlo et al.
(2006) captured HeLa cells in an array of microwells, and observed their
growth in relation to the shear stress on the system, noting that when the
cells divided, the daughter cells also remained trapped in the wells. Cao
et al. (Cao et al., 2015) use microarrays of wells for single cell trapping
of cells, where the cells flowed into the device and allowed to settle into
the microwells. The trapped cells can be further probed, for example for
their extracellular glycans. Park et al. (2010) employ settling to fill their
microarrays also, but their system is open, so the cells are allowed to settle
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from a droplet on top. The open array allows probing of the cell supernatent
with an antibody-conjugated membrane, which can then be used to identify
cells to pick out and subculture.
Pillar arrays have been used to capture cells with antibodies (Nagrath
et al., 2007; Vickers et al., 2011) and with lectins (Vickers et al., 2011).
The cells are forces through convoluted paths and interact with the pillars,
binding where the cell has the appropriate ligand for the capture molecule.
As lectins have poor affinity, the lectin capture pillars were demonstrated to
be not as effective as the antibody pillars.
Using an acoustic field with a wavelength on the same order as the cell
size, Collins et al. (2015) were able to distribute single cells across a plane,
with the ability to keep cells in position while media is exchanged or the
cells are washed. The single cell array can thus be stained and analysed,
and the device is reusable, which is unusual for many lab on a chip devices.
Droplet microfluidics involves encapsulating cells or reagents in aqueous
droplets and transporting them in an oil-based carrier liquid. Single cells
can be trapped in the droplets and merged with droplets containing reagents
to study them. Droplet microfluidics enables relatively easy sorting of the
droplets for recovery afterwards. A summary of the state of droplet microflu-
idics by Guo et al. (2012) covers a number of high throughput applications,
including drug screening, antibody generation and virally infecting cells.
These various microfluidic devices for single cell analysis have advan-
tages and disadvantages. Recovery of cells of interest is not practical from
the acoustic set-up or linear traps, and can be challenging from cup based
systems. Droplet microfluidics allows cell recovery, but as a population of
droplets. Most microfluidic set ups are based on light and epi-fluorescent
microscopy, which for some geometries limits the high throughput capabil-
ities that are often portrayed as a benefit of microfluidics. Microwells and
cup arrays generally allow multiple cells in the field of view of microscopes
at low to moderate magnifications. Microwell arrays and some cup-based
arrays are well suited to multiply probing cells with a variety of probes,
whereas droplet fluidics only permit the summed addition of reagents.
Microfluidic devices are often designed as disposable, made from rela-
tively cheap materials. PDMS is a common material for making microflu-
idic devices in an academic setting as it is easy to use for rapid prototyping
purposes and for casting devices with high aspect ratios. PDMS is how-
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ever, impractical for scaled-up production, not ideal for cell culture, and
hydrophobic (Berthier et al., 2012). In some cases, it may be possible to
manufacture the devices by hot embossing or injection moulding thermo-
plastics such as PMMA, techniques which allow for scale up but can be
beyond the scope of the academic laboratory. Other devices that are made
from materials such as SU-8 on silicon are generally reusable, as the cost of
manufacture is quite high.
All devices also require consideration of sterility for cell work. Some
materials are suitable for autoclaving, such as PDMS, other sterilisation
options include running 70 % alcohol through the system for a time followed
by rinsing with sterile buffer (Lu et al., 2004), gamma irradiation, or low-
pressure plasma treatment (Meyvantsson & Beebe, 2008). Open systems
require the use of antibiotics, and, where possible, carrying out the work in
a sterile environment such as a biological safety cabinet.
Another consideration is the shear force on the captured cells. It is
known that shear forces can influence the physiology of cells (Meyvantsson
& Beebe, 2008; Christophis et al., 2010). For some microfluidic geometries,
such as droplet microfluidics, the cells can be maintained in shear free en-
vironments, whereas other geometries such as shallow cups and microwells,
there is a shear force over the top of the cells at all times there is flow in the
system. Depending on the nature of the cell and the magnitude of the shear
force, shear should be taken into account when observing cells in microfluidic
devices.
1.8 Current use of microfluidics for glycosylation
studies
Microfluidic applications in glycobiology are primarily chromatographic in
nature. For a comprehensive review on microfluidics in glycomics see Lazar
et al. (2011). Microscale columns for liquid chromatography with integrated
ionisation nozzles for direct injection on to mass spectrometers require tiny
sample and reagent volumes and are easily replaced if the column becomes
damaged (Lazar et al., 2011). Lectin affinity columns have also been scaled
down for microfluidic chromatography, and multiple variations of capillary
electrophoresis are well suited to microfluidic platforms. Lectin microarrays
have also been scaled down for automated use in microfluidic channels (Roy
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et al., 2014).
Lectin adhesion assays are another use for microfluidic devices. Lectins
are used to coat microfluidic devices, for capture and elution of cells (Vickers
et al., 2011; Zheng et al., 2007) or for observing the cell interaction with a
lectin coated surface that can promote rolling or adherence (Vickers et al.,
2012). Vickers et al. (2012) used strength of adhesion as a measure of glyco-
sylation and compared it to the strength of signal in related flow cytometry
assays. This sort of comparison relies on the integrity of the cell membrane
under flow, as well as binding strengths that compare to the affinity seen
under staining conditions.
Agglutination within droplets in microfluidic channels has been demon-
strated for ABO blood typing, using the lectin DBA for group A sub-typing
(Kline et al., 2008). Blood typing is traditionally carried out using ag-
glutination assays, with multi-valent anti-A or anti-B antibodies and using
DBA for the detection of ”weak A’s” that are not readily detected by anti-A.
This platform permitted loading of droplets with blood cells and antibody or
lectin, followed by mixing and automated detection at multiple time-points.
Fewer examples of labelling cells with lectins for live cell imaging can
be found in the literature. Gossett et al. (2011) labels cells trapped in
individual cups with a series of stains, including WGA. The fluorescence of
the previous stain is used as the baseline for the next, and so the signal from
a number of probes is summed over the experiment. This results in an upper
limit of probes that can be used, but has the advantage of using a single
channel in an epifluorescent microscope, thus keeping equipment costs low.
Cao et al. (2012b) describe a method for detecting cell surface glycans
by capturing cells on lectin electro-sensors in a microfluidic device. On this
system the cell suspension was divided to pass over four different sensors
and the cells allowed to settle on the sensors for 20 minutes after which the
sensors were washed and detection carried out. This device isn’t suitable
for multiplexed sensing of single cells, however it does have the advantage
of being labelled free. Cao et al. also produced a microfluidic platform that
captured single cells in an array and used it for lectin based labelling of
cells (Cao et al., 2012a) and subsequently performed chemical labelling of
quantum dot based dyes to investigate sialic acid expression in cells (Cao
et al., 2015). While the quantum dots give a very bright signal, and the
ability to see individual cells gives information on population heterogeneity,
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the use of chemical labelling limits the possible glycan detection.
1.9 In summary
While great advances have been made in glycobiology thanks to improve-
ments in mass spectrometry, there is room for more techniques based on
lectins and recombinant carbohydrate binding proteins.
At present, it is challenging to probe a cell surface with multiple lectins
due to the steric hindrance caused by lectins binding to adjacent sugars. The
current state of the art is to label populations of cells with single lectins,
and assume that the population is homogeneous, allowing assumptions about
glycosylation to be drawn. Unfortunately, it is now understood, that even
within apparently homogeneous cell lines, there can be vast heterogeneity
within the population, especially in the glycome. Better understanding of
the nature of cellular glycosylation will require further correlatable data
generation, that allows relationships between the sugars of glycan structures
be determined.
Another area that needs to be addressed is the use of novel carbohydrate
binding proteins as probes for glycans on cells. Plant lectins continue to
dominate the glyco-analytical landscape, with some anti-glycan antibodies
used for specific cases. The adoption of novel carbohydrate proteins would
allow the detection of glycans for which plant lectins have not been identified.
The generation of libraries of CBP’s with similar binding specificities would
allow further confirmation of the specificity of binding, and so the generated
data is controlled for by multiple proteins in the way alternative antibodies
are sometimes used to confirm specificity of binding in immunology. As
many plant lectins can have multiple specificities, and carbohydrate binding
antibodies often show cross-reactivity, the availability of such a library could
vastly improve investigations that use CBP’s to detect glycans. The use of
CBPs can give a great deal of preliminary data on the glycosylation status
of glycoproteins and cells without incurring the costs associated with mass
spectrometry.
1.9.1 Aims and objectives of this work
This work has two primary goals, to use microfluidics to permit sequential
labelling of the cell surface with a number of lectins, and to use novel CBP’s
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to investigate cell surface glycosylation in relation to apoptosis.
The microfluidic lab in a trench platform allows cells to be captured
in a shear-free environment, and to be monitored by microscopy. As the
exchange of fluids in the system is straightforward, it is easy to flow in
fluorophore-labelled lectins for cell labelling. We reasoned that the addition
of free sugars should permit the elution of the lectins from the surface of the
captured cells, and that once the fluorescence had returned to background
levels, a different fluorophore-labelled lectin could be added to the system to
label the same cell. This would remove the steric hindrance caused between
lectin molecules and permit localisation data for multiple lectins binding to
the cell surface, allowing them to be correlated on individual cells.
Chapter 3 describes the rationale and limitations of LiaT for this use,
while chapter 4 describes how this will be achieved, through loading cells in
to the LiaT, observing the cells by bright field and epifluorescent microscopy,
labelling with fluorophore-conjugated lectins, removing the lectin with free
sugar, and subsequent labelling with another lectin.
The Irish Separation Science Cluster has been generating novel carbohy-
drate proteins for a number of years. This project seeks to apply two of their
GlcNAc binders to the study of apoptotic lymphocytes, as it is known that
terminal GlcNAc is exposed during late apoptosis. As AAL-2 has very sim-
ilar specificity to GSL II, they were compared to see if AAL-2 would make a
good substitute probe, bringing with it the flexibility of recombinant probes
and the added benefit of not requiring metal ions. GafD was also trialled
as it is a GlcNAc binder, but as it is an O-GlcNAc binder rather than a
general terminal GlcNAc binder, it was not known how or if it might bind
to the apoptotic cells. The application of these CBPs to apoptotic studies,
will further affirm the use of novel CBP’s in the study of glycobiology.
Chapter 5 expands upon how this will be achieved by biotinylating and
fluorophore-labelling GafD and AAL-2, and using them to stain apoptotic
and non-apoptotic cells by flow cytometry that will be co-stained with apop-
totic markers. In this instance, flow cytometry is a more suitable technique
than LiaT due to time restraints (section 4.2) and the requirement for high
data collection to identify rare cell events. They will be further tested as
blotting probes, and any interesting changes will be further investigated by
identification with mass spectrometry.
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Chapter 2
Methods
2.1 Microfabrication
2.1.1 SU-8 Masters
SU-8 (MicroChem) masters were prepared by photolithography. The lids
were prepared as single layer masters and the channels and trenches were
formed by two layers. Feature heights were confirmed by profilometry, as it
is critical that a ratio of 1:5 between channels and trench height is obtained.
2.1.1.1 Inlet lid
A 100mm silicon wafer was sprayed with nitrogen to ensure there was no
dust on the surface. The wafer was loaded onto the spin coater and SU-8
3025 poured on to cover approximately one third of the disc. The disc was
spun at 500 rpm for 10 seconds and ramped to 2500 rpm for 30 seconds.
The disc was soft-baked at 95 ◦C for 15 minutes. The mask aligner (OAI)
was loaded with the lid mask and the disc exposed for 14 seconds. The disc
was baked, post exposure, for 3 minutes.
The disc was developed in 30 mL of EC solvent, rocking, for 7 minutes.
The solvent was changed and the disc rocked for a further 7 minutes. The
disc was then washed in isopropanol, dried with nitrogen and hard baked at
150 ◦C for 5 minutes.
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2.1.1.2 Trenches and channels
A 100mm silicon wafer was sprayed with nitrogen to ensure there was no
dust on the surface. The wafer was loaded onto the spin coater, and SU-8
3025 was poured on to cover approximately one third of the disc. The disc
was spun at 500 rpm for 10 seconds and ramped to 2500 rpm for 30 seconds.
The disc was soft-baked at 95 ◦C for 15 minutes. The mask aligner (OAI)
was loaded with the channel mask and disc exposed for 14 seconds. The disc
was baked, post exposure, for 3 minutes. The wafer was loaded onto the
spin coater and SU-8 3050 poured on to cover approximately one third of
the disc. The disc was spun at 500 rpm for 10 seconds and ramped to 1000
rpm for 30 seconds. The disc was then soft-baked as before for 20 minutes.
A second layer of 3050 was poured in the same fashion, and the disc
soft-baked for 25 minutes. The trenches mask was loaded on to the mask
aligner (OAI). The alignment marks on the disc and mask were used to
adjust the position of the disc until they were aligned. The alignment was
also confirmed by checking a sample of the features. The disc was exposed
for 20 seconds. The disc was baked for 5 minutes post exposure.
The disc was developed in 30 mL of Microposit EC Solvent (Chestech
Ltd., UK) , rocking, for 7 minutes. The solvent was changed and the disc
rocked for a further 7 minutes. The disc was then washed in isopropanol. If
there was any residue, the disc was given a further 7 minutes in EC solvent,
before washing again with isopropanol. It was then dried with nitrogen and
hard baked at 150 ◦C for 5 minutes.
2.1.1.3 Profilometry
Feature heights were measured on the Dektak profilometer. Lid features
should be at least 20 µm in height. Channel features should be 25-40 µm
and trenches should be 150-200 µm where the ratio of channel height to
trench height is at least 1:5.
2.1.2 OTS coating of masters
OTS coating is performed to prevent the PDMS from bonding to the SU-8
masters during moulding.
Masters were stacked feature-side down in a glass dish, using pieces of
glass to raise the discs from the dish and any underlying discs. 30 mL of
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heptane per disc was added to the dish, with 4.7 µL OTS added per disc,
yielding a final concentration of 400 µM OTS. The dish was sealed to prevent
evaporation of the heptane. The discs were left submerged for 2 hours. The
OTS was discarded and fresh heptane added. The discs were sonicated in a
sonic bath in the fresh heptane for 1 minute. The discs were then washed in
methanol, followed by isopropanol and dried with nitrogen gas. They were
then baked on a hot plate at 100 ◦C for 30 minutes.
2.1.3 PDMS Casting (optimised method)
The lid was prepared with 45 g elastomer to 2 g of curing agent. The trenches
were prepared with 5 g elastomer to 1 g of curing agent. Partial curing of
the pieces ensured the completed chip had good bond strength between the
layers and didn’t burst when subjected to high pressures during the initial
loading.
Elastomer and curing agent were mixed well and poured evenly over the
masters. The masters were put under vacuum for 30 minutes. The masters
were transferred to an oven at 70 ◦C for 90 minutes. The channel and
trenches master was removed as it cures fully in this time. The lid master
was returned to the oven for a further 30 minutes if the PDMS stuck to a
glove when touched. The lid should be tacky but not elastic. Fully cured
lids do not bond well.
The PDMS was cut, carefully peeled from the masters and placed feature
side up on the cutting mat. A 2 mm punch was used to make inlet holes in
the lid, aligning the punch with the feature markings. The channel PDMS
was cut into sections of 3 to 6 trenches and excess PDMS trimmed away.
Incisions were made into the waste chamber, and the trench pieces mounted
feature side up on cover-slips. Matching sections were cut from the lid PDMS
and the inlets cleared of any fragments of PDMS remaining after punching.
The pieces were then placed feature side down on the channel sections. The
pieces were pressed together to ensure no air gaps near the features.
Chips were placed in an oven at 70oC for 2 hours to overnight to ensure
they were fully cured and bonded together.
43
Figure 2.1: The main structure of the Lab in a Trench platform.
2.1.4 PDMS casting (original method)
Both layers were prepared with 10:1 ratio of elastomer to curing agent.
The lids contain 40g elastomer to 4g curing agent, and the channels were
cast from 10g of elastomer to 1g of curing agents. Plasma treatment of
the surfaces increases the bond strength between the layers; however it was
not always sufficient to prevent bursting of the chips during the initial high
pressure of loading.
Elastomer and curing agent were mixed well and put under vacuum for
30 minutes. The PDMS was then poured onto the masters carefully to avoid
air bubbles and transferred to an oven at 65 ◦C for 4 hours or overnight.
The PDMS was cut, carefully peeled from the masters and placed feature
side up on the cutting mat. A 2 mm punch was used to make inlet holes in
the lid, aligning the punch with the feature markings. The channel PDMS
was cut into sections of 3 to 6 trenches and excess PDMS trimmed away.
The trench pieces were mounted feature side up on cover-slips. Matching
sections were cut from the lid PDMS and the inlets cleared of any fragments
of PDMS remaining after punching.
The pieces were placed, feature side up, in a Harrick plasma cleaner,
and subjected to 5 minutes of air plasma treatment at an RF setting of high
at a pressure of approximately 1 Torr. The pieces were pressed together
to ensure no air gaps near the features. Chips were placed in an oven at
70oC for 2 hours to overnight to ensure they were fully cured and bonded
together.
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2.2 Lab in a Trench experimental procedures
2.2.1 Preparation of Lab in a Trench chips for cell capture
Chips were plasma treated to hydrophillise the surface to ensure easy prim-
ing and reduce the occurrence of air bubbles.
LiaT chips were placed in a dish in the chamber of a Harrick plasma
cleaner. A vacuum was applied to the chamber until the pressure reached
300 mTorr and air was metered into the chamber to give a pressure of
approximately 1 Torr. The plasma cleaner was set to an RF setting of
’high’ and the chips treated for 5 minutes.
Figure 2.2: A completed LiaT chip with reservoirs in place.
Chips were removed from the vacuum and primed with 20 µL of appro-
priate buffer or media. Priming was performed immediately after removal
from the plasma cleaner to take advantage of the temporarily hydrophillised
surfaces. Pressure was maintained on the pipette until the refractive index
of the channels matched that of the surrounding PDMS. The pipette tip is
left in the inlet to serve as a reservoir.
Chips were examined under the microscope to ensure there was no debris
or fragments of PDMS obstructing the trenches and that the system was
free of air bubbles. Reservoir tips were removed from unsuitable channels
to ensure they would not be used in error.
2.2.2 Cell capture using Lab in a Trench
Cell capture was observed using an Olympus IX81 motorized inverted micro-
scope with an attached Hamamatsu ORCA - ER digital camera C4742-80,
and stopped when sufficient cells were captured. Cell capture was halted
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when up to two thirds of the trench area had been covered. Overfilling of
the trenches is not advised as overlapping cells cause difficulty in subsequent
image analysis.
When used at 37 ◦C, the chamber was humidified to reduce evaporation
effects.
Most of the liquid from the reservoir was removed using a gel loading
tip, until there was less than 1 µL of liquid remaining in the reservoir and
it was below the height of the lid PDMS (but not lower than the tip in the
inlet, so as to prevent bubbles). 0.5 µL of cells at a concentration of 5x105to
5x10 6 cells / mL were added directly to the bottom of the reservoir using
reverse mode pipetting to prevent air bubbles.
Cell capture was observed under the microscope. When cells appeared to
be travelling too fast for capture, some liquid was removed from the reservoir
to reduce the flow rate.
When sufficient cells were captured, 20 µL of appropriate buffer or media
was added to the reservoir to increase the flow rate and flush remaining cells
from the reservoir without any further capture.
Figure 2.3: Ramos cells trapped in a trench. The optimal cell capture should
have single cells that do not overlap, and occupy no more than 70 % of the trench
floor.
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2.2.3 Sequential lectin labelling of live cells using Lab in a
Trench
Lectins can sterically interfere with one another, and so release of lectins
by free sugars on captured cells allows localisation of multiple lectins across
the surface of a single cell. This method is described in detail in O’Connell
et al. (2014).
The experiment was carried out on an Olympus IX81 motorized inverted
microscope with an attached Hamamatsu ORCA - ER digital camera C4742-
80 using a 10× objective. The heated chamber was humidified and main-
tained at 37 ◦C . Images were captured every five minutes.
LiaT chips were primed with TBS with 1 mM CaCl2 (as per section
subsection 2.2.1) and 0.4 µL Ramos cells at a density of 105 cells/mL loaded
(as per section 2.2.2.). After sufficient cells had been captured, 20 µL TBS
with 1 mM CaCl2was added to the reservoir.
Biotinylated lectins were mixed with a five molar excess of DyLight488
labelled streptavidin and diluted with TBS with 1 mM CaCl2to a concen-
tration of 0.1 mg/mL. 0.1 µL of this was added to the reservoir and allowed
to flow into the channel.
Lectin binding was observed until saturation of binding was observed.
Matching free sugar was added to the reservoir at a final concentration of
100 mM and elution of the lectin observed. Trenches were flushed with
TBS with 1 mM CaCl2to remove any free sugar that might interfere with
lectin binding. These steps were repeated with other sugars to complete the
sequential labelling of cell surface glycans.
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Analysis of images was carried out using ImageJ. Cells were selected and
added to the ROI manager. The average pixel intensity for each cell was
recorded in each image and plotted. Overlays of selected cells were also
created using ImageJ.
2.3 Flow cytometry
Flow cytometry was mainly carried out on a BD FACS Aria, with some use
of a BD FACS Calibur. Analysis was carried out using FlowJo.
Compensation controls were set up for every experiment, namely un-
stained controls and singly stained controls for every stain used, such that
at least 20 % of the cells were highly stained and at least 20 % were un-
stained. Compensation was calculated using the built in tool in FACS Diva.
Forward scatter signal was collected in area and height to allow screening
out of doublets. Fluorescence signal was generally collected in logarithmic
format, using biexponential display of the axes. Voltages were set at the
beginning of experiments and left unchanged between samples.
2.3.1 Measuring apoptosis with Annexin-V
Apoptosis was measured using the BD Bioscience Annexin-V kits for flow
cytometry. Annexin-V PE and 7AAD kits were used when another probe
was used with a FITC label. Where the other probe had a violet fluorophore,
Annexin-V FITC and PI kits were used.
The kits were used in accordance with the manufacturer’s instructions,
with the exception that 3 µL of stain was used in place of 5 µL of stain.
2.3.2 Lectin staining
Biotinylated lectins were incubated with fluorophore labelled streptavidin
to allow use of the lectins in flow cytometry. These lectins were bound to
cells prior to annexin-V staining and running on the flow cytometer.
Biotinylated lectin was incubated with a 5 molar excess of fluorophore
labelled streptavidin for five minutes at room temperature. This was then
made up to a final concentration of 10 µg/mL of lectin in 10 mM HEPES
with 1 mM CaCl2.
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Cells were washed twice in PBS before incubation with the labelled lectin
for one hour at 4 ◦C . Cells were then centrifuged and the supernatant
discarded. Cells were resuspended in 10 mM HEPES with 1 mM CaCl2
before further staining and running on the cytometer.
Confirmation of the specificity of binding was carried out using fluo-
rophore labelled streptavidin only and labelled lectin with its specific free
sugar as controls.
2.3.3 Analysis of Flow Cytometry results using FlowJo
Flow cytometry results were analysed using FlowJo. All data was exported
as ungated FCS 3.0 files.
Samples were first gated on FSC-A / FSC-H to exclude debris and dou-
blets. Cells that did not fall close to the diagonal or that had very small FSC
were discarded. Fluorescence gating was carried out against FMO’s or un-
stained samples. Where fluorescence signal was reported, median intensity
was the preferred descriptor.
2.3.4 Cell sorting
Cell sorting was carried out on a BD FACS Aria equipped with a 100 µm
nozzle. A long clean with ethanol was performed prior to sorting. Stream
stabilisation and setting of the drop delay was carried out prior to cell stain-
ing.
2.3.4.1 Sorting for GafD labelling
Cells were induced to apoptose (see subsection 2.9.6.) in a 50 mL volume for
four days to maximise yield. The entire volume was collected for cytometry
and sorting along with a sample of untreated cells.
Cells were washed twice with PBS. Some of the cells were sampled for
setting up compensation controls. Treated and untreated cells were labelled
with GafD and with the Annexin-V FITC / PI kit (see subsection 2.3.1)
alongside singly stained and unstained compensation controls.
The bulk cells for sorting were labelled with 10 µg/mL GafD with a
Dylight 405 fluorophore and incubated on ice for one hour. Cells were then
spun down and resuspended in 10 mL of 10 mM HEPES with 1 mM calcium
50
and 50 µL of propidium iodide from the BD Annexin-V FITC kit added.
These bulk cells were kept on ice during the sort.
Cytometry was carried out on the treated and untreated samples and
controls. Polygon gates were drawn on the GafD/PI plots to allow isolation
of the GafD+/PI+ and GafD-/PI+ populations. Two-way sorting was car-
ried out using a 16-16-0 mask to optimise purity without drastically reducing
yield.
Cells were transferred from the bulk tube on ice to the sampling tube
on the cytometer, 1 mL at a time. Cells were sorted into 15 mL tubes
containing 1 mL PBS and 10X HALT protease inhibitor without EDTA.
When the volume in the tubes reached approximately 10 mL, the tubes
were swapped out and stored on ice.
Collected cells were stored at -20 ◦C until required. Pelleting of the cells
was not carried out, as the apoptotic cells largely burst during the sorting
procedure.
2.4 Purification of apoptotic cells using AAL-2 bound
to magnetic beads
Biotinylated AAL-2 was bound to 10 µm streptavidin coated magnetic beads
(New England Biosciences). These beads were used to bind to late apoptotic
cells in culture and a magnet used to pull down the beads and attached cells.
Streptavidin coated magnetic beads were mixed with a 10 molar excess
of biotinylated AAL-2. The beads were then washed twice in PBS, using a
neodymium magnet to pull the beads out of solution for washing. The beads
were resuspended in cell culture medium supplemented with 1 % pennicillin
/ streptomycin and left for 24 hours in order to reduce any microbial load.
Ramos cells were induced to apoptose (see subsection 2.9.6) for 24 hours.
The AAL-2 beads were mixed with the cells (allowing 0.5 mg beads per mL)
and mixed for ten minutes. The beads were captured at the side of the tube
with a neodymium magnet and the cell suspension swirled past the magnet
five times. The cell suspension was then transferred to a fresh tube and
the level of apoptotic cells remaining determined by flow cytometry (see
subsection 2.3.1).
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2.5 Microscopy
Cells were labelled with lectins and nuclear stain, then imaged using a Nikon
Eclipse Ti-E.
Cells were centrifuged at 210 g for 5 minutes and the supernatant dis-
carded. The cells were washed twice in PBS to remove background glycans
from the media. Cells were resuspended in 1 - 10 µg/mL of lectin labelled
with Dylight-488 conjugated streptavidin. Cells were incubated in the dark
for 1 hour at 4 ◦C. Samples were centrifuged and the cells resuspended in
10 µL of NucBlue Hoescht stain (Life Technologies). Samples were kept in
the dark, on ice, until their turn for imaging. 5 µL of cells was placed on
a clean glass slide and a cover-slip placed on top. Cells were imaged using
a Nikon Eclipse Ti-E in the centre of the coverslip. Edges of sample where
evaporation was occurring were avoided.
Unstained controls were run in each microscopy session.
2.6 Western and lectin blotting
2.6.1 Preparation of Cell Lysates for SDS-PAGE
Cells can be lysed mechanically or chemically using detergent. Mechanical
lysis is appropriate where proteins embedded in lipid membranes are to be
isolated. Detergent lysis is rapid and suitable when whole cell lysates are to
be run on SDS-PAGE gels.
2.6.1.1 Mechanical Lysis (30G needle)
Cells were aspirated through a needle to form a single cell suspension, and
then aspirated through a fine gauge needle to mechanically disrupt the cells.
This rapid method is suitable for applications where the membrane will be
separated, and also where whole cell lysates are required.
Cells were washed twice with PBS and the pellet resuspended at a con-
centration of 108 cells / mL in PBS with protease inhibitors. Where cells
were acquired through sorting and a pellet could not be isolated, the com-
plete contents of the sorting tube were lysed and the entire volume brought
for ultracentrifugation.
Cells were passed three times through a 20G needle to disrupt any cell
clumps and then mechanically lysed by passing them three times through a
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30G needle. Lysates were centrifuged at 14,000 g for 20 minutes to pellet
unlysed cells and organelles. The lysate was then be used for further purifi-
cation of membrane proteins or prepared directly for SDS-PAGE in Laemelli
buffer (see subsection C.2.3).
2.6.1.2 Mechanical Lysis (Dounce homogeniser)
Cells were aspirated through a needle to form a single cell suspension, and
then disrupted in a Dounce homogeniser. This method is suitable for appli-
cations where membranes will be isolated, and also where whole cell lysates
are required.
1 x 107 cells were centrifuged at 210 g for 5 minutes and washed twice
in PBS. The cells were then resuspended in 3 mL of buffer containing pro-
tease inhibitors and passed through a 20G needle. This was then transferred
to a Dounce homogeniser. The cells were lysed with 20 strokes of the ho-
mogeniser. The lysate was transferred to a fresh centrifuge tube for further
purification or prepared directly for SDS-PAGE in Laemelli buffer (see sub-
section C.2.3).
2.6.1.3 Detergent Lysis (Laemelli buffer)
Cells can be lysed in Laemelli buffer to allow rapid preparation of samples
for SDS-PAGE.
Laemelli buffer was prepared with fresh reducing agent. Laemelli buffer
was added to the washed cells, allowing 100 µL for every 1-2 x 106 cells.
The cells were mixed well with the buffer and incubated on ice for one hour,
with occasional vortexing.
Samples are centrifuged at 100 g in a benchtop microfuge for 20 minutes
at 4 ◦C to separate the insoluble fraction. The samples are then heated to
101 ◦C for 10 minutes. The sample was loaded directly onto an SDS-PAGE
gel.
Where required, the protein concentration of the sample was measured
directly by the 660 nm method using the ionic detergent compatibility kit.
2.6.2 SDS-PAGE
SDS-PAGE gels were run for Western and lectin blotting and also to prepare
samples for mass spectrometry.
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2.6.2.1 Precast gels
4-20 % Precise Tris-Glycine gels from Thermo Scientific were used accord-
ing to the manufacturer’s instructions with the standard SDS-PAGE Tris-
Glycine buffer (see subsection C.2.4). PageRuler Plus (Thermo Scientific)
prestained ladder was used as a molecular weight marker and gels were run
until the green (10 kDa) marker neared the end of the gel. Empty wells
were loaded with Laemelli buffer to ensure a constant resistance across the
gel and to reduce the effect of smiling.
2.6.2.2 In-house poured gels
Gels were cast using the ATTO mini gel rig. APS was made fresh on the
day the gel was to be poured. APS and TEMED were added at the last
moment before mixing well and pouring each gel.
Table 2.2: Volumes for SDS PAGE gels
Per 1 minigel 10 % 12.5 % Stacking
dH2O 3.0 mL 2.4 mL 1.54 mL
Acrylamide/bis acrylamide (Sigma) 2.5 mL 3.1 mL 325 µL
0.5 M Tris (pH 6.8) - - 625 µL
1.5 M Tris (pH 8.3) 1.88 mL 1.88 mL -
10 % SDS 75 µL 75 µL 25 µL
10 % APS 37.5 µL 37.5 µL 12.5 µL
TEMED 3.75 µL 3.75 µL 2.5 µL
Any empty wells were filled with loading buffer to ensure a constant
resistance across the gel and to reduce the effect of smiling. PageRuler
Plus (Thermo Scientific) prestained ladder was used as a molecular weight
marker, and gels were run until the green (10 kDa) marker neared the end
of the gel.
2.6.3 Coomassie staining of SDS-PAGE gels
2.6.3.1 Standard Coomassie staining
Standard Coomassie staining is suitable for most gels. It can detect between
0.3-1 µg of protein per band.
The gel is placed in a designated staining box and covered with Coomassie
stain (see subsection C.2.5) to a depth of 1 cm. The gel is allowed to
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stain at room temperature on a rocker for at least 20 minutes to overnight.
Coomassie stain is poured off and collected in a bottle for reuse.
Coomassie destain (see subsection C.2.6) is added to a depth of 2 cm.
A piece of paper towel that has been rolled and tied in a knot was placed
in the container with the gel and destain to capture Coomassie dye. The
container is placed on a rocker at room temperature and allowed to destain
overnight and up to two days if background is high.
The destain and paper towel were discarded and the gel placed in water.
The stained gel was imaged, and where required was stored in distilled
water at 4 ◦C in a labelled zip lock bag.
2.6.3.2 Colloidal Coomassie staining
Colloidal Coomassie staining is more sensitive than standard Coomassie
staining. It is less sensitive than silver staining, but it is more appropriate
for samples that will go for mass spectrometry as it does not reduce the
proteins. Colloidal Coomassie staining can be used to detect as little as 8 -
10 ng of protein per band.
The gel was fixed in 40 % v/v ethanol with 10 % v/v acetic acid for a
minimum of 60 minutes. The gel was then washed in two changes of dH2O
for ten minutes. The gel was flooded with colloidal Coomassie working
solution (C.2.7) for a minimum of two days.
The gel was transferred to a new container and washed with several
changes of 1 % v/v acetic acid until there was minimal background staining
of the gel.
2.6.4 Silver staining of SDS-PAGE gels
When protein yields are low, silver staining helps visualise the proteins on
the gel. It is not ideal for staining proteins that are intended to be used on
mass spectrometry. Silver staining is sensitive down to 2 ng of protein.
The gel was fixed for at least 1 hour in 30 % ethanol with 10 % acetic
acid. It was then washed for 15 minutes in 20 % ethanol, followed by 15
minutes in water. The gel was sensitised for 1 minute in 0.1 % sodium
thiosulphate and rinsed twice with water for 20 seconds. Staining is carried
out for 30 minutes in 0.1 % silver nitrate with 0.026 % formaldehyde followed
by further rinsing of the gel, twice for 20 seconds in water.
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The gel was developed in 3 % sodium carbonate with 0.019 % formalde-
hyde and 0.000198 % sodium thiosulphate until there was satisfactory vi-
sualisation of the bands. Bands with high concentration of protein develop
rapidly. Development of the bands was halted with 5 % Tris base with 2.5 %
acetic acid for 1 minute. The gel was then transferred to water and imaged.
Over-development of the molecular weight marker was common, and
overdevelopment of some lanes of proteins occurred while trying to develop
lanes with low protein content.
2.6.5 Transfer of gels to blots
2.6.5.1 Semi-dry transfer
Semi-dry transfer can be used with nitrocellulose or PVDF membranes.
The gel was soaked for 30 minutes in semi-dry transfer buffer (see sub-
section C.3.1) at 4 ◦C. Pieces of nitrocellulose membrane were cu to size,
and soaked in the semi-dry transfer buffer with four blotting filter papers
per membrane for fifteen minutes. When PVDF was used in place of nitro-
cellulose, it was soaked for 30 seconds in methanol before continuing as for
the nitrocellulose.
The blotting sandwich was assembled in the blotter (2 x filter paper,
membrane, gel, 2 x filter paper), ensuring there were no air bubbles. The
transfer was run at 10 V for 30 minutes to transfer a wide range of proteins.
After transfer was complete, the ladder was checked to see if it had trans-
ferred fully before disassembling the blot sandwich. If it had not transferred
satisfactorily, the blot sandwich was not disassembled and was transferred
for a further 10 minutes at 10 V.
The membrane was then placed in fresh PBS or TBS to remove any
transfer buffer. The membrane was then stained for protein and blocked.
The gel was also Coomassie stained to confirm protein loading and trans-
fer.
2.6.5.2 Thermo G2 fast blotter
The G2 fast blotter is used for rapid transfer of proteins from SDS-PAGE
gels to membranes.
The gels were soaked in the rapid transfer buffer (Thermo Pierce). Ni-
trocellulose membrane was cut to size, and soaked with four blotting filter
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papers per membrane for 5 minutes. Where PVDF was used in place of
nitrocellulose, it was soaked for 30 seconds in methanol before continuing as
for nitrocellulose.
The blotting sandwich was assembled in the blotter (2 x filter paper,
membrane, gel, 2 x filter paper), ensuring there were no air bubbles. The
blotter cartridge was assembled and placed in the control unit. The ”Mixed
Range Proteins” setting was used for transferring a range of glycoproteins
for lectin blotting, as a particular size of protein was not expected.
Satisfactory transfer of the prestained ladder was checked before disas-
sembling the blot sandwich. The blot was then transferred to fresh TBS or
PBS for protein staining and blocking.
The gel was Coomassie stained after blotting to check protein loading
and transfer.
2.6.6 Ponceau total protein staining
Ponceau is a rapid total protein stain that is used for visual confirmation of
the quality of transfer.
The transferred blot was washed and covered with Ponceau stain. The
Ponceau was washed off with distilled water until the background is reduced.
The blot was then imaged, while taking care not to let the blot dry out. The
blot was further washed with water to reduce the amount of Ponceau. Any
remaining Ponceau was flushed from the blot during the blocking process.
2.6.7 MemCode total protein staining
MemCode is a reversible stain that allows for stable imaging of total protein
on the transferred blot. It can be used to check the quality of transfer and
also as a total protein loading control. The MemCode reversible protein
stain for nitrocellulose membranes was purchased from Thermo Scientific.
The MemCode was applied as per manufacturer’s instructions, with the
exception that the volumes were reduced such that the liquid just covered
the blot rather than filled the tray.
2.6.8 Probing of blots
PVA gives a carbohydrate free blocking solution. Milk and BSA are tradi-
tional for antibody probed blots.
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2.6.8.1 Lectin blots
Lectin blots use lectins as a primary probe, antibodies as a secondary probe,
and PVA as a carbohydrate-free blocking agent.
Blots were blocked with 0.5 % PVA in TBS for at least 2 hours or
overnight at room temperature on a rocking platform. The blot was then
incubated with lectin in TBST at a concentration recommended in table 2.3
for 2 hours at room temperature, rocking. The blot is then washed twice
in TBST for five minutes. Secondary antibody (anti-his / anti-biotin) at a
concentration of 1:10,000 in TBST is incubated with the blot for 1-2 hours.
The blot is then washed three times in TBST for 10 minutes and imaged
according to section 2.6.9..
2.6.8.2 Antibody blots
Antibody blotting uses antibodies for both primary and secondary probes,
with BSA and/or non-fat milk used as a blocking agent.
Blots were blocked with 5 % BSA or 2.5 % BSA with 2.5 % non-fat
milk powder in PBS for two hours at room temperature or overnight at
4 ◦C . The blot was then incubated with appropriate antibody in TBST
at a concentration recommended in 2.3, rocking, for two hours at room
temperature or overnight at 4 ◦C . The blot is washed twice with TBST
for five minutes. The blot is then incubated with appropriate secondary
antibody (according to Table 2.3) for 1 hour, rocking at room temperature.
The blot is washed three times for 10 minutes in TBST and imaged according
to subsection 2.6.9..
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2.6.9 Imaging of Blots
2.6.9.1 Imaging of blots using colourimetric substrate
Where a 2 ◦antibody with HRP was used, the Sigma TMB for membranes
was the substrate used. For alkaline phosphatase labelled antibodies, NCBIP
liquid substrate for membranes was used. The blot was drained of buffer,
but not allowed to dry. The blot was covered with up to 5 mL of colouri-
metric substrate and allowed to develop on the bench at room temperature.
Once the blot had sufficiently developed, the substrate was washed off with
appropriate buffer and blot imaged. With slow development of substrate,
the blots were left at 4 ◦C overnight to develop.
2.6.9.2 Imaging of blots using chemiluminescent substrate
Thermo-Pierce Femto reagent gives good signal even when there is low initial
loading of protein. It is used with HRP labelled secondary antibodies.
The Femto reagent was made up as per manufacturer’s instructions. The
blot was removed from the buffer and placed in a plastic sleeve. The Femto
reagent mix was evenly pipetted over the blot and the plastic sleeve closed.
This was then placed in the imager (Syngene GelDoc).
White light images were taken to allow alignment of the ladder with the
chemiluminescent blot. A series of 30 s exposures of the blot were taken,
with the imager set to sum the previous exposures for each image.
Where insufficient signal was achieved, 5 minute exposures were taken
for up to 30 minutes.
The blot was returned to buffer solution and stripped and re-probed
where required.
2.6.10 Stripping of blots
Antibody blots in particular can be reliably stripped and re-probed to save
running valuable samples on multiple blots. It also permits the use of loading
control antibody stains on lectin blots where all protein bands are of interest.
The membrane was washed in TBST, and covered with just enough
stripping buffer (Thermo) to cover the entire blot. The blot was then shaken
by hand for 10 minutes at room temperature. The blot was then transferred
to a new container and washed with TBST.
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The blots were then re-blocked with appropriate blocking buffer for at
least 30 minutes. Chemiluminescent substrate was added and imaged to con-
firm stripping was sufficient. Where stripping was insufficient, the blot was
stripped for a further 10 minutes and blocking and stripping confirmation
repeated.
Blotting then continued for the next antigen of interest.
2.6.11 2DE of membrane preps
7cm Immobiline DryStrip IPG strips (GE Healthcare) with a linear pH gra-
dient of 3 -10 were rehydrated with rehydration buffer (see subsection C.2.8)
containing 20 µg of the protein sample. The strips were rehydrated overnight
in a rehydration chamber at room temperature.
The strips were run on an Ettan IPGphor (GE Healthcare) under the
following conditions:
• Step and hold (300 V) 150 minutes
• Gradient (1000 V) 30 minutes
• Gradient (5000 V) 80 minutes
• Step and hold (5000 V) 25 minutes.
Strips were placed in the equilibration buffer (see subsection C.2.9) for 30
minutes at room temperature. The ends of the strip were trimmed to fit
the width of the SDS-PAGE rig and the strip placed on the surface of a 15
% SDS-PAGE gel. The strip was then covered with a 4 % stacking gel. A
comb with a single tooth was used to prepare a lane in the stacking gel, so
molecular weight marker could be run alongside.
The gels were run at 30 mA / gel until the bromophenol blue ran off the
end of the gel. The gels were blotted, stained or imaged as appropriate.
2.7 Membrane protein isolation
2.7.1 Isolation of plasma membrane by ultracentrifugation
As cytosolic proteins are often O-GlcNAcylated, it was necessary to frac-
tionate the cell lysates to obtain proteins only from the outer membrane of
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the cells. Ultracentrifugation was the method of choice, as the use of mem-
brane extraction kits gave low protein yields or enriched for glycoproteins
in a way that might bias further experiments.
Lysates were obtained by mechanical lysis, whether by 30G needle or
Dounce homogeniser (2.6.1.). Lysates were spun at 14,000g for 20 minutes
at 4 ◦C to pellet organelles and undisrupted cells. The supernatant was
retained and spun at 90,000g for 90 minutes at 4 ◦C . The supernatant
was discarded and the membrane pellet resuspended in PBS with protease
inhibitors and 100 mM NaCl to wash cytosolic proteins that may have been
non-specifically bound to the membrane. This was then spun at 90,000g
for 90 minutes at 4 ◦C . The supernatant was discarded and the membrane
pellet resuspended in 50 - 100 µL PBS with protease inhibitors and 0.5 %
Triton-X100. The resuspended pellet was be stored at -20 ◦C until required.
2.7.2 Membrane isolation by solvent extraction
Solvent extraction allows for enrichment of membrane bound proteins with-
out the use of an ultracentrifuge and without biasing the sample toward
particular glycoproteins as with a WGA pull-down column. The method is
described in Methods in Protein Chromatography (Walls & Loughran 2011)
Lysates were obtained by mechanical lysis, whether by 30G needle or
Dounce homogeniser (2.6.1). Lysates were then spun at 25,000 g for 60 min-
utes at 4 ◦C . The supernatant was discarded and the pellet resuspended
in TE buffer. The resuspended pellet was mixed with an equal quantity of
1-butanol. The suspension was centrifuged at 500 g for 10 minutes to im-
prove phase separation. The aqueous phase should then contain solubilised
membrane proteins.
The interphase and butanol were back extracted by mixing with an equal
volume of TE buffer and the separation repeated. The initial aqueous phase
was combined with the back extract and concentrated using a Vivaspin 500
ultrafilter with a molecular weight cut off of 10 kDa.
The concentrated protein was then quantified and used for further in-
vestigations.
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2.7.3 Confirmation of membrane isolation quality by blot-
ting
Western blot was performed on membrane isolates to confirm the removal
of cytosolic proteins. GAPDH was used as a marker of cytosolic proteins
as beta-actin is a cytoskeletal protein with anchorage to the membrane.
Blotting was carried out as per section 2.6).
2.8 Mass spectrometry identification of proteins
2.8.1 In-gel trypsin digestion
Bands are cut from Coomassie stained gel and destained. Proteins are then
digested in the gel and collected for MS. The method is based on (Shevchenko
et al. 2006)
The gel was rinsed in distilled water for at least 2 hours or overnight.
The bands / spots were cut into 1 mm x 1mm cubes by pressing a scalpel
or cut pipette tip into the gel. Care was taken to not drag the blade but
press it so as not to tear the gel.
Fresh 100 mM ammonium bicarbonate was made up daily. 100 µL of
a 1:1 mix of ammonium bicarbonate and acetonitrile was added to the gel
pieces. The gel pieces were incubated at room temperature for 30 minutes,
vortexing every 10 minutes.
The liquid was removed from the tube and 100 µL of acetonitrile added.
The gel pieces shrank and turned white as they were dehydrated. The
acetonitrile was discarded. At this point the gel pieces could be frozen.
A 1:10 dilution of the 1:1 mix of ammonium bicarbonate and acetonitrile
was made up and 1500 µL used to resuspend a vial of trypsin. [volume] was
added to the gel pieces and allowed to rehydrate on ice for two hours. If the
pieces had absorbed all the buffer, more was added to ensure excess. After
two hours incubation, the gel pieces were transferred to 37 ◦C overnight for
the digestion to take place.
The gel pieces were sonicated on ’high’ for 10 minutes. The pieces were
then centrifuged at 20,000 g for 10 minutes and the supernatant removed
to a fresh tube. The gel pieces were stored at -20 ◦C in case they were
required for further extraction. The supernatant was dried on medium in
a speedy-vac for 2 hours. The dried peptides were stored at -20 ◦C until it
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was time for sample clean up.
2.8.2 Sample clean-up for MS
C18 zip tips (Millipore) were used to desalt the peptides for mass spectrom-
etry.
Samples were resuspended (no more than seven at a time) in 20 µL 0.5 %
TFA. Samples were then sonicated for 2 minutes to resuspend the peptides
and centrifuged briefly. Samples were kept on ice during clean up.
A zip tip was wetted by aspirating and dispensing 10 µL of 0.1 % TFA in
80 % acetonitrile five times. The tip was then equilibrated by aspirating and
dispensing 10 µL of 0.1 % TFA five times. The sample was aspirated and
dispensed 15 times to bind the peptides to the C18. The sample was washed
by aspirating and dispensing 10 µL of 0.1 % TFA into a waste container five
times. Elution was carried out by aspirating and dispensing 10 µL of 0.1 %
TFA in 60 % acetonitrile into a fresh tube five times. Samples were dried
down in a speedy-vac set to medium for two hours. Samples were stored at
-20 ◦C until required.
2.8.3 Mass spectrometry of trypsinised peptides
Peptides were resuspended in 20 µL of 2 % (v/v) Acetonitrile, 0.5 % (v/v)
TFA and sonicated for 2 minutes. The samples were then centrifuged briefly
and 19 µL transferred to a vial for loading on the mass spectrometer, en-
suring there were no bubbles in the vial.
The peptide mixtures were analysed via a Thermo ScientificQ-Exactive
mass spectrometer coupled to a Dionex RSLCnano using an EASY-Spray
column 75 µm ID x 50 cm Pepmap RSLC C18 2 µm.. The LC gradient
ran from 3-40 %B (A: 0.1 % (v/v) formic acid, B: 80 % (v/v) acetonitrile,
0.1 % (v/v) formic acid) over 65 min, and data was collected using a Top15
method for MS/MS scans. The LC gradient in more detail is as follows; 0-10
min 3 % B, 10-40 min increase from 10 % to 40 % B, 40-45 min increase to
90 % B, hold at 90 % B for 4 min before returning to 3 % B for 15 min.
Samples were analysed using Proteome Discoverer (Thermo) with Se-
quest against the Uniprot human database followed by Percolator to reduce
false negatives.
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Results were filtered to ensure only proteins with at least two unique
peptides of high confidence were included.
2.9 Cell culture
Ramos cells (ATCC no. CRL-1596), a B cell line of Burkitt’s lymphoma
origin, was used as the model cell for apoptosis induction.
2.9.1 Maintenance of suspension cultures
Ramos were cultured in suspension flasks which are treated with a hydropho-
bic coating to reduce cell adherence. They were seeded at a density of 2.5-5
x 105 cells / mL and subcultured every two to three days to ensure they did
not reach densities that are too high.
Ramos were maintained at 37oC in a humidified incubator at 5 % CO2
in RPMI-1640 medium supplemented with 10 % heat inactivated foetal calf
serum and 2 mM L-glutamine. Addition of 1 % penicillin/streptomycin is
optional. Medium was warmed at 37 ◦C prior to subculturing cells.
The cell suspension was drawn up through a pipette a number of times
and washed along the lower face of the flask. A sample of the cells were
taken for cell viability measurements and counted (Section 2.9.2.). Based
on the viable cell count, and desired culture volume, enough cells to reseed
the flask were taken and centrifuged, with the remaining cell suspension
discarded appropriately.
Where cell viability was good, cells were spun at 210 g for 5 minutes
and the supernatant discarded. If cell viability was poor, cells were spun at
90g for 10 minutes to enrich for viable cells and the supernatant carefully
discarded.
The cells were then resuspended in the desired volume of warmed fresh
media and returned to the original flask or a differently sized fresh flask.
2.9.2 Measurement of cell viability using Trypan Blue
Cell viability was measured routinely using Trypan Blue and occasionally
using Annexin-V staining and flow cytometry (section 2.3.1.).
An aliquot of cell suspension was removed from the culture flask and
transferred to a centrifuge tube. 100 µL of this was added to a fresh tube
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with 10 µL of Trypan Blue solution (Sigma) and mixed well. 10 µL of stained
cells were loaded onto a haemocytometer. The cells in a 1mm x 1mm square
were counted, with counts of multiple 1x1mm squares averaged. Cells lying
on or touching the top and left borders were included and cells lying on or
touching the bottom and right borders are excluded from the count.
Viable cells appeared clear, while non-viable cells took up the blue stain.
Percentage viability is calculated from the number of viable cells as a pro-
portion of total cells counted.
Cell count per mL was calculated by multiplying the average number of
cells in a 1mm x 1mm square by 1.1 (dilution factor) and 1 x 104 (accounting
for the volume of the square). For most purposes, only viable cells were
counted.
2.9.3 Measurement of cell viability using MTS assays
Cell metabolism was measured using the Promega one-step MTS assay. This
assay can be roughly correlated to cell numbers. A triplicate standard curve
was run with every assay. Optimum cell concentration was identified by
selecting a midpoint from the linear portion of the sigmoid standard curve.
The standard curve was set up such that the highest point on the curve was
higher than the concentration used for the toxicity assays.
A concentration of [cells/mL] was used for assays in which reduced via-
bility was expected. The reagent was used according to the manufacturer’s
instructions and readings were referenced to the standard curve that was
run with each experiment.
2.9.4 Cryogenic storage of cultures
Cells are frozen at peak growth. For suspension cultures this is the point
where the cells have just doubled.
Cells were seeded in 50 mL at 5 x 105 cells / mL. The cells were then
counted after seeding to confirm their starting density. After 26 hours, the
cells were counted again. When the cell count had doubled that of the
previous day, the cells were collected and centrifuged at 210 g for 5 minutes.
The supernatant was discarded and the cells resuspended in freezing stock
solution (C.4.2) at a concentration of 1 x 107cells / mL. This was then added
to cryovials in 1mL aliquots.
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The vials were transferred to a Mr. Frosty and stored at -80 ◦C overnight.
Vials were then transferred to liquid nitrogen for long term storage. After a
number of days, cells were recovered and grown for one week to determine
the viability of the stored cells.
2.9.5 Recovery of cell stocks from cryogenic storage
Media was warmed to 37 ◦C before the cells were retrieved from storage.
The cryovial was then defrosted at 37 ◦C and the entire contents of the vial
added to 9 mL of warmed media. Cells were spun at 210 g for 5 minutes and
resuspended in 7 mL of warm media and transferred to a T25 suspension
flask.
An aliquot was taken for counting and viability measurement. After two
days, the cells were counted and reseeded in fresh media.
2.9.6 Induction of apoptosis in B-lymphocytes
Activation of the B-cell receptor (BCR) in the absence of a co-stimulus
induces apoptosis in B-lymphocytes. Anti-IgM binds the BCR in vitro and
initiates apoptosis.
Cells were counted and sufficient cells to seed the experimental volumes
at a concentration of 5 x 10 5 cells / mL were measured out. The cells are
spun down at 210g for 5 minutes and the supernatant discarded. Cells are re-
suspended in media that has been mixed with anti-human IgM (Biosciences)
at a final concentration of 1µg / mL. Cells were returned to the incubator
under normal conditions, and were be collected as usual for experiments.
Anti-human IgM was not be added directly to the cells in suspension as
it caused rapid clumping and necrosis in some of the population.
2.10 Preparation of Lectins for experiments
2.10.1 Biotinylation of lectins
Lectins were biotinylated with the NHS-sulfo linker kit from Thermo Fisher.
Lectin concentration was carried out by BCA assay or 660nm assay.
Biotinylation was carried out as per manufacturer’s instructions.
Molecular mass of GafD : 21 kDa
Molecular mass of AAL2 : 45 kDa
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2.10.2 ELLA to confirm lectin activity
Enzyme-linked lectin assay was used to confirm the specificity and activity
of the lectins, whether after long storage or after biotinylation.
200 µL of relevant control glycoprotein or sample at a concentration of
10 µg / mL was added to the wells of 96 well microtitre plate and allowed to
adsorb for at least two hours at room temperature. The plate was washed
with TBST and 250 µL of 0.5 % polyvinylalchohol in TBS was added to the
wells for blocking. The wells were blocked for a minimum of one hour at
room temperature. The plate was washed with TBST and 200 µL of lectin
at a concentration between 1-10 µg / mL in TBST added and incubated for
2 hours. The plate was washed twice with TBST and 200 µL of secondary
antibody at is added and incubated for 1 hour.
The plate was washed three times with TBST and developed with the
relevant substrate. The plate was then measured on a Tecan Saffire II to
determine the binding of the lectins.
2.10.3 Protein measurement assays
2.10.3.1 BCA Assay
The Thermo-Pierce BCA kit is used for all BCA assays. The assay is sensi-
tive from 20 µg / mL to 2000 µg / mL. The BCA assay is compatible with
Triton-X100 up to 1 % and is not compatible with reducing agents or urea.
Standard curves were prepared in the same background as the samples.
The kit was used according to the manufacturer’s instructions for the
microtitre plate version of the assay
2.10.3.2 Pierce 660 nm protein assay
The Pierce 660 nm protein is a rapid assay that is compatible with Triton-
X100, and compatible with SDS when using the ionic compatibility reagent.
A standard curve from 1 mg/mL to 18 µg/mL was prepared in the same
buffer as the sample. Buffer is used for the blank.
Assays were carried out according to the manufacturer’s instructions for
the microtitre plate version of the assay.
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2.10.3.3 Bradford assay
The Bradford assay is used when there are reducing agents in the sample
buffer. The standard curve should be prepared in the same buffers as the
sample. A standard curve from 1 mg/mL to 18 µg/mL is prepared in the
same buffer as the sample. Sample buffer is used for to blank. Where sam-
ples are made up in IEF buffer, prepare the standards in IEF buffer. Then
dilute both the samples and standards 1:9 in PBS to reduce the interference
of urea.
Bradford reagent was diluted 1:4 with dH2O. This working reagent is
stable at 4 ◦C for up to two weeks and was be brought to room temperature
before use.
980 µL of Bradford working reagent is added to a cuvette. 20 µL of
sample or standard is added to this and the cuvette mixed well.
The cuvettes were incubated at room temperature for 5 minutes and
read at 595 nm on a UV-vis spectrophotometer
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Chapter 3
Lab in a Trench: design and
manufacturing considerations
3.1 Lab in a Trench
Lab-in-a-Trench (LiaT) is a microfluidic platform developed by Dimov et al.
(Dimov, 2010; Dimov et al., 2011; Kijanka et al., 2011) in which cells are
contained and analysed in a shear-free environment. The platform relies on
gravity-driven flow and gravity-based capture of particles that are too heavy
or slow moving to pass over a trench. The sudden widening of the channel
near the trench allows for a reduction in flow rate and therefore the speed of
the cells travelling in the system. It is known that hydrodynamic forces can
alter cell morphology and physiology (Elliott, 2009), and so LiaT removes
this possibility from interfering.
The Lab in a Trench system relies on capturing cells as they fall into a
trench by gravity. When the cells are trapped, we can exchange the buffers
and media by diffusion. As the cells remain in situ, it is possible to track
cells after the addition (or elution) of probes.
LiaT has been used to observed the effect of LPS on the appearance of
CD86 on the surface of murine macrophages by adding labelled anti-CD86
antibody and watching its binding (Dimov et al., 2010; Kijanka et al., 2014).
Kijanka et al. (2014) further used it to observe macrophages phagocytosing
Escherichia coli that express green fluorescent protein, using time lapse
microscopy and tracking the increasing fluorescence of the macrophages as
they accumulated the green bacteria.
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As reagent delivery is diffusion based, the Stokes radius of the probes
and sugars determines their diffusion rate. The diffusion of the lectins is
correspondingly longer than the diffusion of the free sugars.
Although the depth of the trench allows it to hold an volume of free
fluorophore that is much larger than the cells, the bulk signal is much less
than that of the concentrated fluorophore near the cells surface.
Table 3.1: Requirements for Lab in a Trench
Biological
requirements
Ability to track cells Cells trapped in the trench remain in
place.
Ability to exchange reagents For sequential labelling in particular,
it must be possible to completely re-
place fluids within the system.
Compatible with cells PDMS is not an ideal material for this,
so the time live cells can usefully be
monitored in the system is on the or-
der of hours.
Optically clear with no fluores-
cent signal
The device is intended for use with mi-
croscopy imaging.
Can be used at 37 ◦C This is a physiological requirement for
working with live cells.
No glycans on the device sur-
faces
This could cause background signal
with lectins. PDMS is a glycan free
polymer.
Engineering requirements
Ease of prototyping and man-
ufacture
PDMS cast from SU-8 masters meets
both of these requirements.
Strong bonding of surfaces The small channels necessitate high
pressures for initial loading.
Compatible with aqueous
buffers
Plasma treatment of the surfaces
makes the PDMS hydrophilic, permit-
ting flow of aqueous solutions in the
channels.
Micro-scale features Permits rapid diffusion of reagents
within the system. Reduces reagent
cost.
Adjustable flow rates Flow rates can be adjusted to im-
prove or prevent capture by varying
the height of fluid in the reservoir.
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3.1.1 Lab in a Trench - Microfluidic Theory
The LiaT platform contains a deep, micron-scale indentation within a con-
tinuous channel that enables the capture and retention of cells purely based
on gravity (Dimov et al., 2011; Kijanka et al., 2011) (Figure 3.1). LiaT fol-
lows a well-known working principle that is based on the Camp-Hazen model
of a settling basin (Saady, 2011). In this model, the velocity of cells over
the trench is the most critical parameter for ensuring their gravity-driven
capture.
(a)
(b)
Figure 3.1: Overview of the Lab in a Trench microfluidic platform.
(a)Cells of the Lab in a Trench platform. Fluid exchange is performed by dif-
fusion permitting a shear free environment at the bottom of the trench structure.
(b) 3D schematic of the Lab in a Trench Platform.
Cells are suspended in a flow of PBS buffer of density ρ = 1.0×103 kg m−3
and viscosity η = 1.09× 10−3 Pa s under the influence of gravitational accel-
eration g = 9.81 m s−2. A pressure head ∆p = 1.5 hPa built up by a pipette
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filled to a liquid level σ = 1.5 mm applies across the main channel which has
total length lchannel = 14 mm, constant height hchannel = 35µm and width
wchannel = 40µm which broadens to wtrench = 250µm above the trench of
stream-wise length ltrench = 100µm (Figure 3.1 (b) & (c)). Neglecting the
trench section, the (average) flow of velocity then amounts to
vchannel =
hchannelwchannel∆p
Cncηlchannel
≈ 430µm s−1
with the numerical coefficient for the rectangular channel Cnc ≈ 32.14. The
(average) flow velocity even reduces to
vtrench =
wchannel
wtrench
· vchannel ≈ 70µm s−1
within the sector above the trench. The resulting Reynolds numbers
Re =
ρvw
η
 1
indicates that flow conditions are strictly laminar within the channel as well
as in the trench for typical flow speeds v and widths w. Hence, streamlines
will only penetrate into the uppermost region of the trench and molecular
(reagent) transport across streamlines into the trench occurs solely through
diffusion (Dimov et al., 2011) (Figure 3.1).
With the speed of sedimentation
vsed =
gd2
18η
(ρcell − ρ)
for cells of density ρcell and diameter d we can determine the ratio
tsed
tin
=
18ηhchannel
gd2(ρcell − ρ) ·
vchannel
lchannel/2
between the sedimentation time
tsed(h) = hchannel/vsed
across the entire channel height hchannel and the (minimum) residence time
of the cells in the incoming segment tin = 0.5lchannel/vchannel located at
about 0.5lchannel after the inlet. For Ramos cells with a density of ρcell =
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1.02×103 kg m−3 and a typical diameter d = 10µm suspended in PBS buffer,
this ratio is much smaller than unity so that the entire population of Ramos
cells will have settled to the bottom of the channel way before reaching the
downstream trench (Figure 3.1).
Due to the parabolic flow profile, their speed of cell migration will hence
be significantly reduced with respect to the above calculated (average) flow
velocity vtrench. The cell velocity in the trench region
vcell ≈ 2vtrench
(
hcell
hchannel/2
)2
= 8vchannel
wchannel
wtrench
(
hcell
hchannel
)2
depends on the distance of the cell from the bottom of the channel hcell.
If, for instance, a cell was touching the bottom of the channel (Figure 3.1
(b)), i.e. hcell = d/2, their speed of horizontal migration would amount to
vcell10µm s
−1, only.
For efficient trapping, the ratio
tsed
tres
=
18ηh
gd2(ρcell − ρ) ·
vcell
ltrench
≈ 18ηh
gd2(ρcell − ρ) ·
2vchannelwchannel
wtrenchltrench
(
d
htrench
)2
< 1
of the cell sedimentation time (to a depth d into the trench) and the cell
residence time in the trench region needs to be lower than unity. This implies
an upper limit
v∗channel =
g(ρcell − ρ)wtrenchltrenchh2trench
36ηhwchannel
for the flow speed in the (main) channel. Assuming that the cell will be
irreversibly trapped after penetrating a distance corresponding to the chan-
nel height into the trench, i.e. h = hchannel, we obtain a speed limit of
v∗channel = 545µm s
−1 > vchannel = 430µm s−1 as calculated above.
3.1.2 Forces on particles in the system
All cells in the LiaT system experience gravity, and also experience buoy-
ancy. Cells travelling in the channel experience wall lift, which drives the
cell away from the wall towards the centre of fluid flow (?). This tendency
towards the centre of fluid flow is countered by a shear effect from the
parabolic flow profile of the fluid in the channel. As the channel widens
at the trench, fluid flow rate drops and the walls of the device are further
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from the cell. At the point where the fluid flow rate drops, the cell travels
forward with the inertia that is countered by the Stoke’s drag, causing the
cell to decelerate with the liquid. In the trench itself, wall lift and shear are
no longer significant forces acting on the cell. Gravity pulls the cell towards
the bottom of the trench, with buoyancy and Stokes drag slowing the cells
descent.
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(a)
(b)
Figure 3.2: Cells in Lab in a Trench experience a variety of forces. (a)
When the cell is in the channel, the cell experiences wall lift, which drives the
cell away from the wall, and shear force away from the centre of fluid flow (?).
In addition, the cell experiences the forces of gravity and buoyancy. These forces
balance to produce zero net lift at an equilibrium location. This location is is a
function of channel geometry, carrier fluid properties, flow velocity, cell density and
morphology. As the cell does not move laterally in the flow it is not subject to
Stokes drag. (b) When the cell reaches the channel expansion (trench), the fluid
flow is much reduced and so the shear force becomes negligible. The distance from
the bottom of the trench ensures the wall lift is similarly negligible. The combined
forces of buoyancy and the weight of the cell results in a nett downward motion
of the cell across streamlines as it sinks. This downward motion is retarded by an
additional drag force, caused by the cell motion through the carrier fluid, called the
Stokes drag.
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3.2 Rationale for the use of Lab in a Trench
Lab in a Trench offers some advantages over many of the microfluidic meth-
ods described in section 1.7 and section 1.8. In particular it permits the ex-
change of fluids over the cells, the possiblity to track individual cells through
the experiment, and ease of manufacture.
The small volumes in LiaT allow reduction in reagent costs, and in par-
ticular, allow rapid diffusion of reagents in the system. The diffusion times
of the reagents in the system relates to their molecular mass, with larger
molecules taking longer to diffuse than smaller molecules. A system that
was larger in scale would necessitate longer analysis times.
As the system fits on a microscope slide, it can be easily used with
existing equipment. The small volumes leads to increased pressure in the
system, in particular with respect to the initial loading of the chip, but
optimised assembly of the chips reduces the stress that this can put on the
chip (subsection 3.3.1).
As LiaT is an open system, fluids can be easily removed and exchanged
from the system without introducing air bubbles or introducing valving.
By the use of a narrow pipette, the reservoir can be emptied and refilled
as required. The disadvantage of this open system is that it renders the
device non-sterile, and the use of antibiotics is required to reduce bacterial
contamination of experiments.
Operating LiaT at 37 ◦C lowers the viscosity in the system and thus
raises the Reynolds number of the system slightly. However, operation at
37 ◦is required for work with live cells.
The LiaT system is ideal for working with cultured suspension cell lines
or with blood cells, as the cells can be added to the system in their physio-
logically relevant state and measured. Adherent cell lines can be loaded into
the system after resuspension, however, they are not left in the system for
long enough that they can adhere to the base of the trench. PDMS is not
an ideal material for manufacturing devices used for medium to long term
culturing of cells, as unpolymerised molecules can diffuse in to the system
and distress the cells (as discussed in section 1.7).
PDMS is an ideal material for rapid prototyping, but it is not a preferred
material for cell culture work. The high aspect ratios of the trench to channel
makes hot-embossing of the channels challenging without specialised moulds.
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Milling of the device removes the optical clarity of the trench and makes
it unsuitable for microscopy. Further, manufacture in a elastic material
such as PDMS makes the addition of reservoirs at the inlets as easy as
sticking a pipette into the device. Inelastic materials would require sealing
of the reservoirs to the device, with the risk that the sealant might block the
channels. As PDMS does not contain any glycans, it is a suitable material
for glycoanalysis applications.
3.3 Preparation of chips
Chips were manufactured in PDMS cast from SU-8 masters as described
in subsection 2.1.3. Multiple revisions of the chip manufacturing process
were required to address issues during sample loading. The assembly of the
PDMS was optimised to reduce bursting of the chips during loading (see
subsection 2.1.3). Hydrophilisation of PDMS surfaces is also required to
permit fluid flow and reduce the occurrence of bubbles within the system.
Despite the improved manufacturing process, there is some variability
in the chip assembly process, which can lead to differing distances from the
inlet to the trench itself. This reduces the predicted control over the system
somewhat, but can be countered by experience using LiaT with a range of
distances from the inlet. The velocity of the cells appears to vary with the
distance of the inlet to the trench, and this may be due to the cells not
having time to reach an equilibrium state in the fluid flow.
3.3.1 The move to partial curing
In initial experiments, the PDMS had been fully cured and plasma treated
before bonding the lid and channel segments together (as described in sub-
section 2.1.4). The bond between the surfaces was of variable quality and
the upper and lower parts of the chips regularly separated on loading.
Partial curing of the PDMS before assembly eliminated bursting of chips.
The PDMS was more difficult to manipulate, and more prone to collecting
debris during assembly, but these issues were offset by the improved loading.
Partial curing gives a high bond strength between the layers without resort-
ing to adhesive (Eddings et al., 2008). Punching inlet holes in the partially
cured PDMS also gave cleaner inlet walls and made them less inclined to
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leak around the reservoirs. The fully cured PDMS tended to crumble on
punching, and could leave fractures around the inlet that leaked on loading.
In addition, the chips were assembled in groups of 3 to 6 trenches, rather
than attempting to align the entire disc as was initially performed. This
improves alignment, and is also much easier to manipulate, especially when
working with the partially cured polymer.
3.3.2 Hydrophilisation of channel surfaces
The hydrophobic nature of the PDMS surface made loading with aqueous
solutions challenging. When loading the plasma bonded chips, loading was
easiest when the chips had been bonded on the same day as the assay was to
be performed. However, small air bubbles often accumulated and expanded
as the surface wetting was not always complete.
The chips assembled from partially cured PDMS were particularly dif-
ficult to fill if they were not treated for hydrophilisation. The use of pro-
teinaceous buffers, such as 5 % BSA in TBS, improved loading but was not
always desirable as it can interfere with upstream applications that require
low protein background.
Plasma treatment of the channels in the completed chip was impossi-
ble using a corona plasma probe (Electro-Technic Products, Chicago), as it
could not reach internal surfaces. The probe tip could be inserted into the
inlet hole and plasma treat the channels in a localised fashion, however the
plasma treatment did not extend for enough of the channel to provide ad-
equate hydrophillicity, and in addition, prolonged plasma treatment caused
damage to the surfaces of the chip.
It was decided to trial plasma treatment in a plasma cleaning cham-
ber (Harrick Plasma, Ithaca) under reduced air pressure. The resulting
hydrophilisation is successful but short lived, requiring that the chips are
loaded immediately after removal from the plasma chamber (see subsec-
tion 2.2.1).
3.3.3 Lab in a Trench in use
The manufacturability of the platform was improved by assembling the chips
using partially cured PDMS instead of fully cured. Furthermore, loading
was improved through the use of plasma hydrophilisation of the channel
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surfaces. Loss of liquid from the reservoir and through evaporation through
the PDMS was reduced by humidifying the microscope chamber.
Loading the chips with cell media containing 10 % serum also improved
loading. In addition, it was noted that the cells were less inclined to stick to
the channel surfaces, possibly due to blocking of the surface by the proteins.
For glycosylation studies however, it is preferred to minimise the amount of
protein loaded into the system as it may contain glycoproteins that could
give a background signal during imaging.
Managing the flow rate is challenging using the current system. As flow
rate is regulated by the height in the channel, it is necessary to adjust the
rate by adding or removing microlitre volumes of liquid. This can be tricky
when working with the small volumes that are required for the slow flow
rates during cell capture. The liquid meniscus is often below the height of
the PDMS, making it hard to see. Moreover, as the reservoir tips are not
always at the exact depth in the PDMS, finding the right liquid height can
often be a case of trial and error.
Sterility of the platform was not considered during testing, as the plat-
form is used as an open system, with the potential for bacteria and yeasts
to fall from the air and the operator into the reservoir. It is possible to
autoclave PDMS chips, but it is uncertain if it would be necessary, as the
present system requires plasma treatment of the device surfaces. Precau-
tions to reduce contamination that were taken include, wearing gloves and
clean labcoats, and using antibiotics in the media to ensure bacteriostatic
conditions.
Optimisation of the system manufacture and loading conditions has im-
proved the robustness of the device for use in the laboratories, although
some further refinements are still required.
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Chapter 4
Sequential glycoprofiling of
single cells using Lab in a
Trench
The Lab in a Trench (LiaT) platform was used to investigate cell surface gly-
cosylation on Ramos B-lymphocytes. It was demonstrated that it is possible
to label cells with lectins and to elute the lectin with free sugar, allowing, for
the first time, sequential glycoprofiling of the cell surface (O’Connell et al.,
2014). The method for sequentially glycoprofiling live cells was further ex-
panded for other uses including investigation of fixation on lectin binding.
4.1 Sequential glycoprofiling of live cells
The LiaT platform was employed to examine the surface glycosylation of
Ramos B lymphoma cells. Ramos cell surface glycans were sequentially
probed using a panel of two and subsequently four fluorescently-labelled
lectins, as described in subsection 2.2.3. The interference of free sugar
from previous lectins was assessed with three mannose-binding lectins, LCA,
ConA and NPL. An additional wash step was incorporated between sugar
elution and addition of the next lectin in the probing sequence.
The sugar elution steps were rapid (in the order of minutes), thus min-
imising any potential physiological impact on the cells in the trenches.
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Figure 4.1: Series of images of sequential elution of fluorophore labelled
LCA off Ramos cells. Images i, ii, iii show diffusion of LCA into the channel
and staining of the cells after 0, 5, 10 minutes. Image iv shows the cells after free
mannose had been diffused into the system. Image v was taken after ECL had been
added to the system.
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4.1.1 Glycoprofiling with LCA and ECL
(a)
(b)
(c)
Figure 4.2: Sequential labelling of Ramos cells with LCA and ECL.
(a) Average intensity of individual cell staining as calculated by ImageJ. Images
collected at five minute intervals after addition of LCA (Blue), mannose (red),
ECL (green) and lactose (purple). (b) An example of a cell stained sequentially
with LCA and ECL, and resulting overlay. (c) Average peak intensity values of
individual cell staining. Standard deviation is noted by the bars on each graph.
83
In the first experiment, the two lectins LCA and ECL were used. Stronger
signals were detected with LCA indicating a denser mannose distribution at
the cell surface when compared with ECL, which has an affinity for galactose
residues (Figure 4.2). This is in agreement with general cell surface glycan
structures because galactose is known to be either protected or partially
exposed on live healthy cells which results in poor ECL binding and hence
lower equilibrium concentrations and reduced signals (Tateno et al., 2007).
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4.1.2 Glycoprofiling with three mannose binding lectins
(a)
Figure 4.3: Sequential elution of three mannose binders.(a) Average in-
tensity of individual cell staining as calculated by ImageJ. Images collected at five
minute intervals after addition of LCA (Blue), mannose (red), ConA (green) and
NPL (purple). (b) An example of a cell stained sequentially with LCA, ConA and
NPL, and resulting overlay. (c) Average peak intensity values of individual cell
staining. Standard deviation is noted by the bars on each graph.
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(b)
(c)
Figure 4.3 :Sequential elution of three mannose binders (cont’d).
In a second experiment, three mannose-binding lectins were sequentially
used. The binding of the second and third lectins was not affected by the
presence of mannose during earlier steps in the probing sequence indicat-
ing the effectiveness of the preceding wash step (Figure 4.3). The peak
fluorescence of LCA and ConA was comparable to those achieved in a four-
lectin experiment (Figure 4.5). In that experiment wherein the repertoire of
probes was extended to four lectins, to include ConA and WGA, a higher
signal was obtained with the latter and an intermediate signal with the for-
mer (Figure 4.5). When mannose binders (LCA and ConA) were compared,
fluorescent signal of bound LCA was found to be lower than that of bound
ConA. This is likely to reflect the known difference in affinity between LCA
and ConA, where the former only recognises α-linked fucosylated mannose.
We have confirmed that the free sugars can be washed from the system
such that they do not interfere with the following lectin. This has been
demonstrated by targeting a common carbohydrate (mannose in this case)
with three different lectins (LCA, ConA and NPL) that probe mannose
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and exhibit similar specificities. We found binding of all lectins to similar
positions on the cell surface but with varying intensities (Figure 4.4b).
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4.1.3 Glycoprofiling with four lectins
(a)
Figure 4.5: Sequential glycoprofiling with LCA, ECL, ConA and
WGA.(a) Sequential Profile Steps (5 Minute Intervals): LCA (lectin-Blue), man-
nose (elution-Red), ECL (lectin-Green), galactose (elution-Orange), ConA (lectin-
Purple), mannose (elution-Red), WGA (lectin-Brown), GlcNAc (elution-Black).
(b) An example of a cell sequentially stained with LCA, ECL, ConA and WGA
and resulting images overlaid. (c) Average peak intensity values of individual cell
staining. Standard deviation is noted by the bars on each graph.
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(b)
(c)
Figure 4.5 : Sequential glycoprofiling with LCA, ECL, ConA and WGA
(cont’d.).
This experiment confirmed high GlcNAc and core mannose levels on the
cell surface. GlcNAc was found to have the highest density among all the
extracellular glycans that were probed.
As the lectins were added in an order such that sugar elution would
not interfere with the following lectin, it was possible to image individual
cells without the requirement for wash steps. It was therefore possible to
create glycan density profiles of the cell surface through image overlays with
ImageJ. In addition, the order of lectins was selected so as to minimise
impact on the cells, based on the changes observed when using each lectin
in flow cytometry (Figure D.1). It can be noted that in the three lectin
(mannose binders) sequence and four lectin sequence, LCA was followed
directly or indirectly by ConA (Figure 4.3,4.5). Similar observations were
made in both experiments, indicating that the fucose elution of ECL in the
four lectin experiment had not interfered with the cells’ binding of ConA.
4.1.4 A summary of sequential glycoprofiling
The results generated were analysed with a view to understanding glycan
heterogeneity at the single cell level. An observable difference was obtained
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at the inter-cellular level in the glycan-probing behaviour of lectins on indi-
vidual cells. This further confirms the wide range of glycoforms that can be
displayed on apparently heterogeneous cell populations.
The sequential lectin-elution method has enabled us to detect multiple
sugars on a given live cell, and that is a considerable technical advancement
over current state-of-the-art methods. At present, cell surface labelling is
limited to a single lectin probe, as multiple probes can interfere with each
others binding through steric hindrance as they attempt to interact with
adjacent sugars.
It has been shown here that the LiaT platform also permits the differ-
ential characterisation of diverse glycosylation features at the single cell as
well as at a population level. By overlaying the images of different lectin
probes on can observe glycan distribution profiles over the cell surface. This
allows a map of glycan localisation to be generated, and for the first time,
allow relative distributions of glycans to be observed on the same cell.
Due to the high avidity of many lectins, the sugar concentrations used to
elute the lectins are relatively high. This is necessary in order to overcome
the multiple binding partners of the lectins on the cell surface, and also
to ensure it is at a high enough concentration in the vicinity of the lectin
binding site to have the opportunity to compete with the cell glycan. The use
of disaccharide haptens in place of the free sugars might enable a reduction
in this concentration. The change in local osmolarity caused by high sugar
concentrations may have an adverse effect on the cells, despite only being
under this osmotic pressure for short times.
Priming of the trenches must be carried out immediately after plasma
treatment as the hydrophillicity of plasma-treated PDMS is short lived.
PDMS is not an ideal substrate for this system between its hydrophobicity
and deformability, although it is a popular choice for rapid prototyping and
allows a good seal between the reservoir tips and the LiaT platform.
4.2 Monitoring apoptosis in trench
Attempts were made to monitor apoptosis in trench, with induction of apop-
tosis carried out both in trench and before loading. Unfortunately, due to
the time taken to observe apoptotic changes, coupled with the PDMS envi-
ronment being unsuitable, at present, for long term observations of apoptotic
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changes. Furthermore, as only small numbers of cells can be examined at a
given time, it is unsuitable for identifying rare events, as this requires large
numbers of cells to be analysed. For these reasons, it was chosen to move
forward using flow cytometry for subsequent investigations of the surface
glycosylation of apoptotic cells.
4.3 Future work
Better management of the flow rate is required. The reservoir tips, while
simple, do not allow for tight control of the flow rate. It may be possible
to control the flow rate using syringe pumps, but a great deal of optimisa-
tion will be required to allow easy loading of cells into the system and the
substitution of buffers that is currently facile with the reservoir tips.
In addition, further manufacturing refinements to the platform are de-
sirable. Polystyrene is the traditional plastic used by biologists when per-
forming cell culture work and is more bio-compatible than PDMS (Berthier
et al., 2012). Polystyrene also lends itself to manufacturing scale-up in a
way that PDMS does not (Becker & Ga¨rtner, 2008; Berthier et al., 2012).
Unfortunately, the high aspect ratios of the features limits production to
PDMS in the academic lab. Hot embossing is not possible as the features
may snap off during demoulding, and production of masters for injection
moulding is beyond the scope of rapid prototyping.
Furthermore, work should be carried out to reduce the optical depth of
the base of the trench. At present, the channels are fabricated by spreading
a very thin amount of PDMS on the SU-8 masters by tilting the disc until
the PDMS had covered the area. Spin coating the PDMS onto the master
could allow even thinner bases to the trench, allowing higher resolution
microscopy. If the trench base could be eliminated altogether and the chip
mounted on a coverslip, this would allow optical depths comparable to slide-
based microscopy and would offer the biocompatible surface of the glass for
cell adhesion.
Future experiments might also incorporate dimeric sugars and glycans
bound to proteins as haptens for release of the lectin probes. Using more
complex molecules for elution of the lectin probes may overcome the weak
release seen with some free sugars without the present requirement to use
very high concentrations of free monomeric sugar which may cause inad-
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vertent changes to the cell state. Repeated measurements with the same
lectin may help identify if the high sugar causes changes of the cell surface
glycosylation.
Performing cell synchronisation may also reduce the observed hetero-
geneity in the cells, and it may be a worthwhile step to improve homogeneity
as well as permitting glycosylation changes in the cell cycle to be analysed.
Furthermore, staining to identify cell features may allow one to understand
if the cells adopt a particular orientation when they settle in the trench, or
if differing cell faces are seen, further accounting for heterogeneity.
4.4 Possible applications
The possibility of sequential glycoprofiling with the Lab in a Trench platform
opens up many new routes of investigation of cell surface glycosylation in
the laboratory. With improved manufacturing and shorter optical distances,
LiaT could allow any laboratory to perform sequential interrogation of live
cells with lectins.
It may be feasible to glycoprofile the surfaces of cells that are being
subjected to drug treatments or other stresses in vitro. It would also be
useful to label a cell with a single lectin, elute the lectin and subject the
cell to a particular condition or stress followed by relabelling of the same
cell with the lectin to show any changes in binding that may have been
caused. An example of such an application would be demonstrating potential
differences in lectin binding between cells before and after fixation with a
variety of fixatives. It may be necessary, however, to change the materials
that the system is made from in order to fully realise its potential for long
experiments involving live cells.
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Chapter 5
Labelling late apoptotic cells
with novel carbohydrate
binding proteins
The appearance of terminal GlcNAc (N-acetyl-glucosamine) in late apopto-
sis has been previously characterised by GSL II binding (Meesmann et al.,
2010; Franz et al., 2006). GafD and AAL-2 are recombinant lectins that
bind terminal GlcNAc. They were produced recombinantly and selected for
testing against late apoptotic cells based on the reported binding of GSL II
to such cells.
Testing is primarily carried out using flow cytometry as it is a high
throughput technique that permits analysis of large numbers of cells to iden-
tify rare events. As Lab in a Trench does not meet these criteria (section 4.2),
flow cytometry was deemed to be the more useful technique in this instance,
with western blot and mass spectrometry used as confirmatory techniques.
GafD is specific for binding to O-GlcNAc (Saarela et al., 1996; Merckel
et al., 2003) , whereas AAL-2 binds to both N- and O- linked terminal
GlcNAc in a similar fashion to GSL II (Jiang et al., 2012).
5.1 GafD and AAL-2 do not induce apoptosis in
Ramos cells
As may be seen in Figure 5.1, triply stained cells for flow cytometry (AAL-
2/GafD, Annexin V, PI) show no increased apoptosis over doubly stained
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cells (Annexin V, PI) treated with the same conditions (Figure 5.1) (staining
process described in subsection 2.3.2).
This would indicate that terminal GlcNAc is only exposed on the cell
surface after the cell has entered the late apoptotic phase. Prior to desialya-
tion, the terminal GlcNAc is effectively covered by the sialic acid ’cap’ and is
therefore not exposed for GafD or AAL-2 binding. Any receptor this glycan
may be on will not be activated by lectin binding and therefore, GafD and
AAL-2 may be used for staining cells without inducing apoptotic death.
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(a) Double Stained un-
treated
(b) Double Stained anti-IgM
treated
(c) Triple Stained untreated
(GafD)
(d) Triple Stained anti-IgM
treated (GafD)
(e) Triple Stained untreated
(AAL-2)
(f) Triple Stained anti-IgM
treated (AAL-2)
Figure 5.1: Staining with GafD and AAL-2 does not induce apoptosis
in Ramos B-cells under staining conditions for flow cytometry. All mea-
surements were taken on the same day. All samples were stained with Annexin-V
FITC and PI, with triple staining incorporating V450-labelled GafD or AAL-2.
Compensation causes some adjustment of FITC and PI channels where staining is
seen on the V450 channel.
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5.2 Flow cytometry of apoptotic cells using GafD
5.2.1 GafD binds late apoptotic Ramos B-cells
(a) GafD binds late apoptotic cells
(b) GafD binding is strongest in late apoptotic cells
Figure 5.2: Detection of GafD binding to late apoptotic Ramos B-cells
cells by flow cytometry. Apoptotic Ramos cells were labelled with Annexin-V
FITC, PI and V450 GafD. Cells were measured on the BD FACS Aria and analysed
with FlowJo. Quadrants and histogram gating was set using unstained samples. In
(a) red cells are GafD positive and blue cells are GafD negative based on histogram
gating. In (b) the non apoptotic cells (green) and early apoptotic (orange) show
no GafD staining, where the late apoptotic cells (blue) show strong staining.
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As may be seen in Figure 5.2, apoptotic cells are identified using Annexin-V
and uptake of a nuclear stain that is excluded by the membranes of healthy
cells. In this case, the Annexin-V is FITC labelled and the nuclear stain is
propidium iodide (PI; as described in subsection 2.3.1). Gates are set against
unstained samples. The Annexin-V negative / PI negative quadrant (Q4)
contains healthy cells. The Annexin-V positive / PI negative quadrant (Q3)
contains early apoptotic cells that have flipped phosphotidyl serine (PS) to
the outer membrane of the cell but whose membranes have not lost integrity.
PI positive quadrants (Q2 and Q1) represent dead and late apoptotic cells,
most cells in late apoptosis exhibit Annexin-V binding (Q2) although some
cells are dead without PS expression (Q1).
GafD gating is set on a histogram against the unstained sample. By
gating on Annexin-V/PI and comparing the GafD signal, it can be seen
that the highest signal is found in the Annexin-V positive/PI positive (Q2)
quadrant. Little binding is seen in Annexin-V negative PI positive (Q1),
with no staining seen in the PI negative quadrants (Q3/4).
Changes in display of terminal GlcNAc are known to occur in late apop-
tosis, when desialyation exposes previously hidden GlcNAc. Display of
O-GlcNAc is unexpected as O-GlcNAc is exclusively a nucleo-cytoplasmic
protein (Hart & Akimoto, 2009). Further investigation was carried out to
identify the O-GlcNAc bearing proteins in order to identify whether nucleo-
cytoplasmic proteins were migrated to the cell surface or the exposure was
due to removal of much of the glycan structure of an O-linked glycan (see
section 5.4).
97
5.2.2 GafD binding to cells can be inhibited with free Glc-
NAc
Figure 5.3: GlcNAc inhibits GafD binding to late apoptotic Ramos B-
cells, as observed by flow cytometry. Apoptotic Ramos cells were labelled
with V450 GafD (red); V450 GafD and 10 mM GlcNAc (blue); and left unstained
(orange). Cells were measured on a BD FACS Aria and analysed with FlowJo.
As may be seen in Figure 5.3, when pre-incubated with GlcNAc, GafD
binding to cells was inhibited. This demonstrates that binding of the GafD
to the cells is mediated through the glycan binding site and not by uptake
via an alternative mechanism, nor is this specificity of binding affected by
the damaged membrane of the apoptotic cells.
5.3 GafD as a probe for Western Blotting
Western blotting with GafD was carried out to begin to clarify the changes in
GafD binding observed on the surface of Ramos B-cells using flow cytometry.
Initially it was carried out using whole cell lysates and later using membrane
enriched-fractions that better represented the binding in a flow cytometric
context.
5.3.1 GafD binds to many intracellular components of whole
cell lysates
It is known that O-GlcNAc is found in high abundance in nucleo-cytoplasmic
fractions, and it would therefore be expected to find many bands on blots
of whole cell lysates, as was indeed the case Figure 5.4. Differential bind-
ing between untreated and apoptotic cells was not apparent Figure 5.4.
The abundance of nucleo-cytoplasmic binding may have masked any small
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Figure 5.4: GafD binds nucleo-cytosolic proteins in whole cell lysates of
Ramos B-lymphocytes. Ramos lysates were run on a 4-20 % SDS-PAGE gel with
PageRuler Plus as the molecular weight marker (MWM) and transferred to 0.45 µm
nitrocellulose using the Thermo Fisher G2 fast blotter (as per subsection 2.6.2 and
subsection 2.6.5). Blots were probed with GafD / anti-his. Lanes 1 to 3 contain
lysates of cells induced to apoptose for 0, 24, and 48 hours. Lanes 1 to 3 were
equally loaded.
differences in O-GlcNAc in cell surface proteins. In addition to which, if
the O-GlcNAc change seen on flow cytometry is due to the migration of
nucleo-cytosolic proteins to the surface, the change in localisation will not
be demonstrated on a blot of the whole-cell lysate.
As differential binding is observed on the flow cytometer, where GafD
would have access only to the cell surface, it was decided to enrich the lysates
for plasma membrane proteins.
5.3.2 Plasma membrane enrichment of Ramos B-cell lysates
5.3.2.1 Solvent extract of plasma membrane proteins
As described in subsection 2.7.2, it was attempted to purify membrane pro-
teins by butanol extraction. Butanol extraction relies on the hydrophobic
properties of the trans-membrane domains of proteins embedded in the mem-
brane. It also does not require specialised equipment and may be carried
out on the benchtop. Yields were low, with only 40 µg of protein recovered
from 10 million cells. As may be seen in Figure 5.5, 2D-electrophoresis was
performed on the extracted sample with band visualisation being achieved
following silver staining (see subsection 2.6.4).
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Figure 5.5: Silver stained 2D-electrophoresis of butanol-extracted
plasma membrane proteins from Ramos B-lymphocytes. 50 million Ramos
B-lymphocytes were apoptosed for 24h and butanol extracted as per subsec-
tion 2.7.2. The extracts were run on 2D-electrophoresis and stained as per sections
2.6.11 and 2.6.4.
5.3.2.2 Ultracentrifugal enrichment of plasma membrane pro-
teins
Ultracentrifugation to enrich for plasma membrane proteins gave much bet-
ter yields than the butanol extraction, with 80 µg per 10 million cells. The
membrane enrichment is described in section 2.7.
(a) β-actin (b) GAPDH
Figure 5.6: GafD blotted against the membranes of late apoptotic and
untreated Ramos B-cells. Ultracentrifuged fractions of Ramos lysates were
equally loaded run on a 4-20 % Tris-glycine gel followed by transfer to 0.45 µm ni-
trocellulose using the G2 fast-blotter (see sections 2.6.2, 2.6.5 and 2.6.8.2). Blot (a)
was probed with anti-human β actin and blot (b) probed with anti-human GAPDH.
Lanes contain: 1 - whole cell lysate, 2 - supernatant from 1st ultracentrifugation,
3 - supernatant from salt wash step, 4 - membrane pellet without salt wash, 5 -
membrane pellet after salt washing.
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Ultracentrifugation of whole cell lysates allows for depletion of the nucleo-
cytosolic fraction. A salt wash (100 mM NaCl) was incorporated to further
reduce non-specific binding that may cause cytosolic proteins to be pulled
down with the membranes. As β -actin is a cytoskeletal protein, it is still
seen with the membrane fraction after the salt wash (Figure 5.6). GAPDH
is exclusively cytosolic and is fully depleted.
Depletion of the nucleo-cytosolic fraction reduces its interference in blot-
ting with GafD. This allows investigation of the GafD binding to the cell
membrane as was observed during flow cytometry.
5.3.3 Probing of membrane enriched samples with GafD
GafD was used to probe blots of membrane enriched apoptotic and non-
apoptotic Ramos B-cells (methods described in sections 2.9.6, 2.7, 2.6.2,
2.6.5, 2.6.8.1 and 2.6.9.
Figure 5.7: GafD blotted against the membranes of apoptotic and un-
treated Ramos B-cells. MWM is PageRuler plus. Lane 1 and 2 contain Ramos
membrane fractions enriched by ultracentrifugation. Lane 1 cells were untreated
and lane 2 cells were treated with anti-IgM for three days. Lanes 3 and 4 are the
colloidal coomassie stained gels after transfer. The proteins were electrophoresed
on 4-20 % Tris-Glycine gels and transferred to 0.45 µm nitrocellulose. The blots
were probed with GafD and anti-biotin antibody, followed by imaging with Sure
Signal Femto (Fisher). White light image of the MWM included for alignment as
the chemiluminescent reagent resulted in a strong signal with the ladder.
GafD binds more strongly to the glycosylated proteins of the membrane-
enriched extracts of apoptotic Ramos B-cells than to those of non apoptotic
cells Figure 5.7. There is a change in the distribution of protein sizes seen,
with more small proteins apparent in the apoptotic sample.
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Some binding is seen in non-apoptotic cells. This may be due to con-
tamination by the nucleo-cytosolic fractions or by the presence of a small
number of apoptotic cells in the apparently non-apoptotic sample.
Some of the binding in the apoptotic fraction may be attributable to low
level contamination by the nucleo-cytoplasmic fraction . However, as the
apoptotic and non-apoptotic fractions were prepared in the same fashion,
it is likely that such a contribution would be similar to the binding shown
in the non-apoptotic fraction which is much lower than the overall binding
observed in the apoptotic fraction (Figure 5.7).
This further confirms that increased O-GlcNAc is displayed on the mem-
brane of Ramos B-cells during late apoptosis.
5.4 Proteomic analysis of membrane enriched GafD
binding cells
5.4.1 Sorting of GafD + cells
Enrichment of the GafD binding cells was carried out by flow cytometric
cell sorting (as described in subsection 2.3.4). Cells labelled with GafD were
collected for further analysis by SDS-PAGE and mass spectrometry.
Figure 5.8: GafD binding is strong four days after initiation of apoptosis
in Ramos B-lymphocytes. Cells were incubated with anti-IgM for up to seven
days to determine maximum binding of GafD in order to increase yield for cell
sorting. Cells were labelled with 1 µg/mL GafD with V450 and measured on a BD
FACS Aria.
In order to maximise yield during sorting against sample preparation
time, it was chosen to incubate cells with anti-IgM for four days.
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Calculated sort efficiency was approximately 87 % with approximately
10 million cells collected from the GafD positive / PI positive gate.
Sorting of cells was carried out directly into PBS with protease inhibitors.
It was observed that cell pellets could not be obtained after centrifugation of
the sort collection tubes. It is likely that the already fragile late-apoptotic
cells burst on impact with the sort tubes and buffers.
5.4.2 Selection of bands to prepared for analysis by mass
spectrometry
Ramos cells were induced to apoptose for four days and sorted with a BD
FACS Aria to produce GafD positive / PI positive subpopulation (as per
sections 2.9.6 and 2.3.4). The plasma membranes of these samples were
enriched by ultracentrifugation (as described in section 2.7). In addition,
plasma membrane enrichments were carried out for untreated cells and for
a bulk population of unsorted cells that had been induced to apoptose for
four days.
These membrane-enriched protein extracts were run on a 4-20 % Tris-
glycine SDS-PAGE and blotted on to 0.45 µm nitrocellulose using the G2
fast blotter (as described in sections 2.6.2 and 2.6.5). The gels were retained
and stained with a colloidal Coomassie stain (as per subsubsection 2.6.3.2).
The blots were probed with GafD and developed using the SureSignal Femto
chemiluminescent substrate, see Sections 2.6.8.1 and 2.6.9.
The blots were copied and bands of interest were labelled (Figure 5.9).
The bands were cut from the colloidal coomassie gels by overlaying the gel
with the labelled blots in a clear dish over a white light box. The collected
gel pieces were subjected to an in-gel tryptic digest followed by identification
on a Thermo Q-Exactive, the methods for which are described in section 2.8.
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(a) Original sorted
(b) Repeat sorted
(c) Bulk unsorted
Figure 5.9: Origins of gel pieces cut for mass spectrometry. Printed copies
of the blots had the bands of interest marked out such that colloidal Coomassie
stained gels could be placed in a clear petri dish and aligned with the bands over a
light box for excision with a scalpel. The original sorted blot (a) produced pieces
1 and 23. The repeated sorted blot (b) produced pieces 2, 3, 4, 24, 25. The bulk
unsorted blot produced 5,6A,6B,7-22 and ”22to11”. All were prepared from Ramos
lysates that had been enriched for membrane proteins through ultracentrifugation.
The numbered areas are reproduced to the side of the gel for ease of reading.
The blots were copied and bands of interest were labelled (see Figure 5.9).
The bands were cut from the colloidal coomassie gels by overlaying the gel
with the labelled blots in a clear dish over a white light box. The collected
gel pieces were subjected to an in-gel tryptic digest followed by identification
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on a Thermo Q-Exactive, the methods for which are described in section 2.8.
5.4.3 Preliminary analysis of Mass Spectrometry data
Peptides measured on the Q-exactive were analysed by Proteome Discoverer
(Thermo) to identify their associated proteins. Any instances of keratin
discarded. This resulted in the identification of 903 proteins, of which 652
were unique. All 903 were compared with the dbOGAP’s “O-GlcNAcylated
proteins in dbOGAP with evidence attributions to corresponding PubMed
ID(s)” database (Wang et al., 2011), resulting in 193 matches, of which 103
were unique.
A full list of the proteins identified, along with their corresponding gel
piece and O-GlcNAc status can be found in Appendix D.2.
The 103 matching proteins had their UniProt accessions converted to
Entrez GeneID’s and uploaded to be searched against DAVID (Huang et al.,
2009a,b). Information about pathways and gene ontology was collected and
reported. This information is summarised in Tables 5.3, 5.5, 5.4 and 5.6.
Table 5.1: Results of proteomic searching across 27 gel pieces.
Total proteins identified 1102 (672 unique)
Total proteins after exclusion of keratins 903 (652 unique)
O-GlcNAcylated proteins identified 193 (103 unique)
Table 5.2: KEGG pathway analysis of O-GlcNAcylated proteins from mass spec-
trometry. Functional annotation carried out by DAVID against the KEGG path-
ways database. 56 proteins not clustered.
Term Count
Ribosome 13
Glycolysis / Gluconeogenesis 7
Aminoacyl-tRNA biosynthesis 6
Antigen processing and presentation 7
Spliceosome 8
Pentose phosphate pathway 3
Pyruvate metabolism 3
As seen from Table 5.3, the identified O-GlcNAcylated proteins are pre-
dominantly acetylated and phosphorylated. This fits with the fact that
O-GlcNAcylation often acts as an antagonist to PTM’s such as phosphory-
lation (Hart & Akimoto, 2009).
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Table 5.3: Top 20 keywords associated with identified O-GlcNAcylated proteins.
Term Count
acetylation 95
phosphoprotein 89
cytoplasm 54
nucleus 42
nucleotide-binding 31
rna-binding 29
atp-binding 29
ribonucleoprotein 23
protein biosynthesis 22
dna-binding 17
disease mutation 16
mrna splicing 14
methylation 14
mrna processing 14
ribosome 13
ribosomal protein 13
Chaperone 10
ubl conjugation 10
Spliceosome 9
ATP 9
Cellular compartment results (Table 5.5) associate the identified proteins
as being part of the nucleo-cytosolic compartment. Associations with the
plasma membrane were not apparent from the search. In addition, many
proteins were specifically associated with internal membranes such as the
ribosomal membranes.
Pathway and bioprocess results (Table 5.4, Table 5.6) were most strongly
associated with ribosomal functions. Protein folding proteins and chaper-
ones are also well represented, and may have been translocated from the
endoplasmic reticulum to the cell surface. The display of these proteins
on the cell surface is highly immunogenic and has been linked with various
auto-immune diseases and cancers (Casciola-Rosen et al., 1994; Franz et al.,
2007; Wiersma et al., 2015).
Patching of the failing plasma membrane with intra-cellular membranes
during late apoptosis is likely to be a mechanism by which O-GlcNAc bearing
nucleo-cytosolic proteins are presented on the cells surface (Franz et al.,
2007). As the plasma membrane loses area through blebbing, but the volume
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Table 5.4: KEGG pathway analysis of O-GlcNAcylated proteins from mass spec-
trometry. Functional annotation carried out by DAVID against the KEGG path-
ways database. 56 proteins not clustered.
Term Count
Ribosome 13
Glycolysis / Gluconeogenesis 7
Aminoacyl-tRNA biosynthesis 6
Antigen processing and presentation 7
Spliceosome 8
Pentose phosphate pathway 3
Pyruvate metabolism 3
(a) Healthy cell (b) Late apoptotic cell
Figure 5.10: Ribosomal membranes may be transported to the surface
during apoptosis. It is possible that exposure of O-GlcNAcylated proteins on the
cell surface is due to the movement of ribosomal membranes (yellow), which are
rich in O-GlcNAcylated proteins, to patch the degrading extracellular membrane.
of the cell is not lost at a matching rate, it is necessary for the cell to
maintain its membrane through patching with internal membranes. Were
the membrane to fail, the cytosolic compartment would be spilled, resulting
in the exposure of normally-protected immunogenic epitopes that could lead
to an autoimmune response. This would then result in the display of O-
GlcNAcylated proteins on the cell surface, which may also be immunogenic,
but would be a smaller quantity of exposed protein.
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Table 5.5: Cellular localisation of top 20 results from DAVID against GO CC FAT
Term Count
cytosol 50
ribonucleoprotein complex 38
non-membrane-bounded organelle 38
intracellular non-membrane-bounded organelle 38
membrane-enclosed lumen 32
intracellular organelle lumen 31
organelle lumen 31
nuclear lumen 26
cytosolic part 17
nucleoplasm 16
ribosome 15
nucleolus 15
cell fraction 15
soluble fraction 14
ribosomal subunit 13
cytosolic ribosome 12
cytoplasmic membrane-bounded vesicle 12
membrane-bounded vesicle 12
cytoplasmic vesicle 12
vesicle 12
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Table 5.6: Bioprocess involved in identified O-GlcNAcylated proteins. Top 20
processes identified by DAVID against GO BP FAT database.
Term Count
translation 24
RNA processing 24
mRNA metabolic process 20
RNA splicing 19
mRNA processing 18
macromolecular complex assembly 17
macromolecular complex subunit organization 17
translational elongation 16
RNA splicing, via transesterification reactions with
bulged adenosine as nucleophile
12
nuclear mRNA splicing, via spliceosome 12
RNA splicing, via transesterification reactions 12
protein complex biogenesis 12
protein complex assembly 12
response to organic substance 11
negative regulation of macromolecule metabolic process 11
cell cycle 11
glucose metabolic process 10
protein folding 10
hexose metabolic process 10
posttranscriptional regulation of gene expression 10
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5.5 Summary of GafD results
The recombinant CBP GafD was found to bind to late apoptotic B-cells as
measured by flow cytometry. This finding was unexpected as GafD binds O-
GlcNAc which is reported to be exclusively a post translational modification
of intracellular proteins. Binding was confirmed to be specific and it appears
after deterioration of cell membrane integrity as evidenced by propidium
iodide uptake.
Isolation of the cell plasma membrane was carried out in order to run
western blots and mass spectrometric analysis on membrane-bound proteins.
This was required in order to exclude intra-cellular proteins, as it is known
that many of these are O-GlcNAcylated. It was demonstrated that there is
a clear difference in GafD binding to western blots of membrane enriched
lysates of untreated and late apoptotic B-cells.
Mass spectrometric analysis indicated that many of the proteins col-
lected in the membrane fraction were of nucleo-cytosolic origin. This not
only explains the presence of O-GlcNAc on the cell surface but confirms
existing literature that indicates that intracellular membranes, such as the
endoplasmic reticulum, are recruited to the cell surface during late apoptosis
(Franz et al., 2007; Casciola-Rosen et al., 1994).
The O-GlcNAcylation of proteins is reported to be transient, as it is
easily degraded by lysosyme, and therefore it is possible that the full reper-
toire of O-GlcNAcylated proteins is not represented in this study. Further
methods to clarify and confirm the presence of O-GlcNAc on the cellular
surface are discussed in section 5.6.
The membrane fractionation by ultracentrifugation is a crude method
for enriching plasma proteins. It is possible that some of the membrane
proteins that were identified were from contaminant organelles that were
not sedimented during the first 14,000 g spin. Even low levels of these
contaminant proteins would be to detected by the very sensitive Orbitrap
Mass Spectrometer. The clear difference in GafD binding that was seen
across the blots, implies that the appearance of intracellular proteins in the
membrane lysates were not due to contamination by the nucleo-cytosolic
fraction during sample preparation. As discussed in section 5.6, it may be
wise to perform further separation of the proteins 2D electrophoresis, prior
to blotting.
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5.6 Future Work on GafD
The GafD sorting and membrane fractionation should be repeated and fur-
ther optimised. The membrane fraction should be subjected to a GafD
pull-down and the bound proteins identified by mass spectrometry in order
to confirm the results in subsection 5.4.3. Furthermore, cutting proteins
from a 2D-electrophoresis gel with matching GafD blot would provide much
greater resolution of the O-GlcNAcylated proteins that are displayed on the
cell surface as they would be separated by both size and pI, and would re-
solve to spots rather than bands of many proteins. It may be possible to
perform a cross-linking of the GafD to the O-GlcNAcylated surface proteins
by the use of formaldehyde or gluteraldehyde as is sometimes performed for
immunoprecipation of antibody binding partners (Nadeau & Carlson, 2007).
An assay to inhibit the action of neuraminidase on the cell surface there-
fore preventing desialyation of cell surface glycans could further demonstrate
that the mechanism of GafD binding on the cell surface is due to migration
of intracellular O-GlcNAc-bearing proteins to the surface rather than the
cleavage of surface glycans. In addition, if inhibition of apoptotic blebbing
prevented O-GlcNAc exposure on the cell surface, it would further confirm
that GafD binding is due to transport of intracellular membranes to the
surface.
It should also be attempted to identify GafD binding proteins in late
apoptosis in a number of cell types, in order to see if O-GlcNAc exposure is
specific to B-lymphocytes or a common feature of apoptosis. Of particular
interest would be looking for O-GlcNAc on the surface of late apoptotic
MCF-7 cells which, characteristically, do not bleb in late apoptosis as they
lack -3 (Ja¨nicke, 2009).
Mass spectrometry to confirm the O-GlcNAcylation to complement the
GafD blotting should be carried out. β-elimination and Michael addition
of the membrane isolates would allow identification of the O-GlcNAcylation
site of the exposed protein. In addition, an alternative method such as the
chemical labelling of O-GlcNAcylated proteins via the Thermo Click-IT kit
should be considered, for both western blot and mass spectrometry.
Isolation of blebs could be performed to identify O-GlcNAc heavy blebs.
As mentioned in (Franz et al., 2007), the intracellular-membrane patches on
the cell surface tend to form blebs that are distinct from the extracellular-
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membrane blebs, and it may be possible to test these for O-GlcNAcylation
status.
5.6.1 Possible applications
GafD as a specific probe is another tool that may be added to the glycoana-
lytical tool kit. Although, the ability to identify very late apoptotic cells in
vitro may not seem critical, it may be useful to identify very late apoptotic
cells in relation to overburdened immune systems.
It may be interesting to isolate apoptotic bodies and other microparticles
and attempt to identify if GafD binds to their surfaces. It may be possible to
distinguish blebs that are derived from the outer membrane of the cell from
those of nucleo-cytoplasmic origin. Identification of such blebs in patient
samples could potentially lead to improvements in lupus diagnostics. Such
highly inflamatory, late apoptotic bodies are likely to be a sign of an overbur-
dened immune system. The late-apoptotic bodies display nucleo-cytoplamic
elements which are normally hidden from the immune system. It is now
hypothesised that the display of such self-antigens in conjunction with the
pro-inflamatory nature of late apoptotic cells drives the autoimmune reac-
tivity of lupus (Casciola-Rosen et al., 1994; Dye et al., 2013; Zirngibl et al.,
2014).
5.7 AAL-2 binds late apoptotic Ramos B-cells
AAL-2 is a carbohydrate binding protein with similar glycan specificity to
the commercially available GSL II but with a higher affinity (Jiang et al.,
2012). Unlike GSL II, AAL-2 does not require ions for its binding site to
function. As it is a recombinant lectin it would make a good alternative to
GSL II which is purified from Griffonia simplicifolia. AAL-2 has six binding
sites on a single monomer for terminal GlcNAc (Ren et al., 2015), whereas
GSL II is composed of four subunits but is limited to binding two terminal
GlcNAcs at a time.
AAL-2 was compared with GSL II for use as a flow cytometry label and
as a probe for blotting. An attempt was also made to make use of its higher
binding affinity to remove late apoptotic cells from culture.
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5.7.1 AAL-2 binds the same population as GSL II for flow
cytometry
(a) AAL-2 (b) GSL II
Figure 5.11: Flow cytometric measurements of AAL-2 and GSL II in
relation to Annexin-V and propidium iodide Apoptotic cells are labelled
with Annexin-V FITC, PI and 10 µg /mL of GSL II labelled with DyLight405 or
AAL-2 labelled with V450 (as described in subsection 2.3.2). Cells labelled with
AAL-2 or GSL II are red, where cells that don’t bind lectin are blue. Q1 is annexin-
V negative / PI positive. Q2 is annexin-V positive / PI positive (late apoptotic
cells). Q3 is annexin-v positive / PI negative (early apoptotic). Q4 is annexin-V
negative / PI negative (healthy cells). GLS II and AAL-2 binding is predominantly
seen in the late apoptotic (Q3) quadrant.
It was observed that AAL-2 and GSL II bind exclusively to late apoptotic
Ramos B-cells (Figure 5.11). This is expected as both are terminal GlcNAc
binders. It has been reported that desialyation in late apoptosis exposes
underlying GlcNAc (Meesmann et al., 2010).
The advantage of using AAL-2 is that it is a recombinant lectin , giving a
consistent production , performance and lower cost than GSL-II. In addition
AAL-2 does not require ions for activity of its binding site (Jiang et al.,
2012).
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5.7.2 AAL-2 gives similar binding patterns to GSL II for
blotting
(a) AAL-2 (b) GSL II
Figure 5.12: Western blotting of Ramos whole cell lysates with AAL-2
and GSL II Ramos lysates were run on a 4-20 % SDS-PAGE gel with PageRuler
Plus as the molecular weight marker (MWM) and transferred to 0.45 µm nitrocel-
lulose using the Thermo Fisher G2 fast blotter (as described in sections 2.6.2 and
2.6.5). Blots were probed with AAL-2 / anti-his (a) and GSLII / anti-biotin (b) (as
per subsubsection 2.6.8.1). Lanes 1 to 3 contain lysates of cells induced to apoptose
for 0, 24, and 48 hours. Lanes 1 to 3 were loaded equally.
As seen in Figure 5.12, blotting with AAL-2 and GSL II yield similar bands
on Ramos whole cell lysates. Differences between the sensitivities of anti-his
and anti-biotin antibodies can be resolved by biotinylation of AAL-2 so the
same secondary antibody can be used for both lectins.
Identical binding patterns allows future blotting with AAL-2 in place of
GSL II, as AAL-2 is cheaper to produce with no requirements for ions in
the buffers.
5.7.3 AAL-2 does not pull down late apoptotic cells
As AAL-2 has a higher binding affinity than GSL II, it was attempted to
use AAL-2 to deplete the late apoptotic cells from a culture. Depleting the
late apoptotic cell population would reduce the pro-inflammatory influence
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of late apoptotic cells on the other cells in culture. In particular for suspen-
sion cultures, it can be challenging to separate dead and dying cells, whereas
in adherent culture they can be simply washed away. At present, enrich-
ment of live cells in suspension culture is carried out by centrifuging the
cells at a much lower force, such that the healthy cells pellet more easily,
and the lighter ragged cells that are late apoptotic remain in suspension.
Positively selecting late-apoptotic cells would leave healthy cells untouched.
This would remove the possibility of affecting the healthy population by
activation of a host of receptors by binding with a probe.
Figure 5.13: Flow cytometric analysis of purification of apoptotic Ramos
B-cell suspension using AAL-2 conjugated to 10 µm magnetic beads.
Samples on 6/10/14 were apoptosed for 24h. Samples on 10/10/14 were apop-
tosed for 48h. Bead depletion was carried out as per section 2.4. All samples
were measured on a BD FACS Aria using Annexin-V FITC and propidium iodide.
Analysis was performed using FlowJo. Doublets and debris were excluded using
FSC-A/FSC-H. Setting of positive gates was carried out against unstained samples.
In Figure 5.13, it is shown that there is no significant difference in the
fraction of annexin-V positive / PI positive cells before and after AAL-2
bead depletion. However on the beads themselves, the cells are largely the
PI positive cells that would have exposed terminal GlcNAc, indicating that
the beads could potentially collect or enrich a subset of cells.
It is possible that the fragile nature of the late apoptotic membrane
means that although the beads have bound to the cells, the shear force
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between the bead and the cell allows the bead to rip off parts of the cell
membrane without pulling the entire cell out of suspension.
5.7.4 Summary of AAL-2 results
Recombinant AAL-2 is a useful alternative probe to the commercially avail-
able GSL-II for flow cytometry and western blotting. AAL-2 was shown
to bind exclusively to late apoptotic cells. This was in agreement with the
published literature where GSL II has previously been reported to bind to
late apoptotic cells (Meesmann et al., 2010). Use of AAL-2 as a probe for
western blotting also yielded similar results to GSL II.
Attempts to use AAL-2 with 10 µm magnetic beads to pull late apoptotic
cells from cell suspension were unsuccessful. This is likely due to the shear
force between the large magnetic particle and the fragile cell membrane.
AAL-2 has advantages as an alternative probe to GSL II as it is a recom-
binant protein that may be more easily produced consistently and does not
require calcium ions to coordinate its binding site. However, GSL II is estab-
lished and readily available, whereas AAL-2 is not commercially available
and would need to be produced in-house.
5.7.5 Future Work on AAL-2
The use of AAL-2 for flow cytometry and blotting should be extended to
other cell types and to microparticles, to further demonstrate its potential
as an alternative to GSL II.
A Far Eastern blot may also be an interesting application of the AAL-2.
Thin layer chromatography of the whole cell lysate or membrane isolate of
apoptotic cells is transferred to PVDF and could be probed with AAL-2 to
see if there are changes in the expression of terminal GlcNAc attached the
lipids of the cell membranes(Taki et al., 1994).
A magnetic bead pull down using immobolised AAL-2 would allow for
the removal of late apoptotic cells from a cell culture population. As AAL-2
only interacts with late apoptotic cells, it would not affect healthy cells and
would reduce the pro-inflammatory effects of having late apoptotic cells in
the culture. The magnetic bead pull down assay should be attempted with
various size beads. A fine dust coating of small magnetic beads may result
in less damage of the fragile cell membranes. Shear forces between cell and
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large bead may result in tearing of the membrane and failure to remove the
cell itself from the culture.
Microfluidic devices have been used to examine the effects of shear force
on cells that are adhered to a surface or otherwise captured by antibodies
(Lu et al., 2004; Christ et al., 2010; Christophis et al., 2010). The effect of
shear force on the apoptotic cell membrane could be examined by coating a
microfluidic channel with AAL-2, capturing apoptotic cells and identifying
if the cell membranes tear or if the entire cell shears off intact.
5.7.6 Possible applications
AAL-2 is suitable as an alternative lectin to GSL-II, and has possible uses
everywhere GSL-II is used to interrogate sugars.
AAL-2’s affinity for late apoptotic cells is potentially very useful for sep-
arating dead cells from a culture of suspension cells. Harsh transfection
protocols (Weaver, 1995) or drug screenings can result in late apoptotic
cells that can adversely affect the remaining cells in culture as they become
pro-inflammatory in late apoptosis. Maintaining the few transfected cells,
or isolating the drug effects from the pro-inflammatory dead cells, requires
a way of isolating the dead cells from the population. If magnetic capture in
free solution may not be optimised, it is still possible to have a magnetic sep-
aration of apoptotic cells based on the magnet activated cell sorting method
by Miltenyi Biotec (Miltenyi et al., 1990). The AAL-2 would be conjugated
to kit beads, and the cells passed through a magnet activated cell sorter to
perform the separation.
Use of AAL-2 as the capture protein in supermacroporous cryogels (Ku-
mar & Srivastava, 2010) could also be an efficient, low shear method for
separating apoptotic from non apoptotic cells. The procedure would be
similar to affinity chromatography methods, but the supermacroporous col-
umn would permit the free movement of cells rather than being limited to
smaller molecules.
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Chapter 6
Conclusions
The field of glycobiology , and more specifically glycobiological analysis, is
rapidly emerging as one of the most exciting areas of research in Biology. As
its importance to the diagnostic and biopharmaceutical industries becomes
more recognised, there is a general realisation that new and more specific
methodologies for glycoanalysis are required. During the work of this thesis,
novel combinations of methodologies, microfluidic platforms and new probes
were investigated for their ability to interrogate cell surface glycosylation.
In particular, this work demonstrates, for the first time, the sequential
interrogation of cell surface glycans with a unique combination of labelled
lectin probes in the microfluidic platform, Lab in a Trench (LiaT). This
sequential labelling of the same cell surface is made possible by the use of
selective/specific release of the labelled probes by the corresponding free
sugars.
This work also reports on the recombinant production of novel carbohy-
drate binding protein probes, namely GafD and AAL-2, which were found
to be useful for the interrogation of apoptotic cells through flow cytometry
and western blotting. These findings demonstrated the potential ability of
this bioanalytical approach to observe changes in the glycosylation of the
cell surface as they becomes apoptotic.
These new tools have the potential to transform the field of glycobiology,
as the novel CBP’s can be integrated into existing biological work-flows,
and the LiaT system can be used with existing facilities. This helps achieve
some of the aims of the Glycoscience Roadmap (of Sciences et al., 2012),
whereby glycoanalytical tools would be readily available and usable by non-
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glycoscience specialists to integrate into their own investigations. Changes
in glycosylation may be relevant in all areas of cell biology, and these tools
will make it easier for cell biologists to discover their relevance to their work.
6.1 Lab in a Trench is a new method for observing
cell surface glycosylation
Lab in a Trench has allowed us to realise a powerful new method for observ-
ing cell surface glycosylation through sequential labelling and specific release
of fluorophore-labelled lectins or carbohydrate binding protein probes. This
method allows for the localisation of different glycans on the surfaces of indi-
vidual cells and demonstrates the heterogeneous nature of cell glycosylation
even in an apparently homogeneous cell line.
LiaT can allow for affordable analysis of the cell surface glycosylation, as
the platform needs no special equipment to run and the sequential labelling
requires only a single fluorophore label for the different lectin probes. The
specific release of the bound lectin probe is simply achieved by the use of
the appropriate free sugar.
The manufacture of the device has been greatly improved through lengthy
optimisation of bonding conditions and surface treatments. As bursting was
a common occurance after bonding fully cured PDMS layers that had been
plasma treated, it was decided to use partially cured PDMS as this gives
good strength between the layers during loading. Hydrophilisation of the
channels through plasma treatment facilitates easier loading and reduces air
bubbles.
The system at present requires an operator with empirical experience of
the system, as variability of flow within the system still presents a problem.
Issues of sterility and material compatibility with the cells are presently
resolved through keeping experiments short, but a change in material and
experimental environment may improve this in the future. The ability to
carry out longer experiments would greatly increase the utility of LiaT. Sim-
ilarly reducing the optical depth of the trench would enable higher resolution
imaging. Use of a microscope with auto focus and a programmable stage
would permit higher throughput of image capture and reduce the demands
on the operative.
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6.2 GafD binding demonstrates changes in the late
apoptotic membrane of B-cells
GafD binds to O-GlcNAc displayed on the surface of late apoptotic B-
lymphocytes. O-GlcNAc is a sugar modification seen exclusively on intracel-
lular proteins. The likely mechanism for this exposure of O-GlcNAcylated
proteins is through the transposition of intracellular membranes to the extra-
cellular surface to patch the surface after loss of membrane through blebbing.
This mechanism has been postulated by others (Casciola-Rosen et al., 1994;
Franz et al., 2007) based on observations of ribosomal proteins, but this
is the first demonstration through O-GlcNac binding. Membrane patching
reduces the exposure of the cytosolic compartment to the immune system
in the event that a late apoptotic cell has not yet been cleared.
Measurement with GafD was performed by flow cytometry in order to
gather large volumes of cell data with simultaneous apoptotic marker de-
tection. The GafD binding events corresponded to the late apoptotic pop-
ulation identified by propidium iodide uptake. Unfortunately, due to con-
straints of the LiaT system, it was not possible to perform these experiments
on the system, but it is hoped they could be run on it with optimised con-
ditions in the future.
Investigation of the proteins that bound the GafD was then carried out
to identify the mechanism leading to O-GlcNAc exposure. Enrichment of
cell membranes was essential to remove interfering signals from intracellular
proteins which are O-GlcNAcylated. Identification of the membrane associ-
ated proteins was performed mass spectrometry, with the detection of many
O-GlcNAcylated intracellular proteins. In particular many ribosome associ-
ated proteins were identified. This appears to be in accordance with existing
literature (Franz et al., 2007; Casciola-Rosen et al., 1994).
Further mass spectrometric measurements to directly analyse the O-
GlcNAcylation would be preferable to matching proteins against existing
datasets, and would require access to a specialised source and the facilities
to perform BEMAD on the samples. In addition, multiple cell lines should
be tested to confirm that this is not a feature specific to the Ramos B-cell
lymphoma line.
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6.3 AAL-2 is a good alternative to GSL II for cell
analysis
AAL-2 is an attractive alternative to GSL II for the analysis of cells. It has
the same binding patterns as GSL II in western blot and flow cytometry of
late apoptotic B-cells. Its advantages include higher binding affinity and the
ability to produce it recombinantly. In addition, it has no requirements for
ions to enable binding, making it more flexible in the buffers it can be used
with. This would allow it to be used in a conjunction with a range of stains
where the GSL II buffer might not be ideal.
Although AAL-2’s higher affinity for terminal GlcNAc than GSL II
would imply it would be good for pulling late apoptotic cells from sus-
pension, it would seem that when conjugated to larger beads it does not
succeed in this. It will be valuable to investigate the possibility of using
finer magnetic particles to see if the apoptotic cells could be pulled from
suspension without tearing of their membranes. Future work will include a
range of magnetic bead sizes to see if this isolation method will be of use.
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Abstract: It is now widely recognised that the earliest changes that
occur on a cell when it is stressed or becoming diseased are alterations in
its surface glycosylation. Current state-of-the-art technologies in glycoanal-
ysis include mass spectrometry, protein microarray formats, techniques in
cytometry and more recently, glycoquantitative polymerase chain reaction
(Glyco-qPCR). Techniques for the glycoprofiling of the surfaces of single
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to handle multiple and / or sequential probing. Here, we report a novel
approach of single live cell glycoprofiling enabled by the microfluidic “Lab-
in-a-Trench” (LiaT) platform for performing capture and retention of cells,
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along with shear-free reagent loading. The significant technical improvement
on state-of-the-art is the demonstration of consecutive profiling of glycans
on a single cell by sequential elution of the previous lectin probe using their
corresponding free sugar. We have qualitatively analysed glycan density on
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glycan mapping on the surface of individual live cells with multiple lectins.
The possibility of sequentially profiling glycans on cells will be a powerful
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A portable centrifugal analyser for liver function screening
Accepted to Biosensors and Bioelectronics on 17th January 2014.
Authors:Charles E. Nwankire 1,2, Monika Czugala3, Robert Burger 1,2,
Kevin J. Fraser 3, Tr´ıona M. O’Connell 1, Thomas Glennon 1,Blessing E.
Onwuliri 4,5,Isikaku E. Nduaguibe 5,Dermot Diamond 3,Jens Ducre´e 1,2
1. Biomedical Diagnostics Institute, National Centre for Sensor Research,
Dublin City University, Ireland
2. School of Physical Sciences, Dublin City University, Ireland
3. INSIGHT: Centre for Data Analytics, National Centre for Sensor Re-
search, Dublin City University, Ireland
4. PEPFAR Centralised Laboratory, Abia State University Teaching Hos-
pital, Aba, Nigeria
5. Department of Chemical Pathology, Abia State University Teaching
Hospital, Aba, Nigeria a
Abstract: Mortality rates of up to 50 % have been reported after liver
failure due to drug-induced hepatotoxicity and certain viral infections (Gao
et al., 2008). These adverse conditions frequently affect HIV and tuberculo-
sis patients on regular medication in resource-poor settings. Here, we report
full integration of sample preparation with the read-out of a 5-parameter
liver assay panel (LAP) on a portable, easy-to-use, fast and cost-efficient
centrifugal microfluidic analysis system (CMAS). Our unique, dissolvable-
film based centrifugo-pneumatic valving was employed to provide sample-
to-answer fashion automation for plasma extraction (from finger-prick of
A2
blood), metering and aliquoting into separate reaction chambers for par-
allelized colorimetric quantification during rotation. The entire LAP com-
pletes in less than 20min while using only a tenth the reagent volumes when
compared with standard hospital laboratory tests. Accuracy of in-situ liver
function screening was validated by 96 separate tests with an average coeffi-
cient of variance (CV) of 7.9 % compared to benchtop and hospital lab tests.
Unpaired two sample statistical t-tests were used to compare the means of
CMAS and benchtop reader, on one hand; and CMAS and hospital tests
on the other. The results demonstrate no statistical difference between the
respective means with 94 % and 92 % certainty of equivalence, respectively.
The portable platform thus saves significant time, labour and costs compared
to established technologies, and therefore complies with typical restrictions
on lab infrastructure, maintenance, operator skill and costs prevalent in
many field clinics of the developing world. It has been successfully deployed
to a centralised lab in Nigeria.
A.1.2 Conference presentations
Irish Cytometry Society Annual meeting
University College Dublin. 25th - 26th February 2014.
Poster Title: A novel method for glycoprofiling live cells using Lab in a
Trench
Authors: Tr´ıona M. O’Connell 1,2, Damien King 3, Chandra K. Dixit 3,4,
Brendan O’Connor 1,2, Dermot Walls 1,2, Jens Ducre´e 3,4
1. School of Biotechnology, Dublin City University
2. Irish Separation Science Cluster, Dublin City University
3. School of Physics, Dublin City University
4. Biomedical Diagnostics Institute, Dublin City University
Abstract:
Lab in a Trench (LiaT) is a microfluidic system that allows repeated
probing of cells captured in a shear-free environment. We have demonstrated
a novel method of sequentially glycoprofiling live B-cells using LiaT and an
epifluorescent microscope. Lectins are carbohydrate binding proteins that
can identify specific glycans on a cell surface. Cells were captured with LiaT
and incubated in appropriate buffer. Commercially available plant lectins
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were labelled with DyLight 488, introduced into the system and allowed time
to bind to the cells. These lectins were then eluted using the appropriate free
sugar and further lectins were used to probe the cell.Lab in a Trench analyses
can be carried out in parallel, with the analysis of up to four trenches of
cells at a time. Each trench captures between 5 and 30 cells. The compact
platform is compatible with standard laboratory reagents and microscopes.
Measurements of the cell fluorescence were taken at various timepoints after
addition of the lectin probe and its elution by sugar. Images were analysed
using ImageJ. Sequential images were overlaid to demonstrate localisation
of the lectins and the glycans to which they bind. Image analysis allows
semi-quantitative comparison of glycan density on cells. This is the first
demonstration of sequential analysis of glycan distribution on the surface of
live cells.
CYTO 2015 - 30th Congress of the International Society for
Advancement of Cytometry
Glasgow, Scotland. June 26 - 30, 2015.
Poster Title: Observing surface glycosylation changes on apoptotic B-
cells using the lab in a trench platform
Authors: Tr´ıona M. O’Connell 1,2, Damien King 3, Chandra K. Dixit 3,4,
Brendan O’Connor 1,2, Jens Ducre´e 3,4, Dermot Walls 1,2
1. School of Biotechnology, Dublin City University
2. Irish Separation Science Cluster, Dublin City University, Glasnevin,
Dublin 9, Ireland
3. School of Physics, Dublin City University, Glasnevin, Dublin 9, Ireland
4. Biomedical Diagnostics Institute, Dublin City University , Glasnevin,
Dublin 9, Ireland
Abstract:
Lab in a Trench (LiaT) is a microfluidic system that allows repeated
probing of cells captured in a shear-free environment. We have demonstrated
a novel method of sequentially glycoprofiling live B-cells using LiaT and an
epifluorescent microscope. Lectins are carbohydrate binding proteins that
can identify specific glycans on a cell surface.
Cells were captured with LiaT and incubated in appropriate buffer.
Commercially available plant lectins were labelled with compatible fluor-
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phores, introduced into the system and allowed time to bind to the cells.
These lectins can then be eluted using the appropriate free sugar and further
lectins were used to probe the cell.
Lab in a Trench analyses can be carried out in parallel, with the analysis
of up to four trenches of cells at a time. Each trench captures between 5
and 30 cells. The compact platform is compatible with standard laboratory
reagents and microscopes.
Measurements of the cell fluorescence were taken at various timepoints
after addition of the lectin probe and its elution by sugar. Images were
analysed using ImageJ. Sequential images were overlaid to demonstrate lo-
calisation of the lectins and the glycans to which they bind. Image analysis
allows semi-quantitative comparison of glycan density on cells.
By inducing apoptosis while cells are in the trenches, the lectin binding
profile of the cells can be monitored in real time. It has been reported
(Meesmann, 2010) that de-sialyation of cell surface glycans exposes terminal
N-acetylglucosamine. Here, we can probe this exposure of terminal GlcNAc
as we observe the cells in the trench. Confirmation of this lectin specificity
can be controlled by eluting the lectins with free GlcNAc.
References: H. M. Meesmann et al., Journal of cell science 123, 3347-3356
(2010).
Society for Glycobiology Annual Meeting
San Francisco. December 1-4th, 2015.
Poster Title: Lab in a Trench: a flexible microfluidic system for single
cell imaging using lectins
Authors: Tr´ıona M. O’Connell 1,2, Arnaud Coudray3,4 , Damien King 3,
Laura Santana Gonza´lez 3,4, Jens Ducre´e 3,4, Brendan O’Connor 1,2, Dermot
Walls 1,2
1. School of Biotechnology, Dublin City University, Glasnevin, Dublin 9,
Ireland
2. Irish Separation Science Cluster, Dublin City University, Glasnevin,
Dublin 9, Ireland
3. School of Physics, Dublin City University, Glasnevin, Dublin 9, Ireland
4. Biomedical Diagnostics Institute, Dublin City, Glasnevin, Dublin 9,
Ireland University
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Abstract:
Lab in a Trench is a microfluidic platform that captures cells by a gravity
dependant principle. Cells captured in the trench are in shear free conditions
and can be probed by simply flowing labels into the system. We have pre-
viously demonstrated a method for sequentially labelling single cells with
fluorophore labelled lectins [1], and have extended the system to demon-
strate the binding patterns of lectins to cells before and after fixation. We
have also used the system to induce apoptosis in the trench and monitor the
binding rate of GSL II in comparison to propidium iodide uptake.
Cell surface glycosylation is often examined using fluorescently labelled
lectins. By labelling the cells with lectin and then eluting with free sugar,
the image of the labelled live cell can be captured. The cell can then be
fixed with a variety of fixing agents, including 4 % formaldehyde, and then
reprobed in order to compare the binding patterns of lectins on the same
cell surface. This allows a mix of live and fixed assays to be carried out on
the same cell, while understanding some of the changes in binding that may
occur after fixation.
Captured cells can also be treated and monitored for surface changes over
time. B-lymphocytes are captured in the trench and induced to apoptose
using anti-IgM. Stains such as propidium iodide and labelled lectins are then
flowed through the system and their rate of binding monitored.
[1] O’Connell, Tr´ıona M., et al. ”Sequential glycan profiling at single
cell level with the microfluidic lab-in-a-trench platform: a new era in exper-
imental cell biology.” Lab on a Chip 14.18 (2014): 3629-3639.
Society for Glycobiology Annual Meeting
San Francisco. December 1-4th, 2015.
Poster Title: O-linked β-N-acetylglucosamine is exposed on the surface
of B-lymphocytes in late apoptosis
Authors: Tr´ıona M. O’Connell 1,2, Ruth LArragy 1,2, ,Grainne O’Keefe
3,,Sea´n Doyle3, Brendan O’Connor 1,2, Dermot Walls 1,2
1. School of Biotechnology, Dublin City University, Glasnevin, Dublin 9,
Ireland
2. Irish Separation Science Cluster, Dublin City University, Glasnevin,
Dublin 9, Ireland
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3. Maynooth University Department of Biology, Maynooth University,
Maynooth, Co. Kildare,
Ireland
Abstract:
It is known that apoptosis induces changes in the surface glycosylation
of cells. In particular, exposure of terminal N-acetylglucosamine (GlcNAc)
is characteristic of late apoptosis. Using the bacterial lectin GafD, and flow
cytometry, we have demonstrated the exposure of O-linked β- GlcNAc in
late apoptosis.
Ramos cells (ATCC no. CRL-1596), a B cell line of Burkitt’s lymphoma
origin, were used as a model of apoptosis. Anti-IgM binds to the B cell
receptor, and in the absence of co-signalling by CD40, induces apoptosis in
the cells.
GafD, a fimbrial protein from E. coli with O-β-GlcNAc binding speci-
ficity, was biotinylated and labelled with streptavidin conjugated BV421
(BioLegend). Confirmation of binding specificity was carried out by inhibit-
ing lectin binding using free GlcNAc.
Apoptotic cells were incubated with BV421 GafD for 30 minutes, washed,
and labelled with Annexin V-FITC and propidium iodide(BD Biosciences).
Cells were then measured on a BD FACS Aria and analysed with FlowJo.
A sub population of late apoptotic cells were identified that were positive
for GafD labelling.
These cells exhibiting GafD binding were isolated through cell sorting.
As O-β-GlcNAc is a common intracellular sugar residue, it was necessary
to isolate the outer membrane of the cells by ultracentrifugation in order
to identify the O-β-GlcNAc bearing protein. Membrane proteins were anal-
ysed by western blot and the relevant GafD binding proteins excised from
matching gels for identification by mass spectrometry.
A.2 Outreach Activities
Represented Irish Science Separation Cluster at the national finals of Thesis
in Three (2012) with ”Sugar Coated Cells”.
Delivered a public talk on my work at Pint of Science 2014, PubhD
Dubin (April 2015) and at Soapbox Science Belfast 2015.
National finalist in FameLab competition in 2013 and 2014.
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Appendix B
Lectins
Table B.1: Lectin specificities
Lectin Specificity Mol. Wt. Inhibiting Sugar
ConA α-mannose, α-glucose 104 kDa Mannose
ECL Galβ4GlcNAc 54 kDa Lactose
LCA α-mannose, α-glucose 50 kDa Mannose
NPL α-mannose 59 kDa Mannose
WGA GlcNAc 36 kDa GlcNAc
GSL II α or β GlcNAc 113 kDa GlcNAc
B1
Appendix C
Materials
C.1 Common Buffers
C.1.1 10X TBS
• 24 g Tris Base
• 88 g NaCl
Dissolve in 800 mL dH20. Adjust pH to 7.4 with HCl. Add dH2O to a final
volume of 1 L.
C.1.2 1X TBST
Dilute 1 part 10X TBS in 9 parts dH2O, autoclave if needed. Add 0.1 %
Tween-20 and mix.
C.1.3 PBS
C.2 SDS-PAGE
C.2.1 1.5M Tri HCl pH 8.3
• 157.6 g Tris HCl
Dissolve Tris HCl in 180 mL dH2O. Adjust pH to 8.3. Add dH2O to a final
volume of 200 mL.
C1
C.2.2 0.5M Tris HCl pH 6.8
• 3.94 g Tris HCl
Dissolve in 45 mL dH2O. Adjust pH to 6.8 with HCl. Make up to 50 mL
with dH2O
C.2.3 Laemelli buffer (6X)
• 7 mL 0.5 M Tris 6.8
• 3 mL Glycerol
• 1 g SDS
• 50 µL Bromophenol Blue (2.5 % stock solution)
Mix well and store at room temperature.
To use add 18.6 g DTT per 200 µL or 12 µL beta mercaptoethanol per
108 µL of buffer. Add the reducing agent fresh on the day of use.
C.2.4 SDS PAGE running buffer (10X)
• 30 g Tris
• 144 g glycine
• 100 mL 10 % SDS
Mix well and make up to 1 L with dH2O. Leave the stock solution stirring
until it has fully dissolved. Make up 1 part to 9 parts dH2O for working
solution.
C.2.5 Coomassie Stain
• 45 mL methanol
• 10 mL glacial acetic acid
• 45 mL dH2O
• 300 mg Coomassie Brilliant Blue R250
Add the acetic acid to the dH2O. Dissolve the Coomassie in methanol before
mixing with the water and acetic acid. Filter and store. Coomassie stain
can be recycled.
C2
C.2.6 Coomassie Destain
• 225 mL methanol
• 50 mL glacial acetic acid
• 225 mL dH2O
Add the acid to the water, then add the methanol. Discard appropriately
after destaining of the gels.
C.2.7 Colloidal Coomassie stain
• 20 g O-Phosphoric Acid
• 100 g Ammonium Sulphate
• 1 g Coomassie Brilliant Blue G-250
Dissolve the phosphoric acid and ammonium sulphate in 800 mL of dH2O.
Add the Coomassie while stirring. Make up to 1L with dH2O and allow the
stock solution to stir for at least 24 hours.
Immediately before use, make a working solution by diluting four parts
of stock solution to one part of methanol.
C.2.8 IPG strip rehydration buffer
• 7 M Urea
• 2 M Thiourea
• 2 % w/v CHAPS
• 0.002 % w/v Bromophenol blue
• 20mM DTT (added just prior to use)
• 0.5 % v/v IPG carrier ampholytes 3-10
C3
C.2.9 IPG strip equilibration buffer
• 50 mM Tris
• 6 M Urea
• 30 % w/v Glycerol
• 2 % w/v SDS
• 0.002 % w/v Bromophenol blue
Mixed and pH to 8.8.
C.3 Western Blot
C.3.1 Semi-Dry transfer buffer
• 2.9 g Glycine
• 5.8 g Tris Base
• 3.7 mL 10 % w/v SDS
• 800 mL dH2O
• 200 mL methanol
Dissolve the glycine and Tris in the dH2O and SDS. Add the methanol. Mix
well and store at 4 ◦C .
C.4 Cell Culture materials
C.4.1 Heat inactivation of Serum
Serum is defrosted at 37 ◦C in a water bath until there is no ice remaining.
The serum is then removed from the bath which is set to 56 ◦C . When
the bath has reached temperature, the serum is placed in the bath for 30
minutes with occasional agitation.
The serum is then filtered to remove any particulates. The filtered, heat
inactivated serum is aliquoted into 50 mL and stored at -20 ◦C .
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C.4.2 Freezing stock solution
• 5 mL DMSO
• 10 mL heat inactivated FBS
• 35mL RPMI 1640 (freshly supplemented)
Mix well and filter sterilise through a 0.2 µm syringe filter. Aliquot into 10
mL and freeze at -20 ◦C until required.
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Appendix D
Data
D.1 Flow Cytometry Plots
D.1.1 Supplementary Flow for LiaT paper
D1
Figure D.1: Measuring apoptosis of untreated cells alongside various
lectins. Cells were stained with Annexin V-PE and 7AAD to determine apoptotic
state. Lectins were labelled with BD V450.
D2
Figure D.1 continued.
D3
Figure D.1 continued.
D4
D.2 Proteomic Data
D5
Table D.1: List of all proteins identified in mass spectrometry (exclusive of keratins), correlated with gel piece number, PMID where
the protein is known to be O-GlcNAcylated (PMID) and Site of O-GlcNAcylation where known (Site).
Gel Piece Accession Description PMID Site
1 P60709 Actin, cytoplasmic 1 20305658
2 P10809 60 kDa heat shock protein, mitochondrial
5 P62191 26S protease regulatory subunit 4
5 O43242 26S proteasome non-ATPase regulatory subunit 3
5 P10809 60 kDa heat shock protein, mitochondrial
5 Q01518 Adenylyl cyclase-associated protein 1
5 Q06203 Amidophosphoribosyltransferase
5 C9JM09 Asparagine synthetase [glutamine-hydrolyzing] (Fragment)
5 P14868 Aspartate–tRNA ligase, cytoplasmic
5 P25705 ATP synthase subunit alpha, mitochondrial
5 I3L0H8 ATP-dependent RNA helicase DDX19A
5 O00571 ATP-dependent RNA helicase DDX3X
5 P07814 Bifunctional glutamate/proline–tRNA ligase 16408927
5 P04040 Catalase 18984734 S114;S254
5 C9JFE4 COP9 signalosome complex subunit 1
5 O43175 D-3-phosphoglycerate dehydrogenase 16408927
5 P81605 Dermcidin
5 P15924 Desmoplakin
5 U3KQB9 DNA primase large subunit
5 J3KQ69 DNA replication licensing factor MCM3
5 B4DXV1 Elongator complex protein 3
5 P55884 Eukaryotic translation initiation factor 3 subunit B 16408927
5 B4DVY1 Eukaryotic translation initiation factor 3 subunit D
5 Q9Y262 Eukaryotic translation initiation factor 3 subunit L
5 P11413 Glucose-6-phosphate 1-dehydrogenase 16408927
5 P06744 Glucose-6-phosphate isomerase 16408927
5 E9PKE3 Heat shock cognate 71 kDa protein
5 Q5T6W5 Heterogeneous nuclear ribonucleoprotein K
5 Q00839 Heterogeneous nuclear ribonucleoprotein U 16408927
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
5 B3KRS5 Histone deacetylase
5 P16403 Histone H1.2 20305658
5 P52292 Importin subunit alpha-1 16408927
5 H0Y4R1 Inosine-5’-monophosphate dehydrogenase 2 (Fragment)
5 C9J381 Inosine-5’-monophosphate dehydrogenase
5 F5GWP8 Junction plakoglobin
5 Q9UKX7 Nuclear pore complex protein Nup50
5 H0YHC3 Nucleosome assembly protein 1-like 1 (Fragment)
5 B4E363 Phenylalanine–tRNA ligase alpha subunit
5 P11940 Polyadenylate-binding protein 1 20305658
5 K7EK45 Polypyrimidine tract-binding protein 1 (Fragment)
5 Q9UMS4 Pre-mRNA-processing factor 19
5 B4DLW8 Probable ATP-dependent RNA helicase DDX5
5 G5EA52 Protein disulfide isomerase family A, member 3, isoform CRA b
5 P07237 Protein disulfide-isomerase
5 Q9P258 Protein RCC2 16408927
5 P14618 Pyruvate kinase PKM 16408927
5 F5H4D6 Ras GTPase-activating protein-binding protein 1
5 Q9Y265 RuvB-like 1
5 Q12874 Splicing factor 3A subunit 3
5 K7ENG2 Splicing factor U2AF 65 kDa subunit
5 P17987 T-complex protein 1 subunit alpha 16408927
5 P78371 T-complex protein 1 subunit beta
5 P50991 T-complex protein 1 subunit delta 16408927
5 B7ZAR1 T-complex protein 1 subunit epsilon
5 Q99832 T-complex protein 1 subunit eta
5 B4DUR8 T-complex protein 1 subunit gamma
5 P50990 T-complex protein 1 subunit theta 16408927;17614351
5 P40227 T-complex protein 1 subunit zeta 16408927
5 Q9UJA5 tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6
D
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
5 Q9Y3I0 tRNA-splicing ligase RtcB homolog
5 J3QSA3 Ubiquitin (Fragment)
5 A6NJA2 Ubiquitin carboxyl-terminal hydrolase
5 Q16851 UTP–glucose-1-phosphate uridylyltransferase
5 Q8WU90 Zinc finger CCCH domain-containing protein 15
8 P81605 Dermcidin
8 P15924 Desmoplakin
8 Q5D862 Filaggrin-2
9 K7EJ81 116 kDa U5 small nuclear ribonucleoprotein component
9 Q99460 26S proteasome non-ATPase regulatory subunit 1 16408927
9 F5GZS6 4F2 cell-surface antigen heavy chain
9 Q01813 6-phosphofructokinase type C
9 P17858 6-phosphofructokinase, liver type
9 P08237 6-phosphofructokinase, muscle type 16408927
9 P11021 78 kDa glucose-regulated protein 16408927
9 Q99798 Aconitate hydratase, mitochondrial
9 P13798 Acylamino-acid-releasing enzyme
9 F8WBH3 Aldehyde dehydrogenase family 16 member A1
9 H0YN42 Annexin (Fragment)
9 B4E3P0 ATP-citrate synthase
9 Q08211 ATP-dependent RNA helicase A
9 Q92499 ATP-dependent RNA helicase DDX1 16408927
9 Q9NVP1 ATP-dependent RNA helicase DDX18
9 Q9BQ39 ATP-dependent RNA helicase DDX50
9 P25098 Beta-adrenergic receptor kinase 1
9 P07814 Bifunctional glutamate/proline–tRNA ligase 16408927
9 K7ES02 Bleomycin hydrolase (Fragment)
9 P27824 Calnexin
9 G3V153 Caprin-1
9 P31944 Caspase-14
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
9 E5RHJ4 Cell cycle and apoptosis regulator protein 2 (Fragment)
9 Q12996 Cleavage stimulation factor subunit 3
9 P53621 Coatomer subunit alpha 16408927
9 O75534 Cold shock domain-containing protein E1 20305658
9 E9PHA2 Condensin complex subunit 2
9 Q5JY65 Crooked neck-like protein 1
9 K4DI93 Cullin 4B, isoform CRA e
9 Q13616 Cullin-1
9 Q13618 Cullin-3
9 A8MVQ3 Cysteine–tRNA ligase, cytoplasmic
9 Q08554 Desmocollin-1
9 Q02413 Desmoglein-1
9 P15924 Desmoplakin
9 J3KQ69 DNA replication licensing factor MCM3
9 P33992 DNA replication licensing factor MCM5
9 Q14566 DNA replication licensing factor MCM6 16408927
9 P33993 DNA replication licensing factor MCM7 16408927
9 Q99543 DnaJ homolog subfamily C member 2
9 F5GXT0 Double-strand break repair protein MRE11A
9 G8JLD5 Dynamin-1-like protein
9 P13639 Elongation factor 2 16408927
9 Q92556 Engulfment and cell motility protein 1
9 K7EM90 Enolase (Fragment)
9 P58107 Epiplakin
9 F5H335 Eukaryotic translation initiation factor 3 subunit A
9 P55884 Eukaryotic translation initiation factor 3 subunit B 16408927
9 H3BRV0 Eukaryotic translation initiation factor 3 subunit C
9 E7EQR4 Ezrin
9 Q92945 Far upstream element-binding protein 2 16408927
9 P20930 Filaggrin
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
9 Q5D862 Filaggrin-2
9 P51116 Fragile X mental retardation syndrome-related protein 2
9 P47929 Galectin-7
9 E7EPR3 Gamma-interferon-inducible protein 16
9 P78347 General transcription factor II-I
9 Q06210 Glutamine–fructose-6-phosphate aminotransferase [isomerizing] 1
9 P04406 Glyceraldehyde-3-phosphate dehydrogenase 18794846
9 P41250 Glycine–tRNA ligase 16408927
9 P13807 Glycogen [starch] synthase, muscle 18174169
9 O00178 GTP-binding protein 1
9 P04792 Heat shock protein beta-1
9 P07900 Heat shock protein HSP 90-alpha 16408927
9 P08238 Heat shock protein HSP 90-beta 16408927
9 Q5SWC8 Heterochromatin protein 1-binding protein 3 (Fragment)
9 P52272 Heterogeneous nuclear ribonucleoprotein M
9 O43390 Heterogeneous nuclear ribonucleoprotein R 20305658
9 Q00839 Heterogeneous nuclear ribonucleoprotein U 16408927
9 Q1KMD3 Heterogeneous nuclear ribonucleoprotein U-like protein 2
9 F8W0V1 Histidine ammonia-lyase (Fragment)
9 P01871 Ig mu chain C region
9 Q12906 Interleukin enhancer-binding factor 3 20305658
9 J3KR24 Isoleucine–tRNA ligase, cytoplasmic
9 F5GWP8 Junction plakoglobin
9 C9J315 Lanosterol synthase (Fragment)
9 Q4G0J3 La-related protein 7
9 D6REM6 Matrin-3
9 G5E9X5 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial
9 P35579 Myosin-9 16408927
9 P43007 Neutral amino acid transporter A
9 Q15758 Neutral amino acid transporter B(0)
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
9 Q09161 Nuclear cap-binding protein subunit 1
9 Q7Z417 Nuclear fragile X mental retardation-interacting protein 2 20305658
9 Q9Y3T9 Nucleolar complex protein 2 homolog
9 F5H6G7 Nucleolar protein 10
9 Q9NR30 Nucleolar RNA helicase 2 16408927
9 Q13835 Plakophilin-1
9 B1ANR0 Poly(A) binding protein, cytoplasmic 4 (Inducible form), isoform CRA e
9 Q8TCS8 Polyribonucleotide nucleotidyltransferase 1, mitochondrial
9 O94906 Pre-mRNA-processing factor 6
9 E9PIF2 Probable ATP-dependent RNA helicase DDX10
9 C9JMU5 Probable ATP-dependent RNA helicase DDX17
9 Q9BUQ8 Probable ATP-dependent RNA helicase DDX23
9 Q9Y4C8 Probable RNA-binding protein 19
9 Q9NY61 Protein AATF
9 Q8WVV4 Protein POF1B
9 Q13123 Protein Red
9 E7EW05 Protein SDA1 homolog
9 B3KXI2 Protein transport protein Sec23A
9 Q15437 Protein transport protein Sec23B 20305658
9 Q08188 Protein-glutamine gamma-glutamyltransferase E
9 Q96PZ0 Pseudouridylate synthase 7 homolog
9 O43143 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 16408927
9 P46087 Putative ribosomal RNA methyltransferase NOP2
9 B1ALK7 Rho guanine nucleotide exchange factor 7
9 O76094 Signal recognition particle subunit SRP72
9 P23246 Splicing factor, proline- and glutamine-rich 20305658
9 Q5R363 SRSF protein kinase 1
9 Q9Y5Y6 Suppressor of tumorigenicity 14 protein
9 P52888 Thimet oligopeptidase
9 Q96FV9 THO complex subunit 1
D
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
9 H7C072 THO complex subunit 5 homolog (Fragment)
9 P26639 Threonine–tRNA ligase, cytoplasmic 16408927
9 A2T926 Thymopentin
9 Q13263 Transcription intermediary factor 1-beta
9 J3KNP2 Transducin beta-like protein 3 (Fragment)
9 P55072 Transitional endoplasmic reticulum ATPase
9 P40939 Trifunctional enzyme subunit alpha, mitochondrial
9 E7ET15 U2 snRNP-associated SURP motif-containing protein
9 E7EVD1 U4/U6 small nuclear ribonucleoprotein Prp3
9 J3QSA3 Ubiquitin (Fragment)
9 B4DWJ2 Uncharacterized protein
9 Q96QK1 Vacuolar protein sorting-associated protein 35
9 P26640 Valine–tRNA ligase 16408927
9 Q15061 WD repeat-containing protein 43
9 P13010 X-ray repair cross-complementing protein 5 16408927
9 Q7Z2W4 Zinc finger CCCH-type antiviral protein 1
10 O43242 26S proteasome non-ATPase regulatory subunit 3
10 P10809 60 kDa heat shock protein, mitochondrial
10 P11021 78 kDa glucose-regulated protein 16408927
10 O95782 AP-2 complex subunit alpha-1
10 K7EJ01 AP-2 complex subunit beta (Fragment)
10 P54136 Arginine–tRNA ligase, cytoplasmic
10 F8WEJ5 Asparagine synthetase [glutamine-hydrolyzing]
10 O43776 Asparagine–tRNA ligase, cytoplasmic 16408927
10 P61221 ATP-binding cassette sub-family E member 1
10 B4E3P0 ATP-citrate synthase
10 P46063 ATP-dependent DNA helicase Q1
10 Q08211 ATP-dependent RNA helicase A
10 Q9NVP1 ATP-dependent RNA helicase DDX18
10 O00571 ATP-dependent RNA helicase DDX3X
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
10 F5H5U2 ATP-dependent RNA helicase DDX55
10 O43252 Bifunctional 3’-phosphoadenosine 5’-phosphosulfate synthase 1
10 Q3LXA3 Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing)
10 P07814 Bifunctional glutamate/proline–tRNA ligase 16408927
10 P31939 Bifunctional purine biosynthesis protein PURH 16408927
10 E9PLA9 Caprin-1 (Fragment)
10 Q9NXV6 CDKN2A-interacting protein 20068230 S348;T322
10 Q9UJX2 Cell division cycle protein 23 homolog
10 Q969X6 Cirhin
10 F8WJN3 Cleavage and polyadenylation-specificity factor subunit 6
10 O75534 Cold shock domain-containing protein E1 20305658
10 E7EN77 Condensin complex subunit 1 (Fragment)
10 P17812 CTP synthase 1
10 Q9Y3Z3 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1
10 H0YDD4 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase com-
plex, mitochondrial (Fragment)
10 Q16555 Dihydropyrimidinase-related protein 2
10 P33993 DNA replication licensing factor MCM7 16408927
10 P11387 DNA topoisomerase 1
10 B7Z4L4 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase subunit 1
10 Q9H4M9 EH domain-containing protein 1
10 Q9H223 EH domain-containing protein 4
10 P13639 Elongation factor 2 16408927
10 P55884 Eukaryotic translation initiation factor 3 subunit B 16408927
10 O15371 Eukaryotic translation initiation factor 3 subunit D
10 Q9Y262 Eukaryotic translation initiation factor 3 subunit L
10 E7EQR4 Ezrin
10 Q92945 Far upstream element-binding protein 2 16408927
10 Q96I24 Far upstream element-binding protein 3
10 P49327 Fatty acid synthase
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10 F5H1C6 Fermitin family homolog 3 (Fragment)
10 B4DXZ6 Fragile X mental retardation syndrome-related protein 1
10 Q06210 Glutamine–fructose-6-phosphate aminotransferase [isomerizing] 1
10 O00178 GTP-binding protein 1
10 Q9BVP2 Guanine nucleotide-binding protein-like 3
10 O60832 H/ACA ribonucleoprotein complex subunit 4
10 H3BQZ7 HCG2044799
10 P08107 Heat shock 70 kDa protein 1A/1B 16177265, 17645866
10 P34932 Heat shock 70 kDa protein 4 16408927
10 P11142 Heat shock cognate 71 kDa protein 16408927
10 B4DY72 Heat shock protein 105 kDa
10 P08238 Heat shock protein HSP 90-beta 16408927
10 Q5SSJ5 Heterochromatin protein 1-binding protein 3
10 P14866 Heterogeneous nuclear ribonucleoprotein L 20305658
10 P52272 Heterogeneous nuclear ribonucleoprotein M
10 O60506 Heterogeneous nuclear ribonucleoprotein Q 20305658
10 O43390 Heterogeneous nuclear ribonucleoprotein R 20305658
10 Q00839 Heterogeneous nuclear ribonucleoprotein U 16408927
10 P01871 Ig mu chain C region
10 P52294 Importin subunit alpha-5
10 Q9NZI8 Insulin-like growth factor 2 mRNA-binding protein 1
10 Q9Y6M1 Insulin-like growth factor 2 mRNA-binding protein 2
10 O00425 Insulin-like growth factor 2 mRNA-binding protein 3
10 P19525 Interferon-induced, double-stranded RNA-activated protein kinase
10 Q12906 Interleukin enhancer-binding factor 3 20305658
10 O00139 Kinesin-like protein KIF2A
10 Q9UQ13 Leucine-rich repeat protein SHOC-2
10 Q8N1G4 Leucine-rich repeat-containing protein 47
10 P09960 Leukotriene A-4 hydrolase 16408927
10 B4DJ96 Luc7-like protein 3
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10 Q15046 Lysine–tRNA ligase 20305658
10 D6REM6 Matrin-3
10 P55081 Microfibrillar-associated protein 1
10 H0YN19 Myelin expression factor 2 (Fragment)
10 P35579 Myosin-9 16408927
10 P23368 NAD-dependent malic enzyme, mitochondrial
10 Q9BXJ9 N-alpha-acetyltransferase 15, NatA auxiliary subunit
10 C9JEM7 Negative elongation factor A (Fragment)
10 Q15758 Neutral amino acid transporter B(0)
10 E9PIN3 Nuclear RNA export factor 1 (Fragment)
10 E9PFK5 Nucleolar protein 14
10 O00567 Nucleolar protein 56
10 Q9Y2X3 Nucleolar protein 58
10 Q86U38 Nucleolar protein 9
10 Q9NR30 Nucleolar RNA helicase 2 16408927
10 E9PKP7 Nucleolar transcription factor 1
10 Q8WXF1 Paraspeckle component 1
10 B4DJV5 Periodic tryptophan protein 1 homolog
10 B5MCF9 Pescadillo homolog
10 Q9NSD9 Phenylalanine–tRNA ligase beta subunit
10 Q16822 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial
10 Q9H307 Pinin
10 P13796 Plastin-2
10 P09874 Poly [ADP-ribose] polymerase 1 16408927
10 Q9UHX1 Poly(U)-binding-splicing factor PUF60
10 E7ERJ7 Polyadenylate-binding protein 1
10 Q6UN15 Pre-mRNA 3’-end-processing factor FIP1
10 Q5SRN1 Pre-mRNA-processing factor 17
10 E9PIF2 Probable ATP-dependent RNA helicase DDX10
10 C9JMU5 Probable ATP-dependent RNA helicase DDX17
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10 B4DLW8 Probable ATP-dependent RNA helicase DDX5
10 A8MTP9 Probable ATP-dependent RNA helicase DDX52
10 H7C3E9 Probable ATP-dependent RNA helicase DDX56 (Fragment)
10 O60678 Protein arginine N-methyltransferase 3
10 B4DV00 Protein arginine N-methyltransferase 5
10 Q96GA3 Protein LTV1 homolog
10 Q96PZ0 Pseudouridylate synthase 7 homolog
10 K7EMM8 Putative oxidoreductase GLYR1 (Fragment)
10 O43143 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 16408927
10 P46087 Putative ribosomal RNA methyltransferase NOP2
10 P14618 Pyruvate kinase PKM 16408927
10 Q9BZI7 Regulator of nonsense transcripts 3B
10 I3L4R8 Replication protein A 70 kDa DNA-binding subunit (Fragment)
10 J3QSV6 Ribosomal L1 domain-containing protein 1 (Fragment)
10 Q14692 Ribosome biogenesis protein BMS1 homolog
10 Q96PK6 RNA-binding protein 14 20068230 S244;S254;S256;S280
10 E1P5S2 RNA-binding protein 39
10 P57772 Selenocysteine-specific elongation factor
10 Q08170 Serine/arginine-rich splicing factor 4
10 P10398 Serine/threonine-protein kinase A-Raf
10 Q9BVS4 Serine/threonine-protein kinase RIO2
10 P30153 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 16408927
10 P30154 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform
10 F5H5Y3 Signal recognition particle subunit SRP68
10 G3V4X8 SNW domain-containing protein 1
10 Q9NQZ2 Something about silencing protein 10
10 Q15459 Splicing factor 3A subunit 1
10 E9PJ04 Splicing factor 3B subunit 2 (Fragment)
10 Q15393 Splicing factor 3B subunit 3 16408927
10 P23246 Splicing factor, proline- and glutamine-rich 20305658
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10 Q7KZF4 Staphylococcal nuclease domain-containing protein 1 16408927
10 P38646 Stress-70 protein, mitochondrial 16408927
10 F5H0T1 Stress-induced-phosphoprotein 1
10 Q9UH65 Switch-associated protein 70
10 P17987 T-complex protein 1 subunit alpha 16408927
10 B7ZAR1 T-complex protein 1 subunit epsilon
10 Q99832 T-complex protein 1 subunit eta
10 B4DUR8 T-complex protein 1 subunit gamma
10 P50990 T-complex protein 1 subunit theta 16408927;17614351
10 P40227 T-complex protein 1 subunit zeta 16408927
10 H3BR06 Telomeric repeat-binding factor 2 (Fragment)
10 B4E022 Transketolase
10 Q9UI10 Translation initiation factor eIF-2B subunit delta
10 Q08J23 tRNA (cytosine(34)-C(5))-methyltransferase
10 Q9UIG0 Tyrosine-protein kinase BAZ1B
10 P08621 U1 small nuclear ribonucleoprotein 70 kDa
10 Q9Y5J1 U3 small nucleolar RNA-associated protein 18 homolog
10 Q9NYH9 U3 small nucleolar RNA-associated protein 6 homolog
10 B9A018 U4/U6.U5 tri-snRNP-associated protein 2
10 J3QSA3 Ubiquitin (Fragment)
10 P49748 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial
10 B7Z1R5 V-type proton ATPase catalytic subunit A
10 P13010 X-ray repair cross-complementing protein 5 16408927
10 P12956 X-ray repair cross-complementing protein 6
10 Q96KR1 Zinc finger RNA-binding protein 20068230 S148;S195;T202
11 P62258 14-3-3 protein epsilon
11 C9J9M4 26S proteasome non-ATPase regulatory subunit 1 (Fragment)
11 P49406 39S ribosomal protein L19, mitochondrial
11 P15880 40S ribosomal protein S2 18794846
11 F2Z2S8 40S ribosomal protein S3
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11 D6RG13 40S ribosomal protein S3a (Fragment)
11 P62701 40S ribosomal protein S4, X isoform
11 P62753 40S ribosomal protein S6 20305658
11 C9J9K3 40S ribosomal protein SA (Fragment)
11 F8VU65 60S acidic ribosomal protein P0 (Fragment)
11 P46777 60S ribosomal protein L5 18794846
11 P18124 60S ribosomal protein L7
11 P62424 60S ribosomal protein L7a
11 E9PKZ0 60S ribosomal protein L8 (Fragment)
11 O15144 Actin-related protein 2/3 complex subunit 2
11 Q9UIV1 CCR4-NOT transcription complex subunit 7
11 B5MDQ4 Cell differentiation protein RCD1 homolog
11 Q9Y3Y2 Chromatin target of PRMT1 protein
11 Q96CT7 Coiled-coil domain-containing protein 124
11 F5H7C6 COP9 signalosome complex subunit 7a (Fragment)
11 J3KQ34 COP9 signalosome complex subunit 7b
11 P81605 Dermcidin
11 P29692 Elongation factor 1-delta
11 K7EM90 Enolase (Fragment)
11 Q5RKV6 Exosome complex component MTR3
11 Q9NQT5 Exosome complex component RRP40
11 D6RAU2 Guanine nucleotide-binding protein subunit beta-2-like 1
11 D6R9P3 Heterogeneous nuclear ribonucleoprotein A/B
11 Q13151 Heterogeneous nuclear ribonucleoprotein A0 20305658
11 F8W6I7 Heterogeneous nuclear ribonucleoprotein A1
11 P51991 Heterogeneous nuclear ribonucleoprotein A3 16408927
11 H0YA96 Heterogeneous nuclear ribonucleoprotein D0 (Fragment)
11 Q5T6W2 Heterogeneous nuclear ribonucleoprotein K (Fragment)
11 O60506 Heterogeneous nuclear ribonucleoprotein Q 20305658
11 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 20305658
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11 G3V4W0 Heterogeneous nuclear ribonucleoproteins C1/C2 (Fragment)
11 P26583 High mobility group protein B2
11 P16403 Histone H1.2 20305658
11 P16401 Histone H1.5 20305658
11 Q92522 Histone H1x 20305658
11 P13761 HLA class II histocompatibility antigen, DRB1-7 beta chain
11 Q9UBB5 Methyl-CpG-binding domain protein 2
11 Q9UKD2 mRNA turnover protein 4 homolog
11 Q9HAN9 Nicotinamide mononucleotide adenylyltransferase 1
11 C9JW96 Prohibitin (Fragment)
11 P12004 Proliferating cell nuclear antigen
11 H0YNE3 Proteasome activator complex subunit 1
11 H0YM70 Proteasome activator complex subunit 2
11 K7EMD0 Proteasome activator complex subunit 3 (Fragment)
11 V9GYH7 Proteasome assembly chaperone 2
11 P25786 Proteasome subunit alpha type-1
11 Q9BXY0 Protein MAK16 homolog
11 O95478 Ribosome biogenesis protein NSA2 homolog
11 Q9NRX1 RNA-binding protein PNO1
11 Q9UKM9 RNA-binding protein Raly
11 Q07955 Serine/arginine-rich splicing factor 1
11 B7Z2F4 T-complex protein 1 subunit delta
11 P50990 T-complex protein 1 subunit theta 16408927;17614351
11 Q86V81 THO complex subunit 4
11 P67936 Tropomyosin alpha-4 chain
11 Q9BQE3 Tubulin alpha-1C chain
11 Q5JP53 Tubulin beta chain
11 K7EP07 Tubulin-folding cofactor B (Fragment)
11 P09661 U2 small nuclear ribonucleoprotein A’
11 Q5VU59 Uncharacterized protein
D
19
Table D.1: (continued)
Gel Piece Accession Description PMID Site
11 G3V2S6 V-type proton ATPase subunit D
11 P16989 Y-box-binding protein 3
12 P31946 14-3-3 protein beta/alpha 16408927
12 P31946 14-3-3 protein beta/alpha 16408927
12 P62258 14-3-3 protein epsilon
12 Q04917 14-3-3 protein eta
12 P61981 14-3-3 protein gamma
12 P27348 14-3-3 protein theta
12 P63104 14-3-3 protein zeta/delta
12 K7EJR3 26S proteasome non-ATPase regulatory subunit 8 (Fragment)
12 C9IY40 39S ribosomal protein L2, mitochondrial
12 P15880 40S ribosomal protein S2 18794846
12 P23396 40S ribosomal protein S3
12 D6RG13 40S ribosomal protein S3a (Fragment)
12 P62701 40S ribosomal protein S4, X isoform
12 A2A3R5 40S ribosomal protein S6
12 Q5JR95 40S ribosomal protein S8
12 C9J9K3 40S ribosomal protein SA (Fragment)
12 P05388 60S acidic ribosomal protein P0
12 P26373 60S ribosomal protein L13 20305658
12 Q02878 60S ribosomal protein L6
12 A8MUD9 60S ribosomal protein L7
12 Q5T8U3 60S ribosomal protein L7a (Fragment)
12 Q6DKI1 60S ribosomal protein L7-like 1
12 M0R261 6-phosphogluconolactonase (Fragment)
12 Q9UKK9 ADP-sugar pyrophosphatase
12 Q9HB71 Calcyclin-binding protein
12 Q9NX58 Cell growth-regulating nucleolar protein
12 O00299 Chloride intracellular channel protein 1
12 P27707 Deoxycytidine kinase
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12 P24534 Elongation factor 1-beta
12 E7EUT5 Glyceraldehyde-3-phosphate dehydrogenase
12 D6R9P3 Heterogeneous nuclear ribonucleoprotein A/B
12 Q13151 Heterogeneous nuclear ribonucleoprotein A0 20305658
12 F8W6I7 Heterogeneous nuclear ribonucleoprotein A1
12 P51991 Heterogeneous nuclear ribonucleoprotein A3 16408927
12 H0YA96 Heterogeneous nuclear ribonucleoprotein D0 (Fragment)
12 Q5T6W5 Heterogeneous nuclear ribonucleoprotein K
12 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 20305658
12 G3V5X6 Heterogeneous nuclear ribonucleoproteins C1/C2 (Fragment)
12 P16403 Histone H1.2 20305658
12 Q96GX9 Methylthioribulose-1-phosphate dehydratase
12 B8ZZL5 MIT domain-containing protein 1 (Fragment)
12 P06748 Nucleophosmin 16408927
12 Q9BRP8 Partner of Y14 and mago
12 P18669 Phosphoglycerate mutase 1
12 P13796 Plastin-2
12 Q15365 Poly(rC)-binding protein 1
12 Q9UL46 Proteasome activator complex subunit 2 16408927
12 H0YLC2 Proteasome subunit alpha type
12 P25788 Proteasome subunit alpha type-3
12 O14818 Proteasome subunit alpha type-7
12 Q9BPW8 Protein NipSnap homolog 1
12 H0Y6C3 Pyrroline-5-carboxylate reductase 3 (Fragment)
12 J3KRE2 Rho GDP-dissociation inhibitor 1
12 Q5VU10 Ribonuclease P protein subunit p30 (Fragment)
12 Q92979 Ribosomal RNA small subunit methyltransferase NEP1
12 H0Y6E7 RNA-binding motif protein, X chromosome, N-terminally processed (Fragment)
12 Q5QPM1 RNA-binding protein Raly (Fragment)
12 M0R0P1 rRNA 2’-O-methyltransferase fibrillarin (Fragment)
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12 Q5JRI1 Serine/arginine-rich-splicing factor 10
12 O75940 Survival of motor neuron-related-splicing factor 30
12 P40227 T-complex protein 1 subunit zeta 16408927
12 F8WBV5 Thioredoxin domain-containing protein 9
12 Q86V81 THO complex subunit 4
12 P62995 Transformer-2 protein homolog beta
12 D6R904 Tropomyosin alpha-3 chain
12 F8VVB9 Tubulin alpha-1B chain (Fragment)
12 P09661 U2 small nuclear ribonucleoprotein A’
12 G3V4C6 UPF0568 protein C14orf166
12 P16989 Y-box-binding protein 3
13 P27348 14-3-3 protein theta
13 J3QKW2 28S ribosomal protein S7, mitochondrial
13 Q5H928 3-hydroxyacyl-CoA dehydrogenase type-2
13 E9PPU1 40S ribosomal protein S3
13 Q5JR95 40S ribosomal protein S8
13 P46781 40S ribosomal protein S9 18794846
13 C9J9K3 40S ribosomal protein SA (Fragment)
13 F8VPE8 60S acidic ribosomal protein P0 (Fragment)
13 F8W7C6 60S ribosomal protein L10
13 P62906 60S ribosomal protein L10a
13 P26373 60S ribosomal protein L13 20305658
13 P40429 60S ribosomal protein L13a 18794846
13 P50914 60S ribosomal protein L14
13 P61313 60S ribosomal protein L15
13 P62424 60S ribosomal protein L7a
13 E9PKZ0 60S ribosomal protein L8 (Fragment)
13 P67870 Casein kinase II subunit beta 20305658
13 O43809 Cleavage and polyadenylation specificity factor subunit 5
13 P81605 Dermcidin
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13 P19388 DNA-directed RNA polymerases I, II, and III subunit RPABC1
13 P24534 Elongation factor 1-beta
13 P20042 Eukaryotic translation initiation factor 2 subunit 2
13 P04406 Glyceraldehyde-3-phosphate dehydrogenase 18794846
13 Q8TAE8 Growth arrest and DNA damage-inducible proteins-interacting protein 1
13 P62826 GTP-binding nuclear protein Ran
13 E9PI65 Heat shock cognate 71 kDa protein (Fragment)
13 D6R9P3 Heterogeneous nuclear ribonucleoprotein A/B
13 Q13151 Heterogeneous nuclear ribonucleoprotein A0 20305658
13 F8W6I7 Heterogeneous nuclear ribonucleoprotein A1
13 P51991 Heterogeneous nuclear ribonucleoprotein A3 16408927
13 D6RF44 Heterogeneous nuclear ribonucleoprotein D0 (Fragment)
13 E9PCY7 Heterogeneous nuclear ribonucleoprotein H
13 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 20305658
13 P16403 Histone H1.2 20305658
13 Q5SRN7 HLA class I histocompatibility antigen, A-68 alpha chain
13 P00492 Hypoxanthine-guanine phosphoribosyltransferase 20305658
13 F8VZJ2 Nascent polypeptide-associated complex subunit alpha, muscle-specific form
13 D6RIC3 Nucleolar protein 16
13 H7C3T4 Peroxiredoxin-4 (Fragment)
13 P30041 Peroxiredoxin-6
13 O75934 Pre-mRNA-splicing factor SPF27
13 P25787 Proteasome subunit alpha type-2
13 P28066 Proteasome subunit alpha type-5 18984734 S198
13 P60900 Proteasome subunit alpha type-6
13 H0Y586 Proteasome subunit alpha type-7 (Fragment)
13 B7Z972 Protein-L-isoaspartate O-methyltransferase
13 H3BMH2 Ras-related protein Rab-11A (Fragment)
13 P51148 Ras-related protein Rab-5C
13 P49247 Ribose-5-phosphate isomerase
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13 J3QR09 Ribosomal protein L19
13 Q92979 Ribosomal RNA small subunit methyltransferase NEP1
13 H0Y6E7 RNA-binding motif protein, X chromosome, N-terminally processed (Fragment)
13 P60174 Triosephosphate isomerase 20305658
13 P08579 U2 small nuclear ribonucleoprotein B”
13 Q9Y224 UPF0568 protein C14orf166
13 P16989 Y-box-binding protein 3
14 Q9Y3B7 39S ribosomal protein L11, mitochondrial
14 E9PPU1 40S ribosomal protein S3
14 P62081 40S ribosomal protein S7
14 Q5JR95 40S ribosomal protein S8
14 P46781 40S ribosomal protein S9 18794846
14 C9J9K3 40S ribosomal protein SA (Fragment)
14 F8W7C6 60S ribosomal protein L10
14 P26373 60S ribosomal protein L13 20305658
14 P50914 60S ribosomal protein L14
14 P61313 60S ribosomal protein L15
14 F8VWC5 60S ribosomal protein L18
14 C9JXB8 60S ribosomal protein L24
14 Q02878 60S ribosomal protein L6
14 D6RAN4 60S ribosomal protein L9 (Fragment)
14 A8MX94 Glutathione S-transferase P
14 P04406 Glyceraldehyde-3-phosphate dehydrogenase 18794846
14 F8W6I7 Heterogeneous nuclear ribonucleoprotein A1
14 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 20305658
14 P16403 Histone H1.2 20305658
14 P62805 Histone H4
14 Q12905 Interleukin enhancer-binding factor 2
14 F8VZJ2 Nascent polypeptide-associated complex subunit alpha, muscle-specific form
14 Q06830 Peroxiredoxin-1 16408927
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14 P20618 Proteasome subunit beta type-1
14 P28070 Proteasome subunit beta type-4
14 P28074 Proteasome subunit beta type-5
14 P61224 Ras-related protein Rap-1b
14 H0Y6E7 RNA-binding motif protein, X chromosome, N-terminally processed (Fragment)
14 B7Z9L0 T-complex protein 1 subunit delta
15 Q9NWU5 39S ribosomal protein L22, mitochondrial
15 F5H702 39S ribosomal protein L48, mitochondrial
15 M0QZC5 40S ribosomal protein S11
15 F2Z2S8 40S ribosomal protein S3
15 P62081 40S ribosomal protein S7
15 Q5JR95 40S ribosomal protein S8
15 P46781 40S ribosomal protein S9 18794846
15 P05388 60S acidic ribosomal protein P0
15 Q5VVC9 60S ribosomal protein L11 (Fragment)
15 P30050 60S ribosomal protein L12
15 P50914 60S ribosomal protein L14
15 J3QS96 60S ribosomal protein L17 (Fragment)
15 F8VUA6 60S ribosomal protein L18 (Fragment)
15 P46778 60S ribosomal protein L21 20305658
15 P62750 60S ribosomal protein L23a
15 C9JXB8 60S ribosomal protein L24
15 J3KTJ8 60S ribosomal protein L26 (Fragment)
15 P47914 60S ribosomal protein L29
15 A8MUD9 60S ribosomal protein L7
15 E9PKZ0 60S ribosomal protein L8 (Fragment)
15 D6RAN4 60S ribosomal protein L9 (Fragment)
15 Q9Y221 60S ribosome subunit biogenesis protein NIP7 homolog
15 F8VR50 Actin-related protein 2/3 complex subunit 3 (Fragment)
15 F8WDD7 Actin-related protein 2/3 complex subunit 4
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15 F5H0C7 ADP-ribosylation factor 3 (Fragment)
15 Q92572 AP-3 complex subunit sigma-1
15 Q9NVP1 ATP-dependent RNA helicase DDX18
15 E9PJK1 CD81 antigen
15 F8WJN3 Cleavage and polyadenylation-specificity factor subunit 6
15 G3V1A4 Cofilin 1 (Non-muscle), isoform CRA a
15 Q02413 Desmoglein-1
15 P15924 Desmoplakin
15 Q9NRW3 DNA dC-¿dU-editing enzyme APOBEC-3C
15 P62487 DNA-directed RNA polymerase II subunit RPB7
15 P68104 Elongation factor 1-alpha 1 16408927
15 O43324 Eukaryotic translation elongation factor 1 epsilon-1
15 P02792 Ferritin light chain
15 P20930 Filaggrin
15 Q5D862 Filaggrin-2
15 P47929 Galectin-7
15 D6R9P3 Heterogeneous nuclear ribonucleoprotein A/B
15 F8W6I7 Heterogeneous nuclear ribonucleoprotein A1
15 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 20305658
15 G3V4C1 Heterogeneous nuclear ribonucleoproteins C1/C2
15 P16403 Histone H1.2 20305658
15 P16401 Histone H1.5 20305658
15 Q86YZ3 Hornerin
15 Q96AZ6 Interferon-stimulated gene 20 kDa protein
15 F5GWP8 Junction plakoglobin
15 P00338 L-lactate dehydrogenase A chain
15 H3BNT4 M-phase phosphoprotein 6
15 P19105 Myosin regulatory light chain 12A
15 Q96J17 NOLC1 protein
15 P67809 Nuclease-sensitive element-binding protein 1 20305658
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15 P06748 Nucleophosmin 16408927
15 P23284 Peptidyl-prolyl cis-trans isomerase B 20305658
15 H0YM70 Proteasome activator complex subunit 2
15 A2ACR1 Proteasome subunit beta type
15 P28074 Proteasome subunit beta type-5
15 Q5JNW7 Proteasome subunit beta type-8
15 P51149 Ras-related protein Rab-7a
15 P61224 Ras-related protein Rap-1b
15 Q86V81 THO complex subunit 4
15 F8VRK0 Tubulin alpha-1B chain (Fragment)
15 Q9NV31 U3 small nucleolar ribonucleoprotein protein IMP3
16 P46783 40S ribosomal protein S10
16 M0QZC5 40S ribosomal protein S11
16 J3KMX5 40S ribosomal protein S13
16 K7EQJ5 40S ribosomal protein S15
16 P0CW22 40S ribosomal protein S17-like
16 P62269 40S ribosomal protein S18 20305658
16 P62266 40S ribosomal protein S23 16408927
16 E7ETK0 40S ribosomal protein S24
16 P62851 40S ribosomal protein S25
16 E9PQ96 40S ribosomal protein S3
16 P05388 60S acidic ribosomal protein P0
16 P30050 60S ribosomal protein L12
16 F8VUA6 60S ribosomal protein L18 (Fragment)
16 G3V1B3 60S ribosomal protein L21
16 K7EMA7 60S ribosomal protein L23a
16 P61254 60S ribosomal protein L26 20305658
16 P61353 60S ribosomal protein L27
16 E9PJD9 60S ribosomal protein L27a
16 H0YLP6 60S ribosomal protein L28
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16 F2Z388 60S ribosomal protein L35
16 E9PKZ0 60S ribosomal protein L8 (Fragment)
16 Q9BPX5 Actin-related protein 2/3 complex subunit 5-like protein
16 E9PLJ3 Cofilin-1 (Fragment)
16 K7ELV6 Cold-inducible RNA-binding protein (Fragment)
16 H0YNW5 Deoxyuridine 5’-triphosphate nucleotidohydrolase, mitochondrial
16 P81605 Dermcidin
16 C9JBJ6 DNA-directed RNA polymerases I, II, and III subunit RPABC3
16 D6R9P3 Heterogeneous nuclear ribonucleoprotein A/B
16 F8W6I7 Heterogeneous nuclear ribonucleoprotein A1
16 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 20305658
16 G3V5X6 Heterogeneous nuclear ribonucleoproteins C1/C2 (Fragment)
16 K7ELW9 Histone chaperone ASF1B
16 P16403 Histone H1.2 20305658
16 P16401 Histone H1.5 20305658
16 P06748 Nucleophosmin 16408927
16 P15531 Nucleoside diphosphate kinase A
16 P20290 Transcription factor BTF3
17 J3KMX5 40S ribosomal protein S13
17 H0YB22 40S ribosomal protein S14 (Fragment)
17 I3L3P7 40S ribosomal protein S15a
17 M0R210 40S ribosomal protein S16
17 P0CW22 40S ribosomal protein S17-like
17 P39019 40S ribosomal protein S19 20305658
17 P62851 40S ribosomal protein S25
17 E9PQ96 40S ribosomal protein S3
17 Q5JR95 40S ribosomal protein S8
17 P30050 60S ribosomal protein L12
17 F8VUA6 60S ribosomal protein L18 (Fragment)
17 P62750 60S ribosomal protein L23a
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17 E9PJD9 60S ribosomal protein L27a
17 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 20305658
17 P06899 Histone H2B type 1-J
17 K7EMV3 Histone H3
17 J3QQQ9 KRAB-A domain-containing protein 2
17 P15531 Nucleoside diphosphate kinase A
18 P46783 40S ribosomal protein S10
18 P62244 40S ribosomal protein S15a
18 M0R3H0 40S ribosomal protein S16
18 P39019 40S ribosomal protein S19 20305658
18 P60866 40S ribosomal protein S20
18 P05387 60S acidic ribosomal protein P2 20305658
18 P62829 60S ribosomal protein L23
18 K7EMA7 60S ribosomal protein L23a
18 P49207 60S ribosomal protein L34
18 P16403 Histone H1.2 20305658
18 C9J0D1 Histone H2A
18 Q16777 Histone H2A type 2-C
18 O60814 Histone H2B type 1-K
18 F8W1R7 Myosin light polypeptide 6
18 F8W1N5 Nascent polypeptide-associated complex subunit alpha, muscle-specific form (Fragment)
18 H7BY16 Nucleolin (Fragment)
18 H0YLA2 Signal recognition particle 14 kDa protein
18 P62314 Small nuclear ribonucleoprotein Sm D1
19 P62244 40S ribosomal protein S15a
19 Q5JR95 40S ribosomal protein S8
19 P05387 60S acidic ribosomal protein P2 20305658
19 J3QSB4 60S ribosomal protein L13 (Fragment)
19 J3KTJ3 60S ribosomal protein L23
19 P62750 60S ribosomal protein L23a
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19 E9PJD9 60S ribosomal protein L27a
19 E5RI99 60S ribosomal protein L30 (Fragment)
19 P16403 Histone H1.2 20305658
19 C9J0D1 Histone H2A
19 P06899 Histone H2B type 1-J
19 P62805 Histone H4
19 P31025 Lipocalin-1
19 K7EJ44 Profilin 1, isoform CRA b
19 Q9Y3B4 Splicing factor 3B subunit 6
19 H0YJW7 SRA stem-loop-interacting RNA-binding protein, mitochondrial (Fragment)
20 P62750 60S ribosomal protein L23a
20 P62805 Histone H4
21 P05387 60S acidic ribosomal protein P2 20305658
21 A6NCN2 Putative keratin-87 protein
22 O00487 26S proteasome non-ATPase regulatory subunit 14
22 P55036 26S proteasome non-ATPase regulatory subunit 4
22 K7EKI4 39S ribosomal protein L4, mitochondrial
22 Q9H9J2 39S ribosomal protein L44, mitochondrial
22 C9J9K3 40S ribosomal protein SA (Fragment)
22 P05388 60S acidic ribosomal protein P0
22 P39023 60S ribosomal protein L3
22 H3BM89 60S ribosomal protein L4
22 P46777 60S ribosomal protein L5 18794846
22 Q02878 60S ribosomal protein L6
22 P60709 Actin, cytoplasmic 1 20305658
22 O15143 Actin-related protein 2/3 complex subunit 1B
22 Q9ULW3 Activator of basal transcription 1
22 O00170 AH receptor-interacting protein
22 P06733 Alpha-enolase 16408927
22 Q13155 Aminoacyl tRNA synthase complex-interacting multifunctional protein 2
D
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
22 P25705 ATP synthase subunit alpha, mitochondrial
22 B4DT24 B-lymphocyte antigen CD20
22 B4DDF4 Calponin-2
22 Q9NX58 Cell growth-regulating nucleolar protein
22 O14579 Coatomer subunit epsilon
22 Q92905 COP9 signalosome complex subunit 5
22 Q8WXX5 DnaJ homolog subfamily C member 9
22 Q15717 ELAV-like protein 1 20305658
22 P68104 Elongation factor 1-alpha 1 16408927
22 P29692 Elongation factor 1-delta
22 P05198 Eukaryotic translation initiation factor 2 subunit 1
22 P20042 Eukaryotic translation initiation factor 2 subunit 2
22 O75822 Eukaryotic translation initiation factor 3 subunit J 20305658
22 A3KFL1 Exosome complex component RRP4 (Fragment)
22 Q15024 Exosome complex component RRP42
22 Q96B26 Exosome complex component RRP43
22 P52907 F-actin-capping protein subunit alpha-1
22 P04406 Glyceraldehyde-3-phosphate dehydrogenase 18794846
22 P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 16408927;18794846
22 E9PKE3 Heat shock cognate 71 kDa protein
22 B0QZK4 Heterochromatin protein 1-binding protein 3 (Fragment)
22 D6R9P3 Heterogeneous nuclear ribonucleoprotein A/B
22 Q13151 Heterogeneous nuclear ribonucleoprotein A0 20305658
22 F8W6I7 Heterogeneous nuclear ribonucleoprotein A1
22 P51991 Heterogeneous nuclear ribonucleoprotein A3 16408927
22 F5H6R6 Heterogeneous nuclear ribonucleoprotein D0
22 O14979 Heterogeneous nuclear ribonucleoprotein D-like 20305658
22 H0YB39 Heterogeneous nuclear ribonucleoprotein H (Fragment)
22 P31942 Heterogeneous nuclear ribonucleoprotein H3
22 Q5T6W1 Heterogeneous nuclear ribonucleoprotein K
D
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
22 O60506 Heterogeneous nuclear ribonucleoprotein Q 20305658
22 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 20305658
22 G3V4W0 Heterogeneous nuclear ribonucleoproteins C1/C2 (Fragment)
22 Q5SRN7 HLA class I histocompatibility antigen, A-68 alpha chain
22 H0Y4R1 Inosine-5’-monophosphate dehydrogenase 2 (Fragment)
22 O75569 Interferon-inducible double-stranded RNA-dependent protein kinase activator A
22 Q01650 Large neutral amino acids transporter small subunit 1
22 P00338 L-lactate dehydrogenase A chain
22 P07195 L-lactate dehydrogenase B chain 20305658
22 G3XAL0 Malate dehydrogenase
22 P40925 Malate dehydrogenase, cytoplasmic 16408927
22 Q9BYG3 MKI67 FHA domain-interacting nucleolar phosphoprotein
22 Q9BU76 Multiple myeloma tumor-associated protein 2
22 H7C3G9 N-acetyl-D-glucosamine kinase
22 F8VZJ2 Nascent polypeptide-associated complex subunit alpha, muscle-specific form
22 Q8NEJ9 Neuroguidin
22 P67809 Nuclease-sensitive element-binding protein 1 20305658
22 P06748 Nucleophosmin 16408927
22 D6RF62 Phosphoribosylaminoimidazole carboxylase
22 E5RHG7 Polyadenylate-binding protein 1 (Fragment)
22 Q15007 Pre-mRNA-splicing regulator WTAP
22 Q9UNQ2 Probable dimethyladenosine transferase
22 Q99848 Probable rRNA-processing protein EBP2
22 Q9NPF4 Probable tRNA N6-adenosine threonylcarbamoyltransferase
22 F5H3X6 Prohibitin-2 (Fragment)
22 Q9Y315 Putative deoxyribose-phosphate aldolase
22 Q9Y383 Putative RNA-binding protein Luc7-like 2
22 Q504U3 Pyruvate kinase
22 P60891 Ribose-phosphate pyrophosphokinase 1
22 Q15050 Ribosome biogenesis regulatory protein homolog
D
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
22 Q5VXN0 Ribosome production factor 2 homolog (Fragment)
22 H0Y6E7 RNA-binding motif protein, X chromosome, N-terminally processed (Fragment)
22 B4DHE8 RNA-binding protein Musashi homolog 2
22 Q9UKM9 RNA-binding protein Raly
22 P22087 rRNA 2’-O-methyltransferase fibrillarin
22 P04279 Semenogelin-1
22 Q07955 Serine/arginine-rich splicing factor 1
22 Q13243 Serine/arginine-rich splicing factor 5
22 Q13247 Serine/arginine-rich splicing factor 6
22 Q5JRI1 Serine/arginine-rich-splicing factor 10
22 C9JAB2 Serine/arginine-rich-splicing factor 7
22 P62714 Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform
22 O00743 Serine/threonine-protein phosphatase 6 catalytic subunit
22 Q96SI9 Spermatid perinuclear RNA-binding protein
22 Q15427 Splicing factor 3B subunit 4
22 B7Z2F4 T-complex protein 1 subunit delta
22 K7ER96 Thioredoxin-like protein 1 (Fragment)
22 P62995 Transformer-2 protein homolog beta
22 Q9BQE3 Tubulin alpha-1C chain
22 Q5JP53 Tubulin beta chain
22 M0R268 U1 small nuclear ribonucleoprotein A (Fragment)
22 B9A008 U3 small nucleolar ribonucleoprotein protein IMP4 (Fragment)
22 E9PQI8 U4/U6.U5 tri-snRNP-associated protein 1
23 P62805 Histone H4
24 P05387 60S acidic ribosomal protein P2 20305658
24 P15924 Desmoplakin
24 P14923 Junction plakoglobin 12847106
24 P02768 Serum albumin
25 Q5D862 Filaggrin-2
22to11 Q9BYD6 39S ribosomal protein L1, mitochondrial
D
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Table D.1: (continued)
Gel Piece Accession Description PMID Site
22to11 Q9P015 39S ribosomal protein L15, mitochondrial
22to11 P15880 40S ribosomal protein S2 18794846
22to11 P61247 40S ribosomal protein S3a
22to11 P08865 40S ribosomal protein SA
22to11 P05388 60S acidic ribosomal protein P0
22to11 P36578 60S ribosomal protein L4 16408927
22to11 P46777 60S ribosomal protein L5 18794846
22to11 Q02878 60S ribosomal protein L6
22to11 P62424 60S ribosomal protein L7a
22to11 O15144 Actin-related protein 2/3 complex subunit 2
22to11 P36542 ATP synthase subunit gamma, mitochondrial
22to11 P11836 B-lymphocyte antigen CD20
22to11 Q9NX58 Cell growth-regulating nucleolar protein
22to11 O14579 Coatomer subunit epsilon
22to11 P06493 Cyclin-dependent kinase 1
22to11 Q8WXX5 DnaJ homolog subfamily C member 9
22to11 Q15717 ELAV-like protein 1 20305658
22to11 P29692 Elongation factor 1-delta
22to11 Q13868 Exosome complex component RRP4
22to11 P04406 Glyceraldehyde-3-phosphate dehydrogenase 18794846
22to11 P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 16408927;18794846
22to11 Q99729 Heterogeneous nuclear ribonucleoprotein A/B
22to11 Q13151 Heterogeneous nuclear ribonucleoprotein A0 20305658
22to11 Q32P51 Heterogeneous nuclear ribonucleoprotein A1-like 2
22to11 P51991 Heterogeneous nuclear ribonucleoprotein A3 16408927
22to11 Q14103 Heterogeneous nuclear ribonucleoprotein D0 16408927
22to11 O43390 Heterogeneous nuclear ribonucleoprotein R 20305658
22to11 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 20305658
22to11 P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 20305658
22to11 P16403 Histone H1.2 20305658
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Gel Piece Accession Description PMID Site
22to11 P16401 Histone H1.5 20305658
22to11 P01903 HLA class II histocompatibility antigen, DR alpha chain
22to11 Q15181 Inorganic pyrophosphatase
22to11 P07195 L-lactate dehydrogenase B chain 20305658
22to11 P22234 Multifunctional protein ADE2 20305658
22to11 Q13765 Nascent polypeptide-associated complex subunit alpha 20305658
22to11 Q9H2J4 Phosducin-like protein 3
22to11 Q9UNQ2 Probable dimethyladenosine transferase
22to11 P32322 Pyrroline-5-carboxylate reductase 1, mitochondrial
22to11 Q96C36 Pyrroline-5-carboxylate reductase 2
22to11 O76021 Ribosomal L1 domain-containing protein 1
22to11 Q07955 Serine/arginine-rich splicing factor 1
22to11 O75494 Serine/arginine-rich splicing factor 10
22to11 Q01130 Serine/arginine-rich splicing factor 2
22to11 Q13435 Splicing factor 3B subunit 2
22to11 Q01081 Splicing factor U2AF 35 kDa subunit
22to11 P50990 T-complex protein 1 subunit theta 16408927;17614351
22to11 Q9P031 Thyroid transcription factor 1-associated protein 26
22to11 Q9BQE3 Tubulin alpha-1C chain
22to11 P07437 Tubulin beta chain
22to11 P16989 Y-box-binding protein 3
6a I3L3P7 40S ribosomal protein S15a
6a P62829 60S ribosomal protein L23
6a Q16777 Histone H2A type 2-C
6a P62314 Small nuclear ribonucleoprotein Sm D1
6a B4DUR8 T-complex protein 1 subunit gamma
6b P62851 40S ribosomal protein S25
6b P05387 60S acidic ribosomal protein P2 20305658
6b Q16777 Histone H2A type 2-C
6b P62805 Histone H4
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Gel Piece Accession Description PMID Site
6b P00338 L-lactate dehydrogenase A chain
6b P07737 Profilin-1 16408927
6b P62316 Small nuclear ribonucleoprotein Sm D2 20305658
6b Q9Y3B4 Splicing factor 3B subunit 6
6b F5GYQ2 tRNA methyltransferase 112 homolog
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Sequential glycan profiling at single cell level with
the microfluidic lab-in-a-trench platform: a new
era in experimental cell biology†
Tríona M. O'Connell,‡ab Damien King,‡c Chandra K. Dixit,‡cd Brendan O'Connor,ab
Dermot Wallsab and Jens Ducrée*cd
It is now widely recognised that the earliest changes that occur on a cell when it is stressed or becoming
diseased are alterations in its surface glycosylation. Current state-of-the-art technologies in glycoanalysis
include mass spectrometry, protein microarray formats, techniques in cytometry and more recently, glyco-
quantitative polymerase chain reaction (Glyco-qPCR). Techniques for the glycoprofiling of the surfaces of
single cells are either limited to the analysis of large cell populations or are unable to handle multiple
and/or sequential probing. Here, we report a novel approach of single live cell glycoprofiling enabled by
the microfluidic “Lab-in-a-Trench” (LiaT) platform for performing capture and retention of cells, along with
shear-free reagent loading and washing. The significant technical improvement on state-of-the-art is the
demonstration of consecutive, spatio-temporally profiling of glycans on a single cell by sequential elution
of the previous lectin probe using their corresponding free sugar. We have qualitatively analysed glycan
density on the surface of individual cells. This has allowed us to qualitatively co-localise the observed
glycans. This approach enables exhaustive glycoprofiling and glycan mapping on the surface of individual
live cells with multiple lectins. The possibility of sequentially profiling glycans on cells will be a powerful
new tool to add to current glycoanalytical techniques. The LiaT platform will enable cell biologists to
perform many high sensitivity assays and also will also make a significant impact on biomarker research.
Introduction
In this report we present a novel method for sequential cell
surface glycoprofiling at a single cell level that allows for the
mapping of multiple glycans on a cell's surface. Here we
demonstrate the method itself by using a microfluidic LiaT
platform. Analysis of the surface glycosylation profile of a
single cell is crucial for disease biomarker research in order
to correctly elucidate the alteration of expression of a given
biomarker.1 This is important because the abundance of
a given biomarker depends on several factors, the most
important of which are regulatory molecules, such as chemo/
cytokines and an abundance of other biomolecules on
neighbouring cells that may affect the biomarker synergisti-
cally. Current methods mainly focus on the co-expression of
two or more biomarkers, which are an important aspect
for prognosis and understanding cell population signalling
dynamics. However, this may lead to a loss of specific infor-
mation about an individual biomarker.2 Major classes of bio-
markers currently employed in disease diagnosis are genetic
and proteomic in nature. More recently, glycans or more
specifically cell surface glycoproteins have been reported to
be excellent early biomarkers for some disease states.3
Carbohydrates are one of the most abundant, naturally
occurring organic molecules; they are central to the synthesis
and metabolism of all living systems. Glycans are highly
complex carbohydrate molecules and, unlike proteins, they
are not encoded directly by the genome.4 Instead, they are
processed and incorporated at specific sites on proteins and
lipids in various combinations during post-translational
modification by tightly regulated, enzyme-mediated path-
ways. Their ability to form complexes within themselves and
with other biomolecules, such as proteins, makes them a
key component of cellular physiology. Examples of glycan-
mediated signalling include embryonic development, cell
differentiation and growth, cell–cell recognition, contact inhi-
bition and cell signalling. They also have been shown to play
a role in immune functions including host–pathogen inter-
actions and appropriate immune response generation.5,6
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Glycans therefore constitute an advanced class of informa-
tion molecules and the full potential of glycan bio-profiling
has yet to be realized.
There are several challenges that must be overcome to fur-
ther the field of glyco-biology as described in a recent report
by the National Academy of Science and Engineering.7,8 An
important challenge is the identification of glycans as poten-
tial disease biomarkers, and investigations on their distribu-
tion and altered expression between various cell states. A
significant hurdle in biological glycoanalysis is the limited
availability of glycan-recognition biomolecules. Currently,
lectins are the most commonly used probes for glycan analy-
sis. Lectins are proteins that recognise and bind reversibly to
specific glycan structures.9 Although lectin binding affinities
for monosaccharaides are generally quite low, they do bind
to disaccharides and more complex oligosaccharide structures
with significantly higher affinities and exquisite specificity.9
The binding specificity of lectins can depend not only on spe-
cific sugar residues, but also on whether the residue is located
at the terminus or within the carbohydrate structure, and on
the positions and anomeric configurations (α- or β-) of the
linkages between the constituent monosaccharide subunits.9
The limited repertoire of methods for glycoanalysis is also
a major challenge. State-of-the-art glycoanalytical techniques
include mass spectrometry (MS), lectin-based methods,10
modified microarrays,11,12 western blotting (protein immuno-
blotting) and whole cell cytometry methods13 such as mass
cytometry. More recently, glyco-quantitative polymerase chain
reaction (Glyco-qPCR) has been developed for the ultra-
sensitive detection and quantification of glycans in biological
samples.14 Glyco-PCR offers the potential to study low-
abundance glycans on cell surfaces and to quantitatively ana-
lyse interactions between carbohydrates and proteins that are
important for the development and progress of a disease.
However, in spite of the above methodologies, glycan pro-
filing of individual cells is not yet possible due to the limited
amount of sample involved; analytical techniques such as
microarrays and mass spectrometry need concentrated and
high purity glycan fractions which are usually prepared by
lysis and concentration of the glycoprotein extracts from a
cell population. Thus the potential for single cell resolution
and the identification of heterogeneity within the sample are
lost. Flow cytometry or Fluorescence Activated Cell Sorting
(FACS) demands a comparatively large number of cells
(usually 50 000–100 000), and recovery and identification of
individual cells for sequential analysis is again not possible.
In addition cells are either destroyed (mass spectrometry,
mass cytometry, Glyco-qPCR and microarray) or are subjected
to large hydrodynamic shear forces (FACS and microarray).
Therefore, these techniques are not appropriate for sequen-
tial lectin-based glycoanalysis. Furthermore, and most impor-
tantly, the samples involved are usually non-recoverable
(Table 1). Glyco-qPCR is limited to glycans with a free reduc-
ing end and a carboxyl group.14 Although these properties
are common in N-glycans, O-glycans, and glycosaminoglycans,
some glycans lack carboxyl groups. The various drawbacks to
established methods for extensive glycoprofiling at the single
live cell are summarised in Table 1.
In this paper we present a novel method of lectin-based
glycoanalysis with single cell resolution by the use of a micro-
fluidic LiaT platform.15,16 This analytical approach for
the first time permits repeated probing of the cell surface
glycome through the sequential binding and elution of a
series of labelled lectins. The key problems that are addressed
by employing this approach are:
(i) Glycan profiling of live cells either requires many
thousands of cells (FACS) or is restricted to probing only one
glycan per cell (microarray). We address this issue by using a
LiaT platform that allows for the sequential introduction of
reagents by regulating the fluid properties in the micro-
channels in a low-volume (4 nL), shear-free platform. Thus,
using LiaT allowed us to handle smaller cell samples and to
deliver low-affinity reagents to the cell surface under vanishing
flow field, both prerequisites for the successful implementa-
tion of the developed glycoprofiling method.
(ii) The binding of multiple lectins on the cell surface at
the same time may result in inaccuracies due to inter-lectin
steric hindrance. We address and eliminate this issue by
sequentially probing glycans one after another using one
lectin at a time. The ability to exchange lectins through
sequential elution reduces the problem of steric hindrance
between two adjacent binding sites.
(iii) The specificity of lectin binding on the cell surface is
confirmed by a reduction in the level of cell-bound fluores-
cence following elution with the corresponding lectin-specific
monosaccharide.
(iv) The cost of analysis can be significantly reduced
through the use of a single fluorophore for all lectin types,
thereby permitting analysis with a very basic fluorescence
microscopy setup. The LiaT system does not require any
specialist pumps or other auxiliary equipment. The simple
architecture allows cost-efficient mass manufacture of the
microfluidic chips.
Furthermore, it has been demonstrated that our method
and the LiaT platform can be employed for several other
applications.17 In summary, we show that the LiaT-based
multi-lectin technology described here is a significant
advance that enables glycan profiling at the level of a single
live cell.
Theory
Principles of lab in a trench
Lab-in-a-Trench (LiaT) is a microfluidic platform previously
developed by Dimov et al.15,16 in which cells are contained
and analysed in a shear-free environment. We reasoned that
LiaT would permit glycoprofiling at a single cell level. Several
other single cell analysis platforms are available, including
constricted channel-based,18 cup-based,19 and cylindrical
trap-based systems.20 Most of these alternative (non-LiaT)
systems are either shear-based, continuous flow-based or
open (several cell traps in a given area) systems. It has been
Lab on a ChipPaper
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well established that even slight alterations in biophysical
conditions, including hydrodynamic forces, can trigger
changes in cellular morphology and physiology.21 As the LiaT
system allows the merely diffusion-based delivery of lectins,
cells can be probed in a shear-free environment.
The LiaT platform contains a deep, micron-scale indenta-
tion within a continuous channel that enables the capture
and retention of cells purely based on gravity15,16 (Fig. 1).
LiaT follows a well-known working principle that is based on
the Camp–Hazen model of a settling basin.22 In this model,
the velocity of cells over the trench is the most critical param-
eter for ensuring their gravity-driven capture.
Lab in a trench – microfluidic theory
We consider particle trapping in the trench according to the
critical trajectory model for a Camp–Hazen type settling tank
(Fig. 1a). Cells are suspended in a flow of PBS buffer of density
ρ = 1.0 × 103 kg m−3 and viscosity η = 1.09 × 10−3 Pa s under the
impact of the gravitational acceleration g = 9.81 m s−2. A pres-
sure head Δp = 1.5 hPa built up by a pipette filled to a liquid
level σ = 1.5 cm applies across the main channel has total
length lchannel = 14 mm, constant height hchannel = 35 μm and
width wchannel = 40 μm which broadens to wtrench = 250 μm
above the trench of stream-wise length ltrench = 100 μm
(Fig. 1b). Neglecting the trench section, the (average) flow of
velocity then amounts to
v h w p
C lchannel
channel channel
nc channel
 m s    430
1
with the numerical coefficient for the rectangular channel
Cnc ≈ 32.14. The (average) flow velocity even reduces to
v w
w
vtrench channel
trench
channel  m s   70 1
within the sector above the trench. The resulting Reynolds
number
Re  
vw
1
indicates that flow conditions are strictly laminar within the
channel as well as in the trench for typical flow speeds v and
widths w. Hence, streamlines will only penetrate into the
uppermost region of the trench and molecular (reagent)
transport across streamlines into the trench occurs solely
through diffusion15 (Fig. 1a).
Table 1 Comparison of state-of-the-art technologies for glycoanalysis
Glycoprofiling strategies Limitations Advantages Ref.
Whole cell-based approaches
Flow cytometry Requires huge number of cells High-throughput and quantitative 6–8
Works at population level Routinely employed in clinical
set-ups and industriesCostly instrumentation
Inability to localise multiple glycans on cell surface
and on protein domains
Cells are exposed to tremendous pressures that may
induce changes leading to false characterization
Inability to correlate the retrieved cells to their FACS
data for further validation
Microscopy Inability to perform multi-lectin glycoprofiling Possible to localise glycans
on cell surface
9
Multiple staining is laborious with a high probability
of inter-stain steric hindrance
Crude cell lysate-based approaches
Microarray Homogeneous cell population required High throughput 10–12
Inability to classify sub-populations Visual; quantitative
Inability to allow single cell multi-lectin glycoprofiling
Expensive, labour-intensive
High detection limits and narrow detection ranges
Of limited diagnostic value
Purified cell lysate-based approaches
Mass
spectrometry
Virtually impossible to analyse intact molecules High-throughput 13–14
Challenging data-interpretation due to glycan complexity, proton/cation
exchange and loss of sulfo groups
Confirmatory
Limited availability of computer assisted programs for complexity analysis
NMR Inability to distinguish isomers
Laborious and time consuming method of sample preparation
Loss of surface sugars mainly O-linked along with some N-linked glycans
during sample preparation
Inability to analyse whole cells and live cell
Costly instrumentation
Lab on a Chip Paper
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With the speed of sedimentation
v gdsed cell  
2
18  
for cells of density ρcell and diameter d we can determine
the ratio
t
t
h
gd
v
l
sed
in
channel
cell
channel
channel /
   
18
22

 
between the sedimentation time tsed (h) = hchannel/vsed across
the entire channel height hchannel and the (minimum) resi-
dence time of the cells in the incoming segment tin =
0.5lchannel/vchannel located at about 0.5lchannel after the inlet.
For Ramos cells with a density of ρcell = 1.02 × 10
3 kg m−3
and a typical diameter d = 10 μm suspended in PBS buffer,
this ratio is much smaller than unity so that the entire popu-
lation of Ramos cells will have settled to the bottom of
the channel way before reaching the downstream trench
(Fig. 1b).
Due to the parabolic flow profile, their speed of cell migra-
tion will hence be significantly reduced with respect to
the above calculated (average) flow velocity vtrench. The cell
velocity in the trench region
v v h
h
v w
wcell trench
cell
channel
chansnel
channel
tr/
 



2
2
8
2
ench
cell
channel
h
h




2
Fig. 1 Principles of the lab in a trench microfluidic platform: (a) simulation of cell capture based on sedimentation of cells to the bottom of the
trench structure.15 (b) Operating principle of the lab in a trench platform. Reagents are exchanged by diffusion permitting a shear-free environment
at the bottom of the trench structure.
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depends on the distance of the cell from the bottom of the
channel hcell. If, for instance, a cell was touching the bottom
of the channel (Fig. 1b), i.e. hcell = d/2, their speed of horizon-
tal migration would amount to vcell ≈ 10 μm s−1, only.
For efficient trapping, the ratio
t
t
h
gd
v
l
h
gd
sed
res cell
cell
trench
cell
     
  
 
18
18
2
2

 

  




2 1
2
v w
w l
d
h
channel channel
trench trench trench
of the cell sedimentation time (to a depth d into the trench)
and the cell residence time in the trench region needs to be
lower than unity. This implies an upper limit
v g w l h
hwchannel
cell trench trench trench
channel
* ( )  
2
36
for the flow speed in the (main) channel. Assuming that the
cell will be irreversibly trapped after penetrating a distance
corresponding to the channel height into the trench, i.e.
h = hchannel, we obtain a speed limit of vchannel* = 545 μm s
−1 >
vchannel = 430 μm s
−1 as calculated above. Please note that
while the derived equations are quite instructive for the
understanding of the system and we even obtain a speed
limit compliant with an experimentally observed flow rate at
which trapping occurs, these “back-of-the-envelope” calcula-
tions are just coarse, order-of-magnitude estimates in a more
quantitative picture.
COMSOL simulations
Liquid flow profiles (Fig. 1a) obtained for channels of these
dimensions have been comprehensively simulated by COMSOL
modelling.15
Lab in a trench – micro-fabrication
The platform is a two layer polydimethylsiloxane (PDMS)
system whereby a lower PDMS panel holds structures (channel
and trenches), while an upper panel has reservoirs. In brief,
PDMS (Dow Corning) was mixed with curing agent in a ratio
of 5 : 1 for the trenches and 20 : 1 for the lid, followed by
degassing for a minimum of 30 min under vacuum. Degassed
PDMS was then poured on the appropriate silicon masters
and partially cured for 3–4 hours at room temperature under
vacuum. Inlet holes (diameter: 1 mm) were then punched in
the lid structure. The two PDMS layers containing the chan-
nels and reservoirs were then aligned, bonded and cured at
70 °C for 24 hours.
Gravity driven flow
Gravity driven flow was implemented by fitting a vertically
aligned, standard pipette tip in the inlet hole of the LiaT chip
and loading it with input fluid. The flow velocity was deter-
mined by the height of the liquid column which was kept at
roughly σ = 1.5 cm over the course of the experiment.
Device priming and cell loading
The fabricated LiaT was O2 plasma treated for 5 min. Then
channels and trenches were immediately primed with 100 mM
Tris-buffered saline (TBS), pH = 7.4, containing 1 mM CaCl2.
Each inlet was then loaded with cells by adding 0.4 μl of
culture (105 cells per mL) to the 20 μL of TBS already present
in the gravity pump.
Capture efficiency close to 100% was routinely achieved
within the system by keeping the flow velocity at the inlet
within the range of ≤430 μm s−1 and ensuring that the chan-
nel to trench depth ratio was kept above 1 : 5. It has been
shown by Manbachi et al. that a shear stress-free environ-
ment exists within the trench under such conditions23 and,
as a consequence, flow velocities are at least three times
lower at the bottom of the trench relative to the top.15,23
Three times the required number of cells to be captured
was loaded. By operating in the critical flow velocity range of
≤430 μm s−1, the required number of cells can be captured
in the trench. Surplus cells were then removed by increasing
the flow velocity (>430 μm s−1) at the inlet and these then
passed over the top of the trench and travelled to the waste
chamber at the bottom of the chip.
Briefly, Ramos cells were suspended in TBS buffer by
adding ~1500 cells to a 20 mL solution of TBS. Cell suspen-
sions and reagents were loaded and pumped through the
system with a hydrostatic pressure-head17 created by liquid
level in the pipette tip. Theoretically, a trench can hold
approximately 60 non-overlapping cells and up to 200 cells if
there is no requirement for such a monolayer. Reagents were
introduced at higher speeds to establish a fixed concentra-
tion on top of the trench. The laminar flow in the channel
ensured an abruptly vanishing flow field below the plane of
the upper flow channel, i.e. essentially throughout the entire
trench (Fig. 1). Therefore, shortly after the cells have entered
the trench, they are irreversibly retained in a flow-free envi-
ronment; as they maintain their location at the bottom of the
trench and can hence be individually observed over time.
Access of reagents and wash buffer to the trench-trapped
cells therefore solely occurs by diffusion and so the hydrody-
namic stress to which these captured cells are exposed, are
negligible. In addition, trench depths as small as 200 μm
(with typical volumes of 4 nL) allow continuous loading of
reagents and nutrients to provide efficient on-chip cell
culturing.
Experimental
Reagents
Biotinylated lectins (WGA, ConA, ECL, LCA, NPL) were
obtained from Vector Laboratories. These were labelled with
DyLight 488 – streptavidin (Vector Laboratories) according
to the manufacturer's instructions. Fucose, mannose, galac-
tose and N-acetylglucosamine were purchased from Sigma.
All lectins and sugars were suspended in TBS pH 7.4 with
1 mM CaCl2.
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Cell culture
Ramos cells (ATCC no. CRL-1596), a B cell line of Burkitt's
lymphoma origin, were cultured in RPMI 1640 (Sigma) sup-
plemented with 10% heat inactivated foetal calf serum
(Gibco) and 1% penicillin/streptomycin (Sigma). Cells were
incubated at 37 °C with 5% CO2, split every two to three days
and seeded at a density of 2.5 × 105 cells ml−1.
Sequential glycan profiling
Each Dylight488-conjugated lectin (1 μl of 0.1 mg mL−1) was
introduced in the inlet with 20 μl buffer reserve. The lectin
flows with the buffer in the channel. The typical time for the
(near) completion of lectin diffusion from the inlet to the
bottom of the trench was 20 s. Lectin binding to cells was
monitored by fluorescence microscopy every 5 min. After
reaching binding saturation, which was different for each
lectin, free sugar (20 μl of buffer with 2 μL 1 M sugar giving a
working concentration of 100 mM) was introduced into the
system to elute bound lectin from the cell surface (Fig. 2).
Elution sugar was chosen according to the specificity of each
lectin as shown in ESI† Table S1. The elution sugar of a pre-
ceding lectin does not hinder the binding of the next incom-
ing lectin unless both lectins have an affinity for the same
sugar. In this case, the liquid in the system was replaced with
fresh TBS. LCA, ConA and NPL bind specifically to mannose
and its derivative arrangements, thus in those cases there
was a need to change inlet buffer after each elution.
Fluorescence microscopy
The trench was imaged with an Olympus IX81 motorized
inverted microscope with an attached Hamamatsu ORCA – ER
digital camera C4742-80 using a 10× objective. The micro-
scope platform was maintained at 5% CO2 and a temperature
of 37 °C for the duration of the experiments. After the intro-
duction of each lectin into the channel, focus was maintained
on the cells for the duration of each lectin binding and
elution event. Images were captured at that focus after 5 min
in TIFF format in order to preserve the original pixel densi-
ties of the image (Fig. 2).
Image analysis with ImageJ
Images were analysed by the software ImageJ (version 1.46r).
Fluorescence intensity was quantitated by ‘region of interest
(ROI)’ analysis. An average intensity was obtained for each
cell through the time series. Fluorescent images of the final
time point of each lectin series were used to create overlays
of individual cells. This allowed a visual depiction of the
glycan distribution across the surface of the cells. Examples
of the overlaid images are shown in Fig. 3b, 4b and 5b.
Results and discussion
Sequential glycan probing
The LiaT platform was employed to examine the surface
glycosylation of Ramos B lymphoma cells, and benchmarked
with characterization of the same features by flow cytometry
(ESI† Fig. S1). Ramos cell surface glycans were thus sequen-
tially probed by a panel of four fluorescently-labelled lectins,
categorized as mannose- (LCA, NPL and ConA), galactose-
(ECL) and N-acetylglucosamine- (GlcNAc) binders (WGA).
A summary of the sequential experiments undertaken is
presented in Table 2. The interference of free sugar from pre-
vious stains was assessed with three mannose-binding
lectins, namely, LCA, ConA and NPL (ESI† Table S1). An addi-
tional wash step was incorporated between sugar elution and
addition of the next lectin in the sequence.
Each trench was loaded with 15–20 cells in TBS with
1 mM CaCl2. Each DyLight488-labelled lectin was introduced
in the LiaT at a concentration of 11 μg μL−1 and diffused to
the cells at the bottom of each trench in less than 30 s, as
also shown to be the case in the COMSOL simulations
performed by Dimov et al.15 The resultant lectin concentra-
tion effectively available for cells to bind was therefore 13 pg
in each 4 nl trench. Lectin-binding events were then recorded
over time by epifluorescence microscopy. They are presented
here in 5 min time steps (Fig. 3–5) as a function of increasing
fluorescence signal until saturation established. This was
followed by elution with the specific sugar substrate of the
bound lectin. A summary of the different sequential profiling
experiments performed is given in Table 2.
In the first experiment with the two lectins LCA and ECL,
stronger signals were detected with LCA indicating a denser
mannose distribution at the cell surface when compared to
ECL, which has an affinity for galactose residues (Fig. 3).
This is in agreement with general cell surface glycan struc-
tures because galactose is known to be either protected or
partially exposed on live healthy cells which results in poor
ECL binding and hence lower equilibrium concentrations
and reduced signals.24
In a second experiment involving three mannose-binding
lectins, the successive binding of the second and third lectins
Fig. 2 Series of images of sequential elution of fluorophore-labelled
lectin off Ramos cells: images i, ii, iii show diffusion of LCA into the
channel and staining of the cells after 0, 5, 10 minutes. Image iv shows
the cells after free mannose had been diffused into the system. Image v
was taken after ECL had been added to the system.
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was not affected by the presence of mannose during earlier
steps in the probing sequence, i.e. indicating the effective-
ness of the preceding wash step (Fig. 4). The peak fluores-
cence of LCA and ConA was comparable to those achieved in
the next experiment (Fig. 5) also including ConA and WGA.
In this 4-lectin experiment, a higher signal was obtained with
the latter and an intermediate signal with the former (Fig. 5).
This experiment confirmed high GlcNAc and core mannose
levels on the cell surface. When mannose binders (LCA and
ConA) were compared, the amount of bound LCA was found
to be lower than that of bound ConA. This is likely to reflect
the known difference in affinity between LCA and ConA,
Fig. 3 (a) Average intensity of individual cell staining as calculated by ImageJ. Each lectin and elution step is represented by an individual colour.
Each step within each colour on the plot represents a 5 minute time interval. Images collected at 5 minute intervals after addition of LCA (blue),
mannose (red), ECL (green) and lactose (purple). (b) An example of a cell stained sequentially with LCA and ECL, and resulting overlay. (c) Average
peak intensity values of individual cell staining.
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where the former only recognizes α-linked fucosylated
mannose. GlcNAc presented with the highest density among
all the exogenous glycans that were probed.
As the lectins were added in an order such that sugar
elution would not interfere with the following lectin, we were
able to image individual cells without the requirement
for wash steps. This allowed us to create spatio-temporal
glycan density profiles of the cell surface using regular image
analysis (ESI† Fig. S2). In addition, the order of lectins was
selected so as to minimise impact on the cells, based on the
Fig. 4 (a) Average intensity of individual cell staining as calculated by ImageJ. Each lectin and elution step is represented by an individual colour.
Each step within each colour on the plot represents a 5 minute interval. The images were collected at 5 minute intervals after addition of LCA
(blue), ConA (green), NPL (purple) and mannose (red). (b) An example of a cell sequentially stained with LCA, ConA and NPL and resulting overlay.
(c) Average peak intensity values of individual cell staining.
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changes observed when using each lectin in flow cytometry
(ESI† Fig. S1). The sugar elution steps were rapid (in the order
of minutes), thus minimising any potential physiological
impact on the cells in the trenches. It can be noted that in
experiments 2 and 3, LCA was followed directly or indirectly
by ConA (Fig. 4 and 5). In experiment 3, similar observations
Fig. 5 (a) Each lectin and elution step is represented by a distinct colour. Each step within each colour on the plot represents a 5 minute time
interval. Sequential profile steps (5 minute intervals): LCA (lectin-blue), mannose (elution-red), ECL (lectin-green), galactose (elution-orange), ConA
(lectin-purple), mannose (elution-red), WGA (lectin-brown), GlcNAc (elution-black). (b) An example of a cell sequentially stained with LCA, ECL,
ConA and WGA and resulting images overlaid. (c) Average peak intensity values of individual cell staining.
Table 2 Summary of experimental procedures
No. of lectins Lectins No. of elutions Elutions No. of cells No. of trenches on chip
2 LCA, ECL 2 Mannose, galactose 93 6
3 LCA, ConA, NPL 3 Mannose (3×) 108 6
4 LCA, ECL, ConA, WGA 4 Mannose (2×), galactose, GlcNAc 75 6
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were made to experiment 2, indicating that the fucose
elution of ECL in experiment 3 had not interfered with the
cells' binding of ConA.
Qualitative cellular glycan map
Through the software Image-J we have generated a qualitative
glycan map by simple co-localisation of individual lectins
and an overlap of all bound lectins (Fig. 3b, 4b and 5b). In
general, a cell population was profiled at successive points in
time and the resulting images were then overlaid with com-
putational tools to produce the glycan map.
In-trench lectin specificity
We have confirmed that the free sugars can be washed from
the system such that they do not interfere with the following
lectin. This has been demonstrated by targeting a common
carbohydrate (mannose in this case) with three different
lectins (LCA, ConA and NPL) that probe mannose and exhibit
similar specificities. We found binding of all lectins to simi-
lar positions on the cell surface but with varying intensities
(Fig. 4b).
Heterogeneity analysis: single cell versus cell population
The results generated were then analysed with a view to
understanding glycan heterogeneity at the single-cell level.
An difference was observed at the inter-cellular (n = 12) level
in the glycan-probing behaviours of lectins on individual cells
as demonstrated by their NPL lectin profile (ESI† Fig. S3).
Lectins are usually low-affinity binders with their dissociation
rate constants (Kd) ranging from 10
−4 to 10−7 mol−1 s−1. The
impact of glycan structure and complexity has been known
for a long time but its functional interpretation has only
begun to be addressed in the last few years.25–27
The sequential lectin-elution method has thus enabled us
to detect multiple sugars over time on a given live cell and
that is a considerable technical advancement over current
state-of-the-art methods. We show here that the LiaT plat-
form also permits the differential characterization of diverse
glycosylation features at the single cell as well as at a popula-
tion level. By overlaying the images of different lectin probes,
one could also effectively perform various other qualitative
and quantitative analyses like the kinetics of lectin binding
to cell-bound sugars and the development of sugar distribu-
tion profiles (ESI† Fig. S4). Coupled to LiaT platforms, this
strategy has the potential to significantly impact on the
advancement of glycoanalysis.
Conclusions
Due to minimisation of cell translocation as well as alter-
ations to the physiological dynamics at their surface, the
sequential binding of lectin probes to glycans on the surface
of individual cells within a population can be analysed the
novel LiaT platform. Furthermore, the simple geometry allows
very cost-efficient mass manufacture. Beyond the here presented
application in glycoscience, the LiaT platform thus also bears
a significant potential to expand the analytical toolbox of cell
biology and biomarker discovery.
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